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Abstract 
The long term objective of this research is to identify quantitative biomechanical 
parameters of postural instability in patients with Parkinson’s disease (PD) that can in turn be 
used to assess fall risk.  Currently, clinical assessments in PD are not sufficiently sensitive to 
predict fall risk, making a history of falls to be the best predictor of a future fall.  Identifying 
biomechanical measures to predict risk of falls in PD would provide a quantitative justification to 
implement fall-reducing therapies prior to a first fall and help prevent the associated debilitating 
fractures or even morbidity. While past biomechanical studies have shown the presence of 
balance deficits in PD patients, which often include a broad spectrum of disease stages, 
compared to healthy controls (HC), no studies have assessed whether such parameters can 
distinguish the onset of postural instability prior to clinical presentation, and if such parameters 
persist following clinical presentation of postural instability.  Toward this end this study had 
three goals: 
 Determine if biomechanical assessment of a quasi-static task, postural sway, 
could provide preclinical indication of postural instability in PD. 
 Define a mathematical model (based on principal component analysis, PCA) 
with biomechanical and clinical measures as inputs to quantitatively score 
earlier postural instability presence and progression in PD. 
 Investigate if biomechanical assessment of a dynamic task, gait initiation, 
could provide preclinical indication of postural instability in PD. 
Specific Aim 1 determined that some biomechanical postural sway variables showed 
evidence of preclinical postural instability and increased with PD progression.  This aim 
distinguished mild PD (Hoehn and Yahr stage (H&Y) 2, without postural deficits) compared to HC 
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suggesting preclinical indication of postural instability, and confirmed these parameters persisted in 
moderate PD (H&Y 3, with postural deficits).  Specifically, trajectory, variation, and peak measures 
of the center of pressure (COP) during postural sway showed significant differences (p < .05) in mild 
PD compared to healthy controls, and these differences persisted in moderate PD.  Schwab and 
England clinical score best correlated with the COP biomechanical measures.  These results suggest 
that postural sway COP measures may provide preclinical indication of balance deficits in PD and 
increase with clinical PD progression. 
Specific Aim 2 defined a PCA model based on biomechanical measures of postural sway 
and clinical measures in mild PD, moderate PD, and HC.  PCA modeling based on a correlation 
matrix structure identified both biomechanical and clinical measures as the primary drivers of 
variation in the data set. Further, a PCA model based on these selected parameters was able to 
significantly differentiate (p < .05) all 3 groups, suggesting PCA scores may help with preclinical 
indication of postural instability (mild PD versus HC) and could be sensitive to clinical disease 
progression (mild PD versus moderate PD and moderate PD versus HC). AP sway path length 
and a velocity parameter were the 2 primary measures that explained the variability in the data 
set, suggesting further investigation of these parameters and mathematical models for scoring 
postural instability progression is warranted.   
Specific Aim 3 determined that a velocity measure from biomechanical assessment of 
gait initiation (peak COP velocity towards the swing foot during locomotion) showed evidence 
of preclinical postural instability in PD. Because balance is a complex task, having a better 
understanding of both quasi-static (postural sway) and dynamic (gait initiation) tasks can provide 
further insight about balance deficits resulting from PD. Several temporal and kinematic 
parameters changed with increasing disease progression, with significant difference in moderate 
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PD versus HC, but missed significance in mild PD compared to HC. Total Unified Parkinson’s 
Disease Rating Scale (UPDRS) and Pull Test clinical scores best correlated with the 
biomechanical measures of the gait initiation response. These results suggest dynamic 
biomechanical assessment may provide additional information in quantifying preclinical postural 
instability and progression in PD.  
In summary, reducing fall risk in PD is a high priority effort to maintain quality of life by 
allowing continued independence and safe mobility.  Since no effective screening method exists 
to measure fall risk, our team is developing a multi-factorial method to detect postural instability 
through clinical balance assessment, and in doing so, provide the justification for implementing 
fall reducing therapies before potentially debilitating falls begin. 
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CHAPTER 1: Introduction 
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Introduction and Motivation 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
(Wirdefeldt, Adami et al. 2011) and affects approximately 1 million people in the USA and 5 
million people worldwide (Olanow, Stern et al. 2009).  Around 50-60,000 new cases are 
diagnosed annually, with the prevalence increasing as the population ages (Huse, Schulman et al. 
2005, Lees, Hardy et al. 2009). The etiology of PD is not well understood and is attributed to a 
combination of genetic and environmental factors (Shulman, De Jager et al. 2011, Wirdefeldt, 
Adami et al. 2011).  Clinically, PD patients typically present with motor symptoms and these 
include tremor, rigidity, and bradykinesia (slowed movement), and later develop shuffling gait 
and postural instability (Rascol, Goetz et al. 2002, Dauer and Przedborski 2003, Fritsch, Smyth 
et al. 2012).  There is no cure for PD, but pharmaceutical, surgical, and physical therapy based 
treatments focus on controlling the symptoms of the disease (Marsden and Obeso 1994, 
Vingerhoets, Villemure et al. 2002, Fahn, Shoulson et al. 2004, Protas, Mitchell et al. 2005, King 
and Horak 2009, Schapira, Emre et al. 2009).  By 2040, the annual cost to the USA associated 
with PD is estimated to exceed 50 billion dollars (Huse, Schulman et al. 2005).  
In a recent survey of individuals with PD, their caretakers and family members, the 
participants identified improving research related to balance and falls as their number one 
priority they would like to see addressed (Deane, Flaherty et al. 2014). Postural instability is 
generally resistant to current therapies and is one of the most incapacitating symptoms of PD 
because it increases fall risk (Olanow, Watts et al. 2001, Michatowska, Fiszer et al. 2005). Falls 
in PD are so debilitating because they lead to further complications like fractures (Martin 2011, 
Matinolli, Korpelainen et al. 2011), decreased quality of life (Michatowska, Fiszer et al. 2005, 
Voss, Elm et al. 2012), and increased morbidity (Morens, Davis et al. 1996). Unfortunately, falls 
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are currently one of the greatest unmet needs in PD because current clinical assessments are not 
sensitive to predict falls (Bloem, Beckley et al. 1998) and interventions typically do not occur 
until after a fall episode has occurred (Bloem, Grimbergen et al. 2001). Although there are 
targeted therapies that may effectively reduce fall risk (Visser, Marinus et al. 2003, Segev-
Jacubovski, Herman et al. 2011, Morris, Martin et al. 2012), if not implemented early, falling and 
often injury have already occurred.  Accurate assessment of postural instability and prediction of 
fall risk is a crucial unmet need in the clinical care of PD patients.  
 There are some promising preliminary biomechanical assessments of postural instability 
in those with PD for various tasks including postural sway, gait initiation, and balance recovery 
(Rosin, Topka et al. 1997, Hass, Waddell et al. 2005, Horak, Dimitrova et al. 2005, Blaszczyk, 
Orawiec et al. 2007, Matinolli, Korpelainen et al. 2007, Buckley, Pitsikoulis et al. 2008, 
Blaszczyk and Orawiec 2011, Mancini, Horak et al. 2011, Stylianou, McVey et al. 2011, 
Ickenstein, Ambach et al. 2012, Mancini, Carlson-Kuhta et al. 2012, Stegemoller, Buckley et al. 
2012). However, these studies typically combine a wide range of disease severities (Hoehn & 
Yahr stages (H&Y) 1-4) so the relation of biomechanical parameters to PD progression remains 
unknown. While these studies show the presence of balance deficits in PD compared to HC, no 
studies have assessed whether such parameters can distinguish early onset of postural instability 
prior to clinical presentation.  Biomechanical markers that are sensitive to early onset of postural 
instability and specific to clinical disease progression could help fulfill this unmet need in fall 
risk assessment. Further, to ensure more robust measures of postural instability related to fall 
risk, these biomechanical parameters should likely encompass a range multi-factorial balance 
assessment tasks (i.e. quasi-static and dynamic tasks). 
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A pilot study done by our group represents a preliminary step for this type of analysis, 
assessing postural instability with biomechanical markers in PD participants, compared to 
healthy controls.  This study demonstrated that the biomechanical assessment of the response to 
a fall provoking balance disturbance exhibited significant differences in mild PD participants 
compared to the healthy controls (McVey, Stylianou et al. 2009) and these deficits persisted in 
moderate PD (McVey, Amundsen et al. 2013) .  Therefore biomechanical assessment of various 
balance tasks may show promise as diagnostic markers of postural instability, and therefore fall 
risk, in PD. The natural next step is to determine if disease progression impacts biomechanical 
markers for other balance tasks such as postural sway and gait initiation. And further, to see if 
the combination of such biomechanical parameters with existing clinical measures can provide 
more information about postural instability onset and progression through the use of increasingly 
sophisticated mathematical models.  Ultimately, using biomechanical parameters along with 
existing clinical measures may represent an opportunity to refine potential parameters that can 
predict fall risk, and be valuable in detecting the transition associated with the onset of postural 
instability and its development with clinical disease progression.   
 
Specific Aims 
 Specific Aim 1 determined that biomechanical postural sway variables showed evidence 
of preclinical postural instability and persisted with clinical PD progression.  Whole body center 
of pressure (COP) trajectory, variation, and peak measures were calculated for healthy controls 
(HC), mild PD (H&Y 2, without postural deficits), and moderate PD (H&Y 3, with postural 
deficits).  It was hypothesized that some postural sway COP parameters could distinguish 
patients with mild PD compared to HC, reflecting evidence of preclinical postural instability and 
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that these parameters would persist in moderate PD. Chapter 3 addresses Specific Aim 1. 
Appendix B.i. includes additional analysis and results related to this aim not included in Chapter 
3.  
 Specific Aim 2 defined a principal component analysis (PCA) model based on a 
standardized input matrix of biomechanical measures of postural sway and clinical measures of 
PD progression.  A correlation matrix structure PCA was performed for the purpose of selecting 
the most influential parameters in the data set and determining if PCA could differentiate 
preclinical postural instability and changes associated with PD progression. We hypothesized 
that parameter selection would result in both biomechanical and clinical measures as the primary 
drivers of variation in the data set, and a PCA model based on these selected parameters would 
be able to significantly differentiate HC, mild PD and moderate PD.  Chapter 4 addresses 
Specific Aim 2. Appendix B.ii includes additional analysis and results related to this aim not 
included in Chapter 4. 
 Specific Aim 3 determined that a velocity measure (peak COP velocity towards the 
swing foot during locomotion) from biomechanical assessment of gait initiation showed 
evidence of preclinical postural instability in PD. The biomechanics of gait initiation from cue 
onset to heel strike of the first step were analyzed and temporal, kinematic, and COP measures 
were analyzed for several stages of this response. It was hypothesized that some gait initiation 
parameters could distinguish patients with mild PD compared to HC, reflecting evidence of 
preclinical postural instability and some parameters would change with increased disease 
progression (moderate PD).  Chapter 5 addresses Specific Aim 3. Appendix B.iii includes 
additional analysis and results related to this aim not included in Chapter 5.  
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Dissertation Content 
This dissertation contains six chapters. Chapter 1 contains an introduction to the area of research 
for this study. Chapter 2 consists of an in-depth review and background of relevant published 
literature related to this study. Chapter 3 contains the manuscript for Specific Aim 1 on postural 
sway as a measure of preclinical postural instability in Parkinson’s disease. Chapter 4 contains 
the manuscript for Specific Aim 2 related to principal component analysis of postural sway for 
tracking preclinical onset and progression of postural instability in Parkinson’s disease. Chapter 
5 is the manuscript for Specific Aim 3 on gait initiation in Parkinson’s disease to assess 
preclinical postural instability and progression. Chapter 6 summarizes the primary findings and 
future directions of this research. 
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Parkinson’s Disease Epidemiology and Etiology 
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder and 
affects approximately 1 million people in the United States and 5 million people worldwide 
(Olanow, Stern et al. 2009, Wirdefeldt, Adami et al. 2011).  PD is a progressive disease that has 
no confirmed cause, with approximately 85% of diagnosed patients having no confirmed genetic 
link to the disease (Corti, Lesage et al. 2011).The average age of diagnosis is approximately 60 
years of age, with approximately 10% diagnosed before the age of 40 (Lees, Hardy et al. 2009, 
Wirdefeldt, Adami et al. 2011).  Around 50-60,000 new cases are diagnosed annually, with the 
prevalence increasing as the population ages (Huse, Schulman et al. 2005, Lees, Hardy et al. 
2009). Men are estimated to be about 1.5 times as likely as women to be diagnosed with PD 
(Wooten, Currie et al. 2004). The etiology of PD is not well understood and is attributed to a 
combination of genetic and environmental factors (Shulman, De Jager et al. 2011, Wirdefeldt, 
Adami et al. 2011).  Recent research suggests that there is a continuum of overall risk factors for 
PD which range from familial genetic factors to unknown environmental variants (Shulman, De 
Jager et al. 2011). By 2040, the annual cost to the United States associated with PD is estimated 
to exceed 50 billion dollars (Huse, Schulman et al. 2005).  
 
Neurophysiology 
 PD is caused by the loss of dopamine containing cells in the substantia nigra pars 
compacta (SNc).  The substantia nigra is a component of the basal ganglia, the part of the brain 
that is involved with voluntary movement. The degeneration of the dopamine containing cells in 
the SNc ultimately results in decreased stimulation to the motor cortex (Centonze, Calabresi et 
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al. 1999). Typically when dopaminergic cells in the SNc decrease to around 50% of normal 
individuals, external symptoms of PD become apparent (Wichmann and DeLong 2003).  
Basal Ganglia Anatomy and Function 
The basal ganglia (BG) are a group of nuclei located at the base of the forebrain 
comprised of a complex network of nuclei that innervate the thalamus, which is responsible for 
motor, sensory, and cognitive function (Middleton and Strick 2002).  Although there are several 
theories as to the precise function of the BG, many theories suggest the BG are responsible for 
facilitating voluntary movement and the associated learning, planning, execution, and 
modulation of these movements (Takakusaki, Saitoh et al. 2004, Lehericy, Benali et al. 2005, 
Obeso, Rodriguez-Oroz et al. 2008, Doyon, Bellec et al. 2009).  There are four main nuclei that 
make up the BG: substantia nigra (composed of the substantia nigra pars compacta (SNc) and the 
substantia nigra pars reticulata (SNr)), striatum (composed of the caudate and putamen), globus 
pallidus (composed of the globus pallidus externa (GPe) and the globus pallidus interna (GPi)), 
and the subthalamic nucleus (STN).   
Substantia Nigra 
The substantia nigra, composed of the SNc and SNp, has both input (SNc) and output 
(SNp) nuclei as part of its structure. The SNc provides dopamine input to the striatum, the main 
input structure of the BG.  Some PD motor symptoms are caused by a loss of the dopaminergic 
cells of the SNc, thus decreasing the input the striatum receives. The SNr is an output pathway of 
the BG that innervates the thalamus  (Wichmann and DeLong 2003, Shulman, De Jager et al. 
2011). (Figure 1)  
Striatum 
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The striatum, composed of the caudate and putamen nuclei is the largest input structure 
of the BG.  The striatum receives input from the cortical areas and the SNc and has an inhibitory 
effect on the GPe and GPi.  When there is dopamine loss due to PD in the SNc, the weaker signal 
sent to the striatum causes the striatum to send an increased inhibitory signal to the GPi and GPe. 
(Figure 1) 
Globus Pallidus & Subthalamic Nucleus 
The globus pallidus, comprised of the GPe and GPi, has both input (GPe) and output 
(GPi) nuclei as a part of its structure. There are two pathways to the output nucleui, the GPi, one 
that is direct: striatum  GPi and one that is indirect: striatum GPeSTNGPi.  In PD, the 
increased inhibitory input signal from the striatum ultimately causes the GPi to send an increased 
inhibitory signal to the thalamus (Utter and Basso 2008).  This over-inhibition of the thalamus 
causes a decrease in the excitatory signal the thalamus sends to the motor cortex, therefore 
affecting normal motor function.  Once dopamine levels decrease to around 50% of levels found 
in a normal brain, parkinsonian symptoms begin to become visible (Wichmann and DeLong 
2003). (Figure 1)  
 
Symptoms 
Motor Symptoms 
Once the levels of the dopaminergic cells of the substantia nigra pars compacta decrease 
to a clinically significant level, the onset of PD motor symptoms starts to occur. Traditionally, 
there are 4 cardinal symptoms of PD: tremor, rigidity, bradykinesia, and postural instability 
(Pahwa and Lyons 2013).  
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Resting Tremor 
Resting tremor is a very common symptom and presents in approximately three-quarters 
of PD patients, with over 70% of patients having tremor as an initial symptom at the time of 
disease diagnosis(Hughes, Ben-Shlomo et al. 2001). The frequency of the tremor typically 
ranges between 4 and 6 Hz and is present in the distal part of the extremities(Jankovic 2008).  
Resting tremor generally does not affect the head, neck or voice in PD.  The onset of a tremor 
typically occurs in just one limb, but over the course of the disease progression expands to affect 
a wider range of areas.  Resting tremor is most apparent when the affected limb is at rest, and 
improves once active or held in a position against gravity (Simuni, Lyons et al. 2009).   
Rigidity 
Rigidity, or stiffness of the muscles, affects the majority of PD patients and is consistent 
with basal ganglia diseases. Rigidity in PD can affect all the muscles and is particularly apparent 
by a ratchety/jerky feeling during passive movement, referred to as “cogwheel” rigidity (Pahwa 
and Lyons 2013).    
Bradykinesia 
Bradykinesia, or the slowness of movement, is a symptom typical of all basal ganglia 
disorders (Jankovic 2008) and is associated with the depletion of dopaminergic neurons of the 
putamen.  This symptom typically presents before diagnosis of a neurological impairment, and 
thus is one of the clinical indicators of a PD diagnosis (Simuni, Lyons et al. 2009). Various 
motor activities are impaired by bradykinesia, namely activities of daily living and writing tasks. 
Bradykinesia affects the velocity of movements, thus this symptom manifests in slowed reaction 
times and slower self-paced movements (Berardelli, Rothwell et al. 2001, Hallett 2011). Because 
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bradykinesia is correlated with dopamine loss, this symptom typically responds well to 
dopaminergic therapy (Simuni, Lyons et al. 2009).   
Postural Instability 
Once the first motor symptoms appear, on average it may take 5-10 years for patients to 
exhibit postural instability symptoms (Zhao et al., 2010). Postural instability, the final cardinal 
motor symptom of PD is characterized by flexed posture that occurs due to a decrease in postural 
reflexes. Postural instability typically occurs later in the disease progression (Jankovic and 
Poewe 2012).  Postural instability is a particularly disabling symptom due to its resistance to 
current therapies and its link to increased fall risk (Olanow, Watts et al. 2001, Michatowska, 
Fiszer et al. 2005).  Additionally, the fear of a future fall can also decrease a PD patients postural 
control, thus further increasing fall risk and decreasing quality of life (Adkin, Frank et al. 2003). 
In a recent survey of individuals with PD , their caretakers, and family members, the number one 
priority participants identified that they would like to see addressed was improving research 
related to balance and falls (Deane, Flaherty et al. 2014). 
Non-motor Symptoms 
In addition to the cardinal motor symptoms of PD, there are various non-motor symptoms 
of the disease that impact quality of life. Namely, neuropsychological, sleep, gastrointestinal, and 
sensory symptoms are typically present throughout the disease progression (Chaudhuri, Healy et 
al. 2006, Chaudhuri and Schapira 2009, Tolosa, Gaig et al. 2009). Neuropsychological symptoms 
like depression, anxiety, apathy, and dementia have been reported (Simuni, Lyons et al. 2009). 
Some type of sleep disorder such as rapid eye movement sleep behavior disorder, restless leg 
syndrome, sleep apnea, excessive daytime sleepiness, and insomnia is reported in up to 90% of 
PD patients (Olanow, Watts et al. 2001, Jankovic 2008). Gastrointestinal disorders such as 
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constipation can precede a PD diagnosis, and in later stage PD dysphagia and increased urinary 
frequency and urgency are also present (Leopold and Kagel 1997, Araki, Kitahara et al. 2000, 
Gage, Kaye et al. 2011). Additionally, sensory disorders like decreased olfactory function, 
increased pain and impaired visual sensitivity are also common (Tinazzi, Del Vesco et al. 2006, 
Jankovic 2008).   
 
Diagnosis and Rating of PD Progression 
Diagnosis 
Because there is a lack of distinct neuroimaging attributes or biomarkers related to PD, 
diagnosis of PD is reliant on clinical presentation of PD symptoms (Wirdefeldt, Adami et al. 
2011).  Typically, PD is diagnosed by a neurologist based on patient history and physical 
examination where the patient exhibits multiple symptoms of PD: tremor, rigidity, bradykinesia, 
and postural instability or responds to dopaminergic therapy (Hughes, Daniel et al. 2001, 
Chaudhuri, Healy et al. 2006, Savitt, Dawson et al. 2006, Kim, Allen et al. 2013). Additionally, 
current research suggests that various other symptoms can precede the typical cardinal symptoms 
of PD like sleep disorders, olfactory dysfunction, dysautonomia, depression, anxiety, 
constipation, pain, and genitourinary problems (Chaudhuri, Healy et al. 2006, Tolosa, Gaig et al. 
2009). Molecular imaging provides some promise in PD diagnostics but is costly and needs to be 
done in combination with pre-motor testing (Siderowf and Stern 2008, Stephenson, Siderowf et 
al. 2009). 
Classification and Rating Scales 
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As PD is a progressive disorder, there are 3 widely used standardized rating scales, 
Unified Parkinson’s Disease Rating Scale (UPDRS), Schwab & England Scale and Hoehn & 
Yahr stages (H&Y) to assess disease progression related to a variety of areas such as the impact 
of PD related to mentation, activities of daily living, and motor control (Factor and Weiner 2007, 
Pahwa and Lyons 2013).  
Specifically, the UPDRS has four scoring components: I. Mentation, behavior, and mood; 
II. Activities of daily living; III. Motor examination; and IV. Complications of therapy.  
Components I, II, and IV are historical and based on patient responses to verbal questioning. 
Component III is completed by a clinician and consists of brief physical tests/examinations to 
assess motor capabilities such as speech, facial expression, rigidity, tremor, finger tapping, hand 
and leg movements, rising from a chair, posture, a balance disturbance test, and walking (Goetz, 
Tilley et al. 2008).    
H&Y assesses disease impairment of motor function related to postural stability and 
consists of stages 0-5.  Below is an outline of the H&Y stages criteria. 
Stage 0 – No signs of disease. 
Stage 1 – Unilateral disease. 
Stage 1.5 – Unilateral plus axial involvement. 
Stage 2 – Bilateral disease, without impairment of balance. 
Stage 2.5 – Mild bilateral disease with recovery on pull test. 
Stage 3 – Mild to moderate bilateral disease; some postural instability; physically independent. 
Stage 4 – Severe disability; still able to walk or stand unassisted. 
Stage 5 – Wheelchair bound or bedridden unless aided. (Hoehn and Yahr 1998) 
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Therapies 
Drug Therapies 
Levodopa continues to be the most commonly used and most effective drug for the 
management of PD symptoms since it was first used in the 1960’s by Cotizias et al (Fahn, 
Shoulson et al. 2004, Fox, Chuang et al. 2008, Jankovic and Poewe 2012).  Levodopa was 
produced with the goal of improving motor symptoms associated with PD through restoring the 
levels of dopamine that were lost due to PD (Schapira, Emre et al. 2009). Today, levodopa 
continues to be a successful oral therapy to combat dopamine loss and to treat the motor 
symptoms of PD (Thanvi, Lo et al. 2007, Jankovic and Poewe 2012). Since the drug’s 
introduction, levodopa has demonstrated efficacy in improving the cardinal PD symptoms 
including bradykinesia, rigidity and resting tremor Levodopa is combined with a dopa-
decarboxylase inhibitor, carbidopa, which improves efficacy increases and reduces side effects, 
particularly nausea (Schapira, Emre et al. 2009, Jankovic and Poewe 2012).   
Despite levodopa’s success in treating the majority of the motor symptoms of PD, other 
motor symptoms, particularly related to gait and balance, are much less responsive.  In addition, 
long-term use of levodopa results in levodopa-induced side effects. Particularly, higher doses and 
long term levodopa use leads to motor complications such as wearing off of symptom control 
before the next dose and period when symptoms are not well controlled (motor fluctuations) and 
involuntary wiggling movements (dyskinesia) (Schapira, Emre et al. 2009).  After years of 
levodopa use, the majority of PD patients will be affected by these levodopa-induced motor 
complications (Contin, Riva et al. 1998, Rascol, Brooks et al. 2000, Schrag and Quinn 2000, Van 
Gerpen, Kumar et al. 2006, Antonini, Chaudhuri et al. 2010).  
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In addition to inducing motor complications like fluctuations and dyskinesias, levodopa 
also does not sufficiently improve some motor symptoms of PD like postural instability and 
freezing of gait. There are conflicting reports as to the extent to which levodopa can (Nova, 
Perracini et al. 2004) or cannot (Bronte-Stewart, Minn et al. 2002, Rocchi, Chiari et al. 2002, 
Mancini, Rocchi et al. 2008) influence functional postural control.  However, some recent 
studies acknowledge that while there is some improvement to PD induced postural instability 
while in the “on” medication state, functional postural control deficits still exist causing PD 
patients to continue to be at increased fall risk despite levodopa use (McNeely, Duncan et al. 
2012).  
In addition to levodopa, dopamine agonists and MAO-B inhibitors have also been used to 
treat the motor symptoms of PD either exclusively or in conjunction with levodopa therapy 
(Chaudhuri and Schapira 2009).  Particularly with use during the early stages of PD progression, 
dopamine agonists and MAO-B inhibitors have been shown to provide symptom relief with a 
lower rate of drug-induced motor complications (Antonini, Tolosa et al. 2009). However over the 
long term, dopamine agonists and MAO-B inhibitors compared with levodopa are less effective 
in managing PD symptoms, but also cause less drug-induced motor symptoms like wearing off 
and dyskinesia (Stacy and Galbreath 2008).   
Surgical Therapy 
Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) or the globus pallidus 
interna (GPi) was first implemented in the early 1990’s as a surgical treatment to improve motor 
symptoms in advanced PD patients (Bronstein, Tagliati et al. 2011). The DBS leads are most 
commonly implanted into the STN or GPi (Hickey and Stacy 2011). Studies have also 
investigated the possibility of the pedunculopontine nucleus (PPN) as a target for DBS in PD 
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patients (Thevathasan, Coyne et al. 2011). DBS of the STN and GPi has been demonstrated to 
improve motor function and reduce dopaminergic drug and PD symptoms like motor 
fluctuations, dyskinesia, rigidity, tremor and bradykinesia (Benabid, Chabardes et al. 2009, 
Hickey and Stacy 2011, Thevathasan, Coyne et al. 2011). Eligibility criteria include: a PD 
diagnosis, motor fluctuations or dyskinesia that cannot be controlled with medication or 
medication adjustments and no significant behavioral or cognitive disorders (Morgante, 
Morgante et al. 2007, Bronstein, Tagliati et al. 2011).   
Physical Therapy 
Studies have investigated the effectiveness of standard physical therapy (PT), exercise, 
balance and gait training programs on reducing mobility impairments and increasing quality of 
life in PD(Stankovic 2004, Nieuwboer, Kwakkel et al. 2007, King and Horak 2009, Allen, 
Canning et al. 2010, Hickey and Stacy 2011, Maki, Sibley et al. 2011, Ransmayr 2011, Morris, 
Martin et al. 2012, King, Salarian et al. 2013, Harro, Shoemaker et al. 2014). While these studies 
have not been able to completely prevent falls, improvements have been observed in balance and 
gait measures for some biomechanical task assessments (Stankovic 2004, Protas, Mitchell et al. 
2005, King and Horak 2009).   
Specifically, Stankovic et al. studied the effect of a 30 day PT program and reported 
improvements in balance measures. While this study was not able to show the effect on falls, it 
did find an improvement in measures used to classify patients as fallers. In addition to PT, gait 
training involving intensive treadmill training and Nordic walking have been shown to improve 
quality of life and gait speed in PD (Herman, Giladi et al. 2007). Although mobility impairments 
caused by PD have been shown to be difficult to treat with medication therapy (Bloem, Beckley 
et al. 1996, Lang and Lees 2002), when standard PT is provided in addition to medication 
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therapy, some benefit is realized in quality of life related to mobility (Morris 2000). Therefore 
standard PT moderately impacts mobility impairments, suggesting that PD specific therapy 
designed to directly target the source of the mobility impairment may be more effective in 
addressing mobility impairments in PD. 
 
Postural Instability  
Postural instability, one of the cardinal motor symptoms of PD, is characterized by flexed 
posture that occurs due to a decrease in postural reflexes. Postural stability is regulated by the 
nervous system through continual adjustments in the body’s center of mass due to both internal 
and external stimuli (Lord 2007). Postural instability is defined as the impairment of these 
postural reflexes, resulting in decreased balance and increased fall risk (Tugwell 2008). Postural 
instability typically occurs later in the disease progression and is particularly disabling due to its 
link to increased fall risk (Bloem, Grimbergen et al. 2001, Olanow, Watts et al. 2001, 
Michatowska, Fiszer et al. 2005).  
Current Clinical Assessments 
Current clinical tests to assess postural instability and/or balance impairment include 
UPDRS item 27 (arising from a chair), item 28 (posture), item 29 (gait), item 30 (response to a 
posterior displacement, “Pull Test”) as well as steady stance positions (2-leg stance, tandem 
stance, single-leg stance, and single leg stance with arms above head) (Fahn, Elton et al. 1987, 
Visser, Marinus et al. 2003). Specifically, for example, posture UPDRS testing consists of a 
rating scale between 0-4 to assess deficits. Below is an outline of the rating scale used to assess 
posture with the UPDRS: 
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0 = Normal erect. 
1 = Not quite erect, slightly stooped posture; could be normal for older person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side. 
4 = Marked flexion with extreme abnormality of posture.(Goetz, Tilley et al. 2008) 
Similarly, postural instability is assessed by the Pull Test with a “Response to sudden, strong 
posterior displacement produced by a pull on the shoulders while the patient is erect with eyes 
open and feet slightly apart” and is also rated on a scale of 0-4 based on the following criteria: 
0 = Normal. 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner. 
3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
While such tests are easily applied in a clinical setting, the qualitative assessment criteria and 
gross-level rating scale do not allow for a detailed or quantitative analysis of balance and 
postural deficits. While these tests are proficient at assessing the severity of postural control 
deficiencies once balance symptoms have progressed, they are less effective in the prediction of 
a future fall if one has not yet occurred (Bloem, Beckley et al. 1998, Bloem, Grimbergen et al. 
2001).  
 
Fall Risk 
Effect of Falls 
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Decreased postural control and the resultant increased fall risk in PD are particularly 
incapacitating because of the impact on activities of daily living and quality of life. Falls in PD 
are debilitating because they lead to further complications like fractures (Martin 2011, Matinolli, 
Korpelainen et al. 2011), nursing home admission (Michatowska, Fiszer et al. 2005, Voss, Elm et 
al. 2012), and increased morbidity (Morens, Davis et al. 1996).  Even if no serious injuries are 
sustained, fear of falling following a fall episode increases a patient’s risk of recurring falls and 
decreases quality of life (Voss, Elm et al. 2012). 
Incidence in PD 
PD patients have an increased risk of falls nine-times that of their healthy counterparts.  
While fall frequency generally increases with increased clinical progression, as PD progresses 
the progressive immobilization may result in a decreased frequency of falls as patients are often 
confined to a wheelchair (Bloem, van Vugt et al. 2001). Overall, reported ranges of around 25-
70% of PD patients fall each year, with the majority of them having more than one falling 
episode (Wood, Bilclough et al. 2002, Wielinski, Erikson-Davis et al. 2005, Voss, Elm et al. 
2012).  Of patients who experience a fall, up to 65% sustained an injury, and of the injured, 75% 
required assistance from a health care provider (Wielinski, Erikson-Davis et al. 2005). Such high 
fall rates and the subsequent injuries and need for assistance in PD patients not only reflect the 
risk of serious risk of injury due to a fall, but the expensive cost of falls on the health care system 
in general.  
Implementation of Fall-Reduction Interventions 
Despite the well documented adverse consequences, prevention of falls is still one of the 
greatest unmet challenges in PD because interventions typically do not occur until after a fall 
episode has occurred (Bloem, Grimbergen et al. 2001), largely due to the fact that current clinical 
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assessments are not sensitive enough to predict when a patient first becomes at risk to fall 
(Bloem, Beckley et al. 1998). Although there are targeted therapies that can successfully reduce 
fall risk (Visser, Marinus et al. 2003, Segev-Jacubovski, Herman et al. 2011, Morris, Martin et 
al. 2012), such interventions are expensive and time consuming for both the patient and provider.  
Therefore, because current assessments are not predictive of fall risk (Bloem, Grimbergen et al. 
2001), such therapies are typically not prescribed until after a fall has already occurred, making 
the best current predictor of a future fall a history of falling.  
Types of Fall Intervention Therapies 
Largely, multi-factorial programs seem to show promise in effectively reducing fall risk 
in PD and elderly patients (Rao 2005, Voss, Biglan et al. 2008, Harro, Shoemaker et al. 2014).  
Other recent studies have tested some novel and targeted balance and fall-risk therapies such as: 
home-based exercise programs (Ashburn, Fazakarley et al. 2007), treadmill gait and step training 
(Protas, Mitchell et al. 2005), group exercise (Allen, Canning et al. 2010), tai chi (Marjama-
Lyons, Smith et al. 2002), and virtual reality (Hausdorff, Mirelman et al. 2010).  With such a 
wide range of therapeutic techniques showing a reduction in fall risk, once a reliable method to 
predict fall risk is established, these targeted therapies can provide significant improvements to 
PD patient outcomes and quality of life.  If targeted biomechanical assessments are utilized that 
can detect postural control deficits prior to a history of falling, then fall interventions can be 
implemented at the appropriate time. Such an assessment system could help eliminate the current 
obstacle to receiving therapy.  With an accurate prediction of being at risk of falls, prescribing 
patients such interventions could avoid undue cost or time for patients and providers.  
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Biomechanics 
 
Postural Control  
The postural control system of the body is responsible for the maintenance of balance, 
posture equilibrium, and the biomechanical support to execute movements (Massion 1998). 
Effective postural control relies on the incorporation of both neural and musculoskeletal systems: 
namely, the vestibular, visual, proprioceptive, and sensory systems (Palmieri, Ingersoll et al. 
2002, Lacour, Bernard-Demanze et al. 2008). Postural position is maintained through adjusting 
postural control and tone to account for gravity, standing surface, and visual input.  Postural 
balance is maintained following internal or external perturbations to stability through integrating 
sensorimotor processes to control the body’s center of mass (COM) (Horak 2006).  The relation 
of the COM to the body’s base of the support (the feet for a standing task) is crucial for the 
maintenance and control of balance. When the COM is within the base of support during a 
standing task, the body is in equilibrium- or in a state of balance.  
For biomechanical assessments, the whole-body center of pressure (COP) is often used to 
assess postural control. The COP path is comprised of the point location of the vertical ground 
reaction force vector obtained from a force platform.  The forces of the body on the force plate 
are dependent on the placement of the foot as well as the motor control of the muscles in the 
ankle. Physiologically, the COP is considered the neuromuscular response of the body to 
perturbations or changes of the COM location. Thus, the COP is directly affected by the 
acceleration of the COM, which is caused by muscle activations and gravity.   The COP position 
is calculated by: 
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𝑪𝑂𝑃 = √(−
𝑀𝑦 + 𝐹𝑥 ∗ 𝑑𝑧
𝐹𝑧
)
2
+  (
𝑀𝑥 − 𝐹𝑦 ∗ 𝑑𝑧
𝐹𝑧
)
2
 
where Fx and Fy are the force parallel to the  top of the force plates, Fz is the force perpendicular 
to the force plates,   Mx and My are the moments parallel to the  top of the force plates, and dz is 
the distance below the top surface at which the origin in located (Palmieri, Ingersoll et al. 2002, 
Winter 2009). 
1
 
While current clinical assessments are able to assess postural control deficits later in the 
disease progression, they are not sufficiently sensitive to predict fall risk in the early stages of 
PD (Bloem, Beckley et al. 1998, Bloem, Grimbergen et al. 2001).  Quantitative biomechanics-
based studies have investigated postural instability and balance deficits in PD with laboratory 
based measures such as force plates, motion systems, and electromyography. Such experimental 
measures can allow for more quantitative and complex analysis to assess kinematic, kinetic, 
temporal and muscular responses compared to currently available clinical assessments.  
These biomechanical assessments of postural stability in those with PD have focused on a 
range of quasi-static and dynamic tasks including postural sway, gait initiation, and balance 
recovery (Hass, Waddell et al. 2005, Horak, Dimitrova et al. 2005, Blaszczyk, Orawiec et al. 
2007, Buckley, Pitsikoulis et al. 2008, Mancini, Horak et al. 2011, Stylianou, McVey et al. 2011, 
Ickenstein, Ambach et al. 2012, Mancini, Carlson-Kuhta et al. 2012, Stegemoller, Buckley et al. 
2012, Greve, Luna et al. 2014, Harro, Shoemaker et al. 2014). Because postural control is a 
multifactorial system, recent studies also suggest incorporating multiple tasks and UPDRS items 
for the assessment of balance can prove more effective at predicting past fall history. However, 
                                                     
1
 Appendix B. COP calculations provides an in-depth explanation of the calculation of the center of pressure in the 
anterior-posterior and  medial-lateral directions. 
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the majority of these studies have not been linked to the effects of disease progression and the 
ability to use parameters to determine preclinical postural instability if the patient does not have 
a history of falls (Jacobs, Horak et al. 2006, Kim, Allen et al. 2013).  
 
Postural Sway 
Biomechanical assessment of postural control using force plates, that measure the force 
and moment reactions the body exerts on the ground, has been performed since the 1970’s. The 
effects of biologic factors and pathologies such as age, neurological disease, visual/auditory 
input, and injuries have been examined using biomechanical parameters extracted from standing 
tasks (Palmieri, Ingersoll et al. 2002). Specifically, postural sway has been investigated in PD 
during static, surface translation, and varied visual input standing tasks (Horak, Nutt et al. 1992, 
Horak, Dimitrova et al. 2005, Blaszczyk, Orawiec et al. 2007, Blaszczyk and Orawiec 2011, 
Mancini, Horak et al. 2011, Stylianou, McVey et al. 2011, Ickenstein, Ambach et al. 2012, 
Mancini, Carlson-Kuhta et al. 2012, Revilla, Larsh et al. 2013, Greve, Luna et al. 2014).    
Although various studies have assessed the effect of PD on postural control during a quiet 
standing task, the effect of PD on biomechanical sway parameters, like COP, remains unclear. 
While some studies report that PD results in a decrease in sway parameters (Horak, Nutt et al. 
1992), others suggest that PD increases sway parameters (Blaszczyk, Orawiec et al. 2007, 
Stylianou, McVey et al. 2011, Ickenstein, Ambach et al. 2012, Mancini, Carlson-Kuhta et al. 
2012).  In order for biomechanical parameters of postural sway to be a useful clinical tool to 
assess disease progression and the related fall risk, a better understanding of PD specific deficits 
in these parameters is needed.  Specifically, to identify postural sway parameters that have the 
potential to diagnose fall risk, significant differences must not only be present early in the 
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disease (mild PD, H&Y 2), but also that these parameters must increase with disease progression 
(moderate PD, H&Y 3).  Several groups have found significant differences between PD and HC 
subjects in general, but no groups have isolated mild and moderate PD patients versus healthy 
controls.  
To better quantify and assess postural instability in PD, several groups have performed 
laboratory based studies to assess how PD affects postural control parameters for quiet stance. 
Our lab has performed such a study in which Stylianou et al. analyzed biomechanical sway 
parameters for 19 mild to moderate PD patients (H&Y 1.5-3) compared to HC and found 
significant differences during eyes open (EO) and eyes closed (EC) static stance on a force 
platform. Specifically, 4 COP sway parameters were significantly different in PD compared to 
the age-matched HC: medial-lateral (ML) sway path length, sway area, and anterior-posterior 
(AP) and ML ranges of motion (Stylianou, McVey et al. 2011).  Ickenstein et al. similarly 
studied 12 mild to moderate PD patients (H&Y <3) compared to HC during quiet EO and EC 
stance on a force platform and found that mean COP sway, radius and marked area were greater 
for PD vs. HC (Ickenstein, Ambach et al. 2012). Such findings reinforce the idea that 
biomechanical markers of postural instability show promise as a diagnostic tool in PD balance 
assessment.  
Other studies have related biomechanical parameters to current clinical assessments of 
disease progression and fall risk.  Blaszczyk et al. studied 55 mild to moderate PD patients 
(H&Y 1-3) compared to HC during EO and EC quiet stance on a force platform. PD subjects had 
greater sway area, length, and range compared with HC, with ML sway range magnitude also 
correlating with H&Y scores (Blaszczyk, Orawiec et al. 2007). Matinolli et al. analyzed the 
relationship between postural sway parameters and fall status in 120 PD patients (H&Y 1-3.5) 
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using an inclinometric device. They found that fallers had significantly greater sway area and AP 
and ML ranges of motion (Matinolli, Korpelainen et al. 2007). Further, increased UPDRS scores 
correlated with increased postural sway parameters (Matinolli, Korpelainen et al. 2007). 
The results of these studies are promising because they further support the idea that 
postural sway parameters can help to distinguish differences between PD versus HCs as well as 
fallers versus non-fallers.   Having COP parameters that differ depending on fall status and 
pathology may provide incite as to which parameters are related to disease progression and fall 
risk.  Further, since these parameters correlate with UPDRS, H&Y, or other clinical scores, this 
suggests that postural sway parameters can be promising candidates for assessing disease 
progression related to fall risk. Unfortunately however, because these studies do not isolate mild 
and moderate patients relative to HC, it is still unclear if such deficits can be detected in the early 
stages of disease progression compared to HC. In order for biomechanical assessment of postural 
sway to be useful in predicting fall risk, such parameters must be correlated to disease 
progression, sensitive to a decrease in subclinical postural stability, and specific to fall risk.   
 
Gait Initiation  
 Gait initiation involves an individual starting in a quasi-static stance, the task described 
above for postural sway, and then the initiation of a step to begin steady-state gait. Gait initiation 
involves the postural control system because an individual must transition from a state of 
equilibrium or balance, where the COP is within the base of support, to a constantly unstable 
state during gait. Gait initiation is able to assess motor planning in addition to motor programing 
since there is an execution of a movement (Halliday, Winter et al. 1998).   Biomechanical 
assessment of postural instability through gait initiation using kinetic, kinematic, and 
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electromyographic parameters has been studied for a range of populations to investigate the 
effect of aging, neurological disorders, and injuries (Rosin, Topka et al. 1997, Martin, Shinberg 
et al. 2002, Chang, Chuang et al. 2004, Brunt, Santos et al. 2005, Hass, Waddell et al. 2005, 
Delval, Krystkowiak et al. 2007). Specifically, gait initiation has been investigated in PD in a 
range of conditions including: no cue, visual-cued, and auditory-cued (Rosin, Topka et al. 1997, 
Martin, Shinberg et al. 2002, Hass, Waddell et al. 2005, King, St George et al. 2010, 
McCandless, Evans et al. 2010, Muniz, Liu et al. 2010, Hass, Buckley et al. 2012, Muniz, Nadal 
et al. 2012, Rocchi, Carlson-Kuhta et al. 2012). 
 Several studies have found significant differences between PD and HCs for both temporal 
and kinematic parameters. Rosin et al. demonstrated that following an auditory cue, PD patients 
compared to HCs have an increased preparation time (time from start signal to motion onset) as 
well as a smaller second step (of the first stride).  These findings suggest that postural instability 
deficits in PD may also be due to motor planning difficulties (Rosin, Topka et al. 1997).  Martin 
et al. investigated the difference between 12 mild to moderate PD (H&Y 1-3) subjects compared 
to young and age-matched HCs.  The group divided the gait initiation movement (from first 
initiation of movement until immediately prior to toe-off of the first step) into 5 stages, and 
found that the COM-COP distance for PD during 4 of these 5 events was significantly smaller 
than the HCs (Martin, Shinberg et al. 2002).  Hass et al. studied the difference between PD 
patients with H&Y ≤ 2 and H&Y ≥2.5 during a verbally cued gait initiation task.  Gait initiation 
was divided into 3 stages, and the COM-COP peak distance was significantly less with increased 
H&Y score for the final stage of the gait initiation: when the COP moved anteriorly under the 
stance foot (at the end of the when the first foot takes a step, but before the foot touches the 
ground) (Hass, Waddell et al. 2005).   
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These results support that gait initiation biomechanical postural parameters have potential 
to distinguish differences between PD versus HCs as well as changes with disease progression.   
Having parameters that differ depending on pathology or disease severity may provide insight as 
to which parameters are related to fall risk.  However, because these studies either do not isolate 
mild and moderate patients relative to HC, or only look at these parameters within PD, it is still 
unclear if such deficits can be detected in the early stages of PD compared to HC. In order for 
gait initiation parameters to be early indicators of postural instability and therefore fall risk, these 
deficits must be demonstrated as different from HC in the early stage of the disease. 
 
Balance Recovery 
 In addition to self-initiated tasks like postural sway and gait initiation, an individual’s 
ability to respond to an external perturbation that disrupts balance and postural stability is 
another key component of decreasing fall risk. Researchers have looked at the response to a 
balance disturbance for various populations such as the elderly and those with neurological 
diseases.  Past research has investigated how biomechanical parameters related to a balance 
disturbance, such as a posterior waist pull, affects those with and without balance impairments. 
Generally, the elderly compared to the young take more steps, take smaller steps, and have a 
lower step height clearance in response to a backwards pull (Luchies, Alexander et al. 1994, 
Schulz, Ashton-Miller et al. 2005).   
 Balance recovery following an external postural perturbation has also been studied in 
those with PD and is the basis for the UPDRS postural instability pull test (Dimitrova, Nutt et al. 
2004, Jacobs, Horak et al. 2006, King, St George et al. 2010, Smith, Jacobs et al. 2012).  
Recently, Smith et al. studied 12 mild to moderate (H&Y 2-3) PD patients compared to HC and 
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their response to a posterior balance disturbance. Those with PD exhibited a slower rate of 
change response of the COP following the external balance disturbance (Smith, Jacobs et al. 
2012).  In a study by King et al., they analyzed the biomechanical response to a backwards 
translational balance disturbance in 17 PD patients (H&Y 1.5-4.0) compared to age-matched 
HCs.  This study found that those with PD, compared to HC took more and shorter steps, used 
more anticipatory postural adjustments, and their COM was more anterior prior to stepping foot 
lift-off (King, St George et al. 2010).  While it is encouraging that PD patients show 
biomechanical deficits when compared to HCs, the relation of these variables to disease 
progression and prediction of fall risk is not addressed. In order for these variables to be helpful 
in predicting fall risk prior to a first fall, the relationship of the biomechanical parameters to 
disease progression must be better understood.  
A pilot study by our lab, McVey et al., has done the preliminary step for this type of 
progression-based analysis, assessing postural instability with biomechanical markers in 
exclusively mild PD patients (H&Y 2, without postural deficits) compared to HC.  This study 
showed that there are several significant differences (p < .05) during a balance recovery task in 
the mild PD group compared to HC.  Specifically, during multiple step responses, mild PD 
caused longer weight shift times (WST), increased dorsiflexion at the ankle, and further posterior 
displacement of the COP prior to foot landing (McVey, Stylianou et al. 2009). Further, in a 
follow up study with moderate PD patients (H&Y 3, with postural deficits), longer WST 
persisted in this group, suggesting that this biomechanical parameter could be a promising 
diagnostic markers of postural instability, and therefore fall risk in PD (McVey, Amundsen et al. 
2013). The natural next step is to determine if disease progression impacts biomechanical 
markers for additional balance tasks and to see if the combination of such biomechanical 
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parameters with existing clinical measures can provide more information about postural 
instability onset and progression through the use of increasingly sophisticated mathematical 
models.   
These quantitative laboratory based studies for a range of balance tasks show that PD 
patients compared to HC have differences in their response to a range of tasks. However the 
study populations have a wide range of disease severities (H&Y 1 - 4) so the relationship of 
these parameters to the early stages of PD is still largely unknown.   By grouping a range of PD 
patients, it is still unclear if these biomechanical parameters are representative of later stage PD, 
or are present throughout the disease progression.  In order for biomechanical parameters of 
postural instability to be predictors of fall risk, parameters present across a wide range of the 
disease must also be present before PD patients have a fall episode, and still present in later 
stages of the disease. Further research is needed to address how these parameters change with 
disease severity for a multi-factorial group of balance assessment tasks. 
 
Principal Component Analysis 
 Because an unmet need in PD is understanding the relationship of biomechanical 
parameters of postural instability across various balance tasks and throughout disease 
progression, a method to elicit the correlations between these variables is needed to gain a better 
understanding of these relationships. Principal Component Analysis (PCA) is such a statistical 
method used to detect and emphasize the similarities, differences and patterns in a data set in 
order to make inferences about a population. PCA involves using a data set of various variables 
to calculate a covariance matrix and the associated eigenvalues and eigenvectors to find the 
direction of maximum variation in the data. The resultant principal components (eigenvectors) 
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are orthogonal matrices that are linear combinations of the ordinal variables that are used to 
make inferences about which variables are primarily responsible for the variation in the data. 
Because each principal component accounts for the effect of each input variable, trends and 
patterns in the data that are not detectable with using each variable independently can be 
determined using PCA (Jolliffe 2002). Therefore, PCA is a useful tool to assess whether patterns 
in a set of variables exist in order to make inferences about across-task correlations and 
population groups.   
 PCA based on biomechanical parameters has recently been shown to help determine 
identifying features for different ages, pathologies and tasks (Rocchi, Chiari et al. 2004, Rocchi, 
Chiari et al. 2006, Labbe, de Guise et al. 2010, Muniz, Liu et al. 2010, Muniz, Liu et al. 2010, 
Mantovani, Lamontagne et al. 2012, Muniz, Nadal et al. 2012, Kobayashi, Hobara et al. 2014). 
PCA has been successfully applied to biomechanical parameters of postural sway and gait 
initiation in PD previously, providing driving variable selection and differentiation of groups 
based on PCA (Rocchi, Chiari et al. 2006, Muniz, Liu et al. 2010, Muniz, Nadal et al. 2012).   
Specifically, PCA has been used in analysis of the quasi-static task postural sway to 
assess feature selection of postural sway characteristics in young healthy adults (Rocchi, Chiari 
et al. 2004) and to assess the impact of “on” versus “off” medication in PD (Rocchi, Chiari et al. 
2006).  In these studies, biomechanical measures of the whole body COP were used as the input 
parameters for the PCA model. COP parameters that reflected the overall COP trajectory and 
variation were found to be the principal drivers of variation within the data set (Rocchi, Chiari et 
al. 2004, Rocchi, Chiari et al. 2006). When comparing the effect of drug therapy (“on” versus 
“off” medication) the 4PCs in the “off” medication state and 3 PCs in the “on” medication state 
accounted for at least 90% of the original variation in the data set (Rocchi, Chiari et al. 2006).   
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In addition to applying a PCA model to postural sway in PD, a study that involved 
members of the current research study (KL and RP) applied PCA modeling to a gait initiation 
task in PD patients with DBS implantation.  PCA was applied to the ground reaction forces 
during gait initiation in 4 different conditions: without treatment, with medication only, with 
stimulation only, and with both medication and stimulation.  Ten PCs explained the overall 
variation in the data set, with 8 being attributed to vertical forces and 2 to horizontal ground 
reaction forces. The standard distance of the resultant PCs was able to differentiate the PD group 
without treatment from the HC as well as the PD group without treatment from the PD group 
with stimulation. The results of this study show promise that PCA can be applied to both better 
understand the variation within a data set, as well as identify attributes related to PD and 
therapeutic (i.e. DBS and medication) states (Muniz, Liu et al. 2010).  
 
Significance 
Since no effective screening method exists to reliably measure fall risk, our team is 
developing a method using laboratory-based measures to detect postural instability before 
recurrent falls manifest. Reducing fall risk in PD is a high priority in the effort to maintain good 
quality of life by allowing continued independence and safe mobility until a treatment is 
discovered which stops the progression of PD and reverses its neurological effects. Determining 
if biomechanical markers for balance tasks of various demands on motor function can provide 
preclinical indication of postural deficits and persist with clinical disease progression is a crucial 
unmet need in PD. And further, through utilizing mathematical modeling to determine which 
biomechanical and clinical parameters are also sensitive to disease severity can potentially 
provide indicators to assess preclinical postural instability and progression. Once the most 
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significant tasks and parameters are identified, this research also has the long term potential of 
translating to a bioinstrumentation development study. Applying the results of this research 
towards a bioinstrumentation device that a clinician can use to assess fall risk quickly and 
accurately would have a direct and tangible positive impact on patient care and the healthcare 
system in general.  
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Figure 2.1. Differences in basal ganglia pathways in a normal versus PD brain due to 
dopaminergic cell loss in the substantia nigra pars compacta (SNc).  Ultimately, this dopamine 
loss of the SNc results in a decreased excitatory signal from the thalmus to the motor area of the 
cerebral cortex. Note: excitatory connections are depicted as open neurons while inhibitory 
connections are shown as filled neurons.  
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CHAPTER 3: Postural Sway as a Measure of Preclinical Postural Instability in 
Parkinson’s Disease 
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Abstract  
Background: Postural instability leading to falls is a debilitating symptom of Parkinson’s disease 
(PD) due to the associated fractures, nursing home placement, and morbidity. However, standard 
clinical assessments are unable to predict falls. Reducing fall risk and fall-related complications 
could positively impact quality of life and life expectancy. While previous studies assessed 
postural instability in PD, an examination of biomechanical parameters to detect preclinical 
postural instability and measure disease progression is lacking. This work investigates the 
efficacy of biomechanical parameters as indicators of preclinical balance deficit and their 
correlation with PD progression.  
Methods: Quiet postural sway was measured in mild PD (n=13), moderate PD (n=10) and age-
range matched healthy controls (HC, n=21) in eyes open and eyes closed conditions.  Foot/floor 
reactions were measured and linear measures of center of pressure (COP) path and velocity were 
calculated.  
Findings: Trajectory (sway path length, sway path area, mean sway speed), variation (medial-
lateral root mean square), and peak (sway path range and peak sway speed) COP measures were 
significantly greater (p < .05) in mild PD versus HC, and further increased in moderate PD.  
Schwab and England clinical score best correlated with the biomechanical COP measures. 
Interpretation: Biomechanical assessment of postural sway may provide preclinical recognition 
of postural instability, providing the missing link in PD fall prediction and the opportunity to 
introduce preventative interventions. To further develop and strengthen postural instability 
detection, biomechanical parameters need to be investigated across balance tests of varying 
motor function demands (quasi-static versus dynamic tasks), along with their persistence 
throughout disease progression and their efficacy in assessing fall risk.   
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Introduction 
Postural instability is a debilitating symptom of Parkinson’s disease (PD) as it leads to 
increased risk of falls (Olanow, Watts et al. 2001, Voss, Biglan et al. 2008). High fall rates in PD 
patients and the associated increased risk of fracture, nursing home admission and morbidity not 
only reflect the serious impact of a fall on health and mobility, but also the significant financial 
impact of falls for both patients and the health care system (Morens, Davis et al. 1996, Rao 2005, 
Martin 2011). Standard clinical assessments are not sufficiently sensitive to predict falls, and 
reducing fall risk in PD could not only delay the associated disability and medical cost, but also 
positively impact patient quality of life and life expectancy (Bloem, Beckley et al. 1998).  While 
targeted therapies that can reduce fall risk are available, they are not commonly implemented 
until after a fall has already occurred owing to the associated cost and time for both patients and 
providers (Palmer, Mortimer et al. 1986, Bloem, Grimbergen et al. 2001, Bloem, van Vugt et al. 
2001).   
Biomechanical assessment of postural control could enhance the efficacy of PD fall 
assessment through the early detection of postural instability and the ability to monitor its 
development and progression. Identifying biomechanical measures to detect the onset of postural 
instability and predict fall risk in PD would provide a quantitative justification to implement fall-
reducing therapies earlier and thus help reduce the associated debilitating fall-related 
consequences (Bloem, van Vugt et al. 2001).  Postural instability in PD can be assessed through 
a range of balance tasks with varying demands on motor control (i.e. quasi-static stance (postural 
sway), surface translation, balance recovery, and gait initiation) (Bloem, van Vugt et al. 2001, 
Kim, Allen et al. 2013).  
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Biomechanical assessment of postural instability during postural sway in eyes open (EO) 
and/or eyes closed (EC) conditions is an attractive option due to ease for clinical implementation 
and previous studies demonstrating its efficacy to distinguish postural deficits in a group of PD 
patients with a range of severities (Hoehn & Yahr stage (H&Y) 1-4) compared to healthy 
controls (HC) (Horak, Nutt et al. 1992, Horak, Dimitrova et al. 2005, Blaszczyk, Orawiec et al. 
2007, Matinolli, Korpelainen et al. 2007, Chastan, Debono et al. 2008, Blaszczyk and Orawiec 
2011, Mancini, Horak et al. 2011, Stylianou, McVey et al. 2011, Ickenstein, Ambach et al. 2012, 
Mancini, Carlson-Kuhta et al. 2012).  However, the effect of PD on biomechanical postural sway 
parameters used to quantify center of pressure (COP) movement characteristics has differed 
across studies. While some studies have reported that PD decreases some COP postural sway 
parameters (Horak, Nutt et al. 1992, Horak, Dimitrova et al. 2005), others report that PD 
increases COP parameters (Blaszczyk and Orawiec 2011, Mancini, Horak et al. 2011, Stylianou, 
McVey et al. 2011, Ickenstein, Ambach et al. 2012, Mancini, Carlson-Kuhta et al. 2012).   
Specifically, previous postural sway studies have shown that COP path trajectory 
measures (i.e. sway path length and area), variation measures (i.e. root mean squared (RMS) of 
COP), and peak measures (i.e. sway path range) increase in PD (H&Y 1-4) compared to their HC 
counterparts (Blaszczyk, Orawiec et al. 2007, Mancini, Horak et al. 2011, Stylianou, McVey et 
al. 2011, Ickenstein, Ambach et al. 2012).  Studies have also found that several COP trajectory 
and peak measures correlate with total Unified Parkinson’s Disease Rating Scale (UPDRS) score 
and medial-lateral (ML) sway path range correlates with H&Y staging (Blaszczyk, Orawiec et al. 
2007, Matinolli, Korpelainen et al. 2007).  It is possible that the differences found between PD 
and HC groups may result from the significant balance deficits often present within the PD group 
in the more severe stages of disease. While past studies have shown the presence of balance 
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deficits in PD patients, which often include a broad spectrum of disease stages, compared to HC, 
no studies have assessed whether such parameters can distinguish the onset of postural instability 
prior to clinical presentation (mild PD, H&Y 2), and if such parameters persist following clinical 
presentation of postural instability (moderate PD, H&Y 3).   
To determine if biomechanical assessment could detect preclinical balance deficits and 
the associated changes with disease progression, this study examined the postural sway of PD 
("on" medication) and HC participants. Postural sway testing requires minimal space to perform 
and lesser demands on motor control than dynamic tasks, making it a feasible task to perform in 
a clinical setting. Further, while the task can be performed “on” or “off “medication, by 
conducting the experiment “on” medication the results should be similar to the data that could be 
collected in routine clinical visits (i.e. no withholding medication). Ultimately in order for 
clinical balance assessment to be comprehensive enough to definitively diagnose the onset of fall 
risk, likely a multi-faceted approach that would cover several dimensions of functional balance 
and clinical measures of disease progression would need to be implemented. The present study is 
a part of a set of studies with the long term goal of developing such a multi-factorial method to 
detect the onset of postural instability through various clinical balance assessments (McVey, 
Stylianou et al. 2009, McVey, Amundsen et al. 2013).   
To address this unmet need in postural instability assessment, this study had three goals.  
First, we investigated the differences between HC and PD (PD patients pooled as a single group), 
a comparison often reported in the literature.  We anticipated that PD, compared to HC, would 
result in greater COP trajectory, variation, and peak measures, consistent with published postural 
sway studies. Second, we stratified our PD patients into mild and moderate PD subgroups to 
identify postural sway biomechanical parameters sensitive enough to detect preclinical balance 
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deficits (mild PD versus HC) and assess their efficacy in monitoring the increasing level of 
postural instability associated with disease progression (moderate versus mild PD). We 
hypothesized that a subset of our COP parameters will be sensitive enough to detect the presence 
of postural instability prior to clinical presentation, and some of these parameters will persist 
with clinical postural instability progression. Third, we explored how these COP measures 
correlate with existing clinical measures of PD progression. We hypothesized that some of the 
postural sway COP measures will correlate with current clinical measures of postural instability 
and disease progression in PD. 
 
Methods 
2.1 Participants 
Twenty three patients with PD and twenty one age-range matched healthy controls 
participated in this study (Table 3.1). A subset of these subjects (n = 12 PD and n = 11 HC) were 
from a previous study which investigated the effect of visual conditions on young healthy, 
elderly healthy and PD (Stylianou, McVey et al. 2011). All individuals gave informed written 
consent as approved by the University’s Institutional Review Board. To characterize the effect of 
PD in general, all PD patients were first considered in a single group; and subsequently in order 
to analyze the effect of postural instability with disease progression, PD patients were divided 
into two groups based on their clinical presentation of postural instability: mild PD group 
(without postural deficits) and moderate PD group (with postural deficits) (Table 3.1).   
PD patients were recruited from the University of Kansas Medical Center (KUMC) 
Parkinson's Disease and Movement Disorder Center. All patients had PD, confirmed by a 
58 
 
neurologist specializing in movement disorders (RP).  PD participants were able to walk without 
assistance, were without severe depression (BDI < 30/63), dementia (MMSE > 24/30), and 
musculoskeletal or neurologic impairments unrelated to PD, had an H&Y score of 2 (mild PD) or 
3 (moderate PD), and had not had neurosurgery for PD.  HC participants were recruited from the 
local community and were without any significant cognitive, musculoskeletal, or neurologic 
impairment.  
2.2 Task 
 The task for this study has previously been published in detail (Stylianou, McVey et al. 
2011). In brief, participants wore standardized footwear and a self-selected natural stance was 
maintained across repeated trials.  Six 30 second postural sway trials (quiet stance with arms at 
sides) were performed with eyes open (EO) or eyes closed (EC) in random order (3 trials per 
condition) (Figure 1a).  PD participants were instructed to maintain their normal medication 
schedule and were tested “on” medication (mean (SD) time since last antiparkinsonian dosage: 
2.1 (1.0) hours). 
2.3 Experimental Measures and Data Analysis 
 Foot/floor kinetic and video data were collected for all postural sway trials.  Kinetic data 
were collected using AMTI six-channel force plates (Advanced Mechanical Technology Inc., 
Watertown, MA, USA) and sampled at 1000 Hz using a 16-bit A/D data acquisition system 
(National Instruments, Austin, TX, USA). Video data were used to ensure subject compliance 
with postural sway task instructions.  
Kinetic data were down sampled to 100 Hz and a low pass second-order Butterworth 
filter was applied with a 12.5 Hz cutoff frequency.  Whole body COP path and velocity was then 
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calculated for each trial (Figure 1b). COP path was calculated from the output signals of the 
force plates in the anterior-posterior (AP) and medial-lateral (ML) direction and COP velocity 
was calculated with a fourth order accuracy derivate of the COP path.  COP trajectory, variation, 
and peak parameters (Table 2) were derived from these measures to quantify postural sway 
characteristics for each participant (MATLAB, Natick, MA, USA).  
2.4 Clinical Measures 
PD subjects were assessed by a specialist from the KUMC Parkinson's Disease and 
Movement Disorder Center, using the following clinical measures (Table 1): 
Unified Parkinson's Disease Rating Scale (UPDRS): assessment of the overall 
progression of PD characterized by: Mentation, Behavior and Mood; Activities of Daily Living; 
and a Motor Examination.  Scores can range from 0 – 180, with higher scores reflecting greater 
impairment.  
Motor Exam: the third section of UPDRS completed by the investigator, that assesses 
motor symptoms related to PD. Scores can range from 0 – 108, with higher scores reflecting 
greater impairment. 
Pull Test (Postural Stability, UPDRS item 33): assessment of how a patient responds to a 
sudden posterior pull in order to characterize the patients' overall postural stability. Scores can 
range from 0 – 4, with higher scores reflecting greater impairment (Fahn, Elton et al. 1987, 
Goetz, Poewe et al. 2003).  
Schwab and England: estimation of the ability to independently perform activities of 
daily living. Scores can range from 100 – 0%, with 100% being completely 
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independent/essentially normal and lower scores reflecting greater dependence (Schwab and 
England 1969). 
2.5 Statistical Analyses: 
T-tests were used to compare baseline demographic and disease severity characteristics 
between groups. Two types of statistical analysis were used to assess the outcome parameters of 
this study.  
First, all individual data means were analyzed using repeated measures Analysis of 
Variance (ANOVA) with group (mild PD, moderate PD, HC) as factors for both EO and EC trials. 
Significant group differences (p < .05) were determined with an ANOVA, Tukey-Kramer multiple 
comparison post hoc tests when appropriate, and a Bonferroni correction for multiple comparisons. 
Second, because we anticipated our PD groups to have high variation (large within group standard 
deviations) for COP measures as has been observed in past literature (Blaszczyk and Orawiec 
2011, Stylianou, McVey et al. 2011, Mancini, Carlson-Kuhta et al. 2012), in order to account for 
this possibility of systematically high variations,  a “normal” threshold was utilized to compare the 
HC to PD groups.  
The HC group mean plus one standard deviation (SD) for each of the biomechanical 
parameters was calculated and then served as a threshold for comparison of the “normal” 
parameter values versus the corresponding parameter values within the mild PD and moderate PD 
groups. Each subjects’ parameters were then compared to this “normal” threshold set to determine 
if the subject fell above (greater than the HC threshold, reflecting increased postural instability 
compared to controls) or below (less than the HC threshold, no difference in postural instability 
compared to controls).  A Fischer’s exact test with a Bonferroni correction for multiple 
comparisons was used to test for significant differences across groups (p < .05) (SAS 9.4, SAS 
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Institute Inc., Cary, NC). Lastly, a Spearman rank correlation analysis was used to characterize the 
relationship between the mean experimental postural sway parameters and the clinical parameters 
for the PD participants (SAS 9.4, SAS Institute Inc., Cary, NC). 
 
Results 
The COP trajectory, variation, and peak postural sway measures were first considered for 
both the general PD (n = 23) versus HC (n = 21) groups and then further analyzed for the mild 
PD (n = 12) and moderate PD (n = 11) subgroups versus HC (n = 21) to explore the relationship 
of these parameters to postural instability. No significant differences in anthropometric data (age, 
height or mass) were found between the groups and these data were not considered further.  
3.1 Effect of PD on Postural Sway Parameters 
Trajectory Measures: During EO and EC trials, sway path length, AP and ML sway path 
length, and mean sway speed were significantly greater (p < .05) in the PD group compared to 
HC.  Sway area was significantly greater in the PD population compared to HC for EO trials but 
not for the EC trials (p = .0556). (Table 3) 
Variation Measures: The PD group compared to HC had significantly greater (p < .05) 
AP RMS of COP during EO and EC trials. ML RMS of COP was significantly greater for PD 
than HC only during EO trials. (Table 3) 
Peak Measures: During EO and EC trials, AP and ML sway path range and peak sway 
speed were significantly greater (p < .05) in the general PD group compared to HC. (Table 3) 
3.2 Effect of Postural Instability on Postural Sway Parameters 
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Trajectory Measures: For both EO and EC trials, the moderate PD group accounted for 
the differences between the PD population and HC (p < .05) for sway path length, AP and ML 
sway path length, sway area, and mean sway speed.  Sway path length, ML sway path length, 
and mean sway speed were all significantly greater in moderate PD compared to mild PD for EO 
and EC conditions. While all trajectory measures trended towards higher means for mild PD 
compared to HC, there were no significant differences between these groups for any trajectory 
measures. (Table 3) 
Variation Measures: For both EO and EC trials, the moderate PD group accounted for 
the differences (p < .05) between the PD population and HC for AP RMS of COP. AP RMS of 
COP was all significantly greater in moderate PD compared to mild PD for both visual 
conditions. Both variation measures trended towards higher means for mild PD compared to HC, 
but there were no significant differences between mild PD and HC for either measure. (Table 3) 
Peak Measures: For the EO trials, AP sway path range was significantly greater (p < .05) 
in the mild PD compared to the HC group.  AP sway path range further increased for the 
moderate PD group, and was significantly greater (p < .05) than the HC group but was not 
significantly different from the mild PD group. For the EC trials, the moderate group accounted 
for the differences from the HC group (p < .05) in AP sway path range.  The moderate PD group 
also accounted for the differences from the HC group in ML sway path range for the EO trials. 
Lastly, while the moderate PD group explained the increased peak sway speed in the EO trials, 
the mild PD group had a significantly faster peak sway speed compared to the HC population for 
the EC trials. Peak sway speed further increased for the moderate PD group for EC trials, and 
was significantly greater (p < .05) than the HC group but was not significantly different from the 
mild PD group. (Table 3) 
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3.3 Effect of Threshold Analysis on Early Postural Instability Indication for Postural Sway 
Parameters 
Trajectory Measures: For the EO trials when comparing the PD groups to the “normal” 
threshold  (mean + SD of the HC mean), there were significantly more mild PD participants 
above the threshold compared to HC for sway path length, sway area, and mean sway speed (p < 
.05). There were no significant differences between the HC and mild PD groups for trajectory 
measures during EC trials (Table 4).  
Variation Measures: For the EO trials, there were significantly more mild PD 
participants exhibiting increased postural instability (above the threshold) compared to HC for 
ML RMS of the COP, however there were no significant differences in these groups during EC 
trials (Table 4).  
Peak Measures: While there were no significant differences between the HC and mild PD 
group for the EO peak parameters, mild PD had a significantly greater frequency of participants 
above the threshold for ML sway path range compared to HC during EC trials (Table 4).  
3.4 Clinical Correlation with Postural Sway Parameters 
Schwab and England score had the highest correlation with the postural sway parameters 
with 7/10 (EO condition) and 6/10 (EC condition) biomechanical parameters being significantly 
correlated (p < .05) with the Schwab and England score. The UPDRS Motor score was 
significantly correlated (p < .05) with 6/10 biomechanical parameters for EO trials and 1/10 for 
EC trials. AP sway path range was the only biomechanical parameter that significantly correlated 
(p < .05) with the total UPDRS score.  Only AP RMS of COP for EC trials was significantly 
correlated with the Pull Test (Postural Stability, UPDRS item 33). (Table 5) 
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Discussion 
This study sought to investigate if a quasi-static biomechanical task could detect 
preclinical postural instability in PD and if changes in postural instability with disease 
progression could be observed. Understanding the effect of PD on postural sway has received 
much attention recently, with studies demonstrating the efficacy of biomechanical parameters to 
distinguish differences between PD and healthy controls (HC) (Blaszczyk and Orawiec 2011, 
Mancini, Horak et al. 2011, Stylianou, McVey et al. 2011, Ickenstein, Ambach et al. 2012, 
Mancini, Carlson-Kuhta et al. 2012), the effects of antiparkinsonian medication (Nantel, 
McDonald et al. 2012, Revilla, Larsh et al. 2013, Greve, Luna et al. 2014), the effect of surgical 
intervention (Krishnamurthi, Mulligan et al. 2012, Nantel, McDonald et al. 2012), and the effects 
of physical therapies (Li, Harmer et al. 2012, King, Salarian et al. 2013).   
This work provides the next step in biomechanical assessment of postural sway in PD 
through investigating if such parameters could serve as biomarkers of early postural deficits. By 
considering postural sway with both eyes opened and closed, this study provided additional 
information as to how PD affects postural control with (and without) reliance of vision to 
stabilize postural control across the clinical progression of postural instability (Chagdes, Rietdyk 
et al. 2009). Parameters that both identify preclinical postural deficits and measure changes in 
postural instability over the course of PD would allow clinicians to identify at risk PD patients 
before they begin to fall and develop interventions to prevent or reduce falling throughout the 
disease course. Sensitive and specific biomarkers of postural instability would also be valuable 
for properly placing PD participants in therapeutic clinical trials. 
4.1 Effect of PD Compared to HC  
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The characteristic, variation, and peak measures from this study were all significantly 
different for the general PD group compared to HC (Figure 1, Quadrant I) and are comparable to 
previously reported values in the literature for both eyes opened and closed trials (Blaszczyk, 
Orawiec et al. 2007, Matinolli, Korpelainen et al. 2007, Chastan, Debono et al. 2008, Ickenstein, 
Ambach et al. 2012, Mancini, Carlson-Kuhta et al. 2012).  Some of the means reported in the 
current study such as sway path length and sway path area are higher than those in previous 
studies, but this is likely due to the large observed variation (standard deviations) across PD 
participants for these parameters and differences in the inclusion/exclusion criteria used across 
studies.  This study included PD patients in the H&Y stages 2-3, where other studies often also 
include PD patients at the less severe H&Y stage 1.   
Further, sway measures in the AP direction tended to be better at discriminating between 
PD and HC than in the ML direction, which is in contrast to studies that have suggested that the 
ML direction may be an equally effective indicator of postural instability changes in PD. These 
differences may be related to methodological differences between studies. For example, if the 
stance width was controlled by placing the feet together, the feet may have been closer compared 
to a natural stance; or if subjects were barefoot compared to wearing a standard shoe, any of 
which could affect ML values compared to this study in which subjects self-selected their stance 
wearing footwear (Mitchell, Collins et al. 1995, Viitasalo, Kampman et al. 2002, Blaszczyk, 
Orawiec et al. 2007, Matinolli, Korpelainen et al. 2007). 
4.2 Effect of Postural Instability Clinical Presentation (mild and moderate PD) Compared to HC 
When comparing the groups based on group means per parameter (ANOVA analysis), 
during both the EO and EC trial conditions the trajectory and variation measures did not reflect 
evidence of preclinical postural instability (mild PD versus HC).  The differences between PD 
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and HC for these parameters were explained by the moderate PD group (H&Y 3) which had 
clinical presentation of postural instability (Figure 2, Quadrant II). Sway path length, ML sway 
path length, mean sway speed and AP RMS of COP were significantly greater in the moderate 
PD group compared to the mild PD group, and therefore, these parameters may be specific to 
clinical progression of postural instability (Figure 2, Quadrant III).  Yet because the mild PD 
group was not significantly different compared to the HC group for these parameters, for this 
mode of analysis they were not sensitive enough to detect preclinical postural instability (Figure 
2, Quadrant III and IV).  
However, the peak measures of AP sway path range (EO trials) and peak sway speed (EC 
trials) did show evidence of preclinical postural instability (Figure 2, Quadrant IV). Despite no 
clinical presentation of postural instability, mild PD had increased AP sway path range and peak 
sway speed that showed evidence of diminished postural control versus HC, and these 
parameters progressed in moderate PD. With visual feedback available (EO trials), increased AP 
sway path range reflected larger excursions of postural control. With visual feedback removed 
(EC trials), increased peak sway speed reflected larger instantaneous changes, possibly reflecting 
an adoption of a more stiff postural control strategy. 
4.3 Threshold Analysis for Early Postural Instability Indication for Postural Sway Parameters 
When comparing the mild and moderate PD groups to the HC group based on the 
“normal” threshold (HC mean + SD), we sought to eliminate the impact of the large variability 
present within the PD groups. By definition, H&Y staging bins subjects based on relative 
postural instability deficit due to PD and is not a continuous measure like postural sway 
biomechanical measures.  As a result, by nature of how our groups were clinically defined in 
combination with the small sample size of this pilot study, our PD groups as expected had larger 
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amounts of variability within their groups (larger group standard deviations) compared to the HC 
group. Through using this “normal” threshold, we hypothesized that similar to the precedent of 
other clinical measures that also rely on a “normal” threshold (i.e. BMI for obesity classification) 
that such threshold analysis may help to significantly elicit the observed trends in the overall 
group means for the mild PD group compared to HC, reflecting preclinical indication of postural 
instability. 
Using the threshold analysis, the frequency of mild PD patients that had larger COP 
parameter values than the “normal” threshold compared to HC was significantly greater (p < .05) 
for trajectory (sway path length, sway area and mean sway speed for EO trials), variation (ML 
RMS of COP for EO trials), and peak parameters (ML sway path range for EC trials) (Figure 2. 
Quadrant IV). However despite these observed differences between the HC and mild PD group, 
this method of group comparison was unable to differentiate between the mild and moderate PD 
groups. While this result is expected due to the nature of this pilot study (small sample size) and 
the definition of the threshold,
2
 this suggests that while both statistical methods help to elicit 
early detection of postural instability in PD, future study with larger sample sizes is needed to 
better understand the sensitivity and specificity of these parameters related to postural instability 
and fall risk in PD.     
4.4 Parameter Selection of Early Postural Instability Onset Methods 
Analysis based on individual subject means (Section 4.2) and thresholds (Section 4.3) 
uniquely provided evidence of preclinical postural instability in mild PD compared to HC. When 
comparing individual means, only peak parameters (AP sway path range and peak sway speed) 
                                                     
2
 A threshold analysis with the mean + 2 SD was also calculated in the preparation of this manuscript to test the 
robustness of the parameters and to see if mild to moderate PD differentiation could occur, however no results were 
significant so they are not presented here. See Appendix B.i. for this additional analysis results. 
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revealed significant differences between mild PD and HC while for the threshold analysis 
trajectory parameters (sway path length, sway area, mean sway speed) had the most significant 
differences. These observed trends are likely possible for two reasons. First, the functional limits 
of sway path range and peak sway speed likely have tighter physiological constraints in order to 
maintain upright balance. There is most likely a limit to the increase in the COP excursions 
and/or increase in COP speed before balance is lost, potentially explaining the smaller within 
group variability for these measures and associated significance when comparing individual 
means. Conversely, trajectory measures are cumulative and are additive over the whole trial, 
explaining why small differences in an individual subject can magnify over 30 seconds, 
potentially explaining the large within group variability and thus significant results only when 
using threshold analysis. Using multiple methods of feature selection may help to account for 
these fundamental differences in the overall nature of the parameters observed, providing greater 
incite as to the subtle changes that may occur early in the disease progression. 
Trajectory, variation, and peak COP postural sway parameters show promise as 
biomarkers for detecting postural instability earlier in PD, however they are unavailable during 
current clinical assessment of postural stability. Because these parameters cannot be quantified 
by visual inspection, use of biomechanical technology in the clinical setting may allow for 
additional information during balance assessment. The ability to detect subtle changes in postural 
control with these parameters may provide early indication of postural instability onset, 
providing additional information for PD fall prediction and the opportunity to introduce fall risk 
interventions.  
4.5 Clinical Correlation  
69 
 
Schwab and England scoring had the strongest correlation with the postural sway 
biomechanical measures, with over half of the biomechanical parameters correlating with this 
clinical score for both EO and EC trials. The Schwab and England score is a measure of 
independent performance of activities of daily living and is not directly based on postural 
stability; however, the correlation of these scores with the biomechanical parameters warrants 
further exploration into this score and the associated correlation with postural instability during 
quasi-static stance. Further, AP sway path range, the biomechanical marker that showed earlier 
evidence of postural instability during the EO trials, was significantly correlated with all 
measured clinical scores except the Pull Test (Postural Stability, UPDRS item 33).  Interestingly, 
despite AP sway path range appearing to be a good indicator of early postural instability during 
EO postural sway, the current clinical measure of postural stability (the Pull Test) is not 
reflective of these differences. If these measures are reflecting task-specific deficits, potentially a 
static measure of postural instability (like postural sway) coupled with existing dynamic 
measures of postural instability (i.e. the Pull Test) could provide further information to assess a 
patient’s overall motor control and balance deficits.  
Limitations of this study include the small sample size, the potential influence of outliers, 
that PD participants were tested "on" medication, and that the balance assessment task was quasi-
static. While it is recognized that outliers can significantly impact the variability of the data for a 
small sample size, the systemic large variations within the PD groups (based on H&Y staging) 
may also demonstrate the need for alternate, more quantitative based parameters to limit within-
group variability when scoring patients.  Because of the clinically driven nature of this research, 
these choices were made in order to reflect a potential clinical balance assessment that is possible 
to implement and does not require patients to alter their dosing schedule (“on” medication) so the 
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task could be more easily translated to routine clinical care. However, future studies should 
include “off” medication assessments or inclusion of de novo subjects to determine if 
medications are masking subtle changes in balance that may further enhance the detection of 
those at risk for postural instability and falling.  In future studies, larger sample sizes are also 
needed to determine if biomechanical parameters can distinguish preclinical postural instability 
for activities of varying demands on motor function (e.g. postural sway, balance disturbances, 
gait initiation, and steady state gait), and if these parameters persist throughout disease 
progression. Further analysis with increasingly sophisticated mathematical models may help 
establish the threshold where the onset of postural instability can be confirmed from multiple 
biomechanical and clinical measures.   
 
Conclusion 
This study is a part of an ongoing effort to ascertain biomechanical parameters to identify 
preclinical postural instability in PD patients. Trajectory, variation, and peak postural sway 
measures show promise as parameters that may detect postural instability earlier than current 
clinical assessment as they were significantly greater in the mild PD group compared to HC, and 
these parameter means increased in moderate PD. Once validated, these biomechanical 
parameters could serve as part of a multi-faceted fall risk assessment that would cover several 
dimensions of functional balance and clinical measures of disease progression. Future work with 
larger sample sizes and additional tasks is needed to ensure such parameters are correlated to 
disease progression, sensitive to a decrease in subclinical postural stability, specific to fall risk, 
and simple enough to perform during routine clinical visits.  
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Table 3.1. Mean (SD) Demographic and Clinical Data for Parkinson’s Disease (PD) Subjects and 
Healthy Controls (HC) 
      
I. Subject Demographic Data      
 Gender Age (years) Height (m) Mass (kg)   
HC  M=13, F=8 66 (8) 1.71 (.08) 79 (28)   
PD  M=15, F=8 65 (7) 1.70 (.09)  85 (17)    
Mild PD M=7 , F=6 62 (8) 1.67 (.08) 74 (11)   
Moderate PD  M=8, F=2 68 (4) 1.73 (.10) 95 (15)   
     
II. Parkinson's Disease Specific Participant Data     
 H&Y Score Years 
Since 
Diagnosis 
UPDRS 
Total 
UPDRS 
Motor 
UPDRS  
item 33 
(Pull Test)  
Schwab & 
England 
(%) 
PD  2.4 (.5) 6 (4) 37 (16) 24 (9) 1 (.9) 84 (8) 
Mild PD 2 (0) 6 (5) 28 (13) 20 (7) .3 (.4) 88 (6) 
Moderate PD 3 (0) 7 (3) 48 (11) 30 (8) 1.8 (.6) 79 (7) 
M – male, F – female, H&Y – Hoehn and Yahr, UPDRS – Unified Parkinson’s Disease Rating 
Scale. 
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Figure 3.1. a. Schematic of the experimental setup for the postural sway task. b. Representative 
center of pressure (COP) traces for HC, mild PD, and moderate PD during eyes open (i) and eyes 
closed (ii) trials.  
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Table 3.2. Abbreviations and Descriptions for COP Postural Sway Parameters 
Abbreviation Parameter Name (units) Description 
Trajectory Parameters:  
SPL Sway Path Length (mm) Total distance the whole body COP travels along 
its path in any direction during the postural sway 
task 
AP SPL AP Sway Path Length (mm) Total distance the whole body COP travels along 
its path in the anterior-posterior direction during 
the postural sway task 
ML SPL ML Sway Path Length (mm) Total distance the whole body COP travels along 
its path in the medial-lateral direction during the 
postural sway task 
SA Sway Area (mm
2
) Total area the COP path encompasses during the 
postural sway task 
MSS Mean Sway Speed (mm/s) Average rate of change of the magnitude of the 
center of pressure displacement during the 
postural sway task 
Variation Parameters:  
AP RMS AP RMS of COP (mm) Square root of the mean squared deviation from 
the average COP value in the anterior-posterior 
direction during the postural sway task 
ML RMS ML RMS of COP (mm) Square root of the mean squared deviation from 
the average COP value in the medial-lateral 
direction during the postural sway task 
Peak Parameters:  
AP SPR AP Sway Path Range (mm) Maximum displacement the COP deviates from 
the center point in the anterior-posterior direction 
during the postural sway task 
ML SPR ML Sway Path Range (mm) Maximum displacement the COP deviates from 
the center point in the medial-lateral direction 
during the postural sway task 
PSS Peak Sway Speed (mm/s) Maximum change in the magnitude of the center 
of pressure displacement over time during the 
postural sway task 
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Figure 3.2. Quadrant chart depicting the significance of each center of pressure parameter per 
group comparison and the relative ability of the parameter to reflect progression and preclinical 
indication of postural instability. Parameters listed in each quadrant are significantly different (p 
< .05) for the groups being compared. Parameters not listed in a quadrant did not have significant 
differences for that group comparison. 
Legend: HC – healthy controls, PD – Parkinson’s Disease, SPL – sway path length, AP SPL – 
anterior-posterior sway path length, ML SPL – medial-lateral sway path length, SA – sway area, 
MSS – mean sway speed, AP RMS – anterior-posterior root mean square, ML RMS – medial-
lateral root mean square, AP SRP – anterior-posterior sway path range, ML SPR – medial-lateral 
sway path range, PSS – peak sway speed.
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CHAPTER 4: Principal Component Analysis of Postural Sway for Tracking Preclinical 
Onset and Progression of Postural Instability in Parkinson’s Disease 
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Abstract  
Background: Postural instability is a debilitating Parkinson’s disease (PD) symptom because it 
increases risk of falls and is resistant to current therapies; however, standard clinical assessments 
are unable to predict falls. Biomechanics based assessment with the ability to more quantitatively 
score postural instability onset and progression in PD could fulfill this unmet need.  
Methods: A principal component analysis (PCA) model based on biomechanical center of 
pressure (COP) measures of postural sway and clinical measures of PD progression for mild PD 
(n=13), moderate PD (n=10) and age-range matched healthy controls (HC, n=21) for eyes open 
and closed conditions was calculated.  PCA was first used for parameter selection of inputs 
primarily driving the variation in the data (PCA initial model). Then, a reduced parameter model 
based on the selected parameters (PCA selection model) was calculated to determine if PCA could 
detect preclinical postural instability and its changes with clinical PD progression. 
Findings: Parameter selection resulted in a combination of biomechanical and clinical measures 
(n=5) based on the PCA initial model. The scores of the first principal component (PC 1) for the 
PCA selection models were able to significantly (p < 0.05) differentiate both preclinical postural 
instability (mild PD versus HC) and changes with disease progression (mild PD versus moderate 
PD and moderate PD versus HC).  COP AP sway path length and a velocity measure were the 2 
most influential parameters for PC 1 in both the eyes open and eyes closed PCA selection models.  
Interpretation: PCA based on postural sway biomechanical parameters and clinical measures 
shows promise as a potential modeling tool for more quantitative scoring of postural instability 
progression in PD. Future work that explores PCA for parameter selection and postural 
instability differentiation in PD with larger sample sizes and predictive modeling is needed.   
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Introduction 
Postural instability is one of the most incapacitating symptoms of Parkinson’s disease 
(PD) because it increases fall risk and is resistant to current therapies (Olanow, Watts et al. 2001, 
Michatowska, Fiszer et al. 2005). Unfortunately, falls are currently one of the greatest unmet 
needs in PD because standard clinical assessments are not sensitive to predict falls (Bloem, 
Beckley et al. 1998) and interventions typically do not occur until after a fall episode has 
occurred (Bloem, Grimbergen et al. 2001).  In a recent survey of individuals with Parkinson’s 
disease, their caretakers, and family members, the number one participant priority for future 
research was identified as improving balance and falls (Deane, Flaherty et al. 2014). Accurate 
assessment of postural instability and prediction of fall risk is a crucial need in clinical care of 
PD patients. Biomechanics based assessment with the ability to more quantitatively score 
postural instability onset and progression in PD could fulfill this unmet need.  
Recognizing that balance maintenance is a complex system, finding a single parameter 
from a balance assessment task that provides a definitive diagnosis of postural deficit onset in 
PD is considered unlikely.  Rather, considering the cumulative effect of biomechanical 
parameters with additional clinically available measures is likely necessary.  In order to have a 
means to combine biomechanical and clinical parameters with the goal of subject differentiation, 
a method to elicit the cumulative effect of the variation within these variables across both healthy 
controls (HC) and PD participants is needed to gain a better understanding of these relationships. 
Principal Component Analysis (PCA) is such a statistical method used to detect and emphasize 
the similarities, differences and patterns in a data set in order to make inferences about a 
population group.  
85 
 
PCA with a correlation matrix structure involves using a data set of various (normalized) 
variables to calculate a correlation matrix and the associated eigenvalues and eigenvectors to find 
the direction of maximum variation in the data. The resultant principal components (eigenvector, 
PCs) are orthogonal matrices that are linear combinations of the ordinal variables used to make 
inferences about which variables are primarily responsible for the variation in the data. Because 
each principal component accounts for the cumulative effect of all the input variables, trends and 
patterns in the data that are not detectable when considering each variable independently can be 
determined using PCA (Jolliffe 2002, Abdi and Williams 2010). Therefore, PCA shows promise 
as a useful tool to assess whether patterns in a set of variables exist in order to make inferences 
about population groups.   
Recent studies have shown the efficacy of using PCA on biomechanical parameters to 
extract information about the traits of static and dynamic tasks (Rocchi, Chiari et al. 2004, 
Rocchi, Chiari et al. 2006, Labbe, de Guise et al. 2010, Muniz, Liu et al. 2010, Mantovani, 
Lamontagne et al. 2012, Muniz, Nadal et al. 2012, Kobayashi, Hobara et al. 2014). PCA based 
on biomechanical parameters has had the ability to select the primary features and variables 
driving the variation in a data set, as well as differentiate different pathologies (Landry, McKean 
et al. 2007, Labbe, de Guise et al. 2010, Muniz, Liu et al. 2010, Muniz, Nadal et al. 2012, 
Kobayashi, Hobara et al. 2014). Specifically, PCA has been used in analysis of the quasi-static 
task postural sway to assess feature selection of postural sway characteristics in young healthy 
adults (Rocchi, Chiari et al. 2004) and to assess the impact of “on” versus “off” medication in 
Parkinson’s disease (Rocchi, Chiari et al. 2006).  In these studies, parameters that reflect the 
overall center of pressure (COP) trajectory and variation were found to be the principal drivers of 
variation within the data set (Rocchi, Chiari et al. 2004, Rocchi, Chiari et al. 2006).  
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Additionally, traditional biomechanical assessment of the postural sway task in PD 
through COP measures has shown promise as this task can distinguish postural deficits in PD for 
a range of severities (Hoehn & Yahr stage (H&Y) 1-4) compared to healthy controls (HC)  
(Horak, Dimitrova et al. 2005, Matinolli, Korpelainen et al. 2007, Chastan, Debono et al. 2008, 
Blaszczyk and Orawiec 2011, Stylianou, McVey et al. 2011, Ickenstein, Ambach et al. 2012, 
Mancini, Carlson-Kuhta et al. 2012).  While no previous studies addressed the use of postural 
sway for preclinical postural instability indication, a recent study by our laboratory found that 
several trajectory (i.e. COP sway path length), variation (root mean square of COP) and peak 
postural sway parameters (peak COP sway path speed) were able to detect preclinical evidence 
of postural instability in PD patients without clinical presentation of postural instability (mild 
PD, H&Y 2 versus HC). And further, these parameters continued to increase with disease 
progression (moderate PD, H&Y 3, with clinically present postural instability, was significantly 
different than HC, and their mean values trended higher than mild PD). However, no individual 
parameter was able to reach statistical significance in detecting both preclinical onset of postural 
instability (mild PD versus HC) and specificity to clinical disease progression (mild PD versus 
moderate PD) (Barnds Dissertation Chapter 3).  
Past studies reflect the ability of PCA to be successfully applied to the postural sway task, 
and postural sway shows promise as a potential indicator of preclinical postural instability in PD. 
However, no studies have assessed whether PCA could be a valuable tool to score the overall 
progression of postural instability related to preclinical onset and clinical disease progression of 
postural instability. To address this unmet need in tracking the onset and progression of postural 
instability, this study used PCA modeling toward two goals: parameter selection and group 
differentiation.  
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Toward our first goal, our object was to determine if PCA based on biomechanical and 
clinical parameters could reduce the number of variables needed to explain the overall variation 
in the data. Based on a PCA model with clinical (i.e. Unified Parkinson’s Disease Rating Scale 
(UPDRS), Schwab and England scores) and biomechanical (i.e. COP trajectory, variation, peak 
postural sway measures) parameters as inputs, we performed a feature selection process on the 
PCA model to determine which parameters were primarily responsible for the variation in the 
overall data set. We hypothesized that a combination of clinical and biomechanical parameters 
would account for the variation in the data for the HC, mild PD and moderate PD participants. 
For our second goal, we sought to determine if a PCA model based on parameter selection could 
not only detect preclinical balance deficit (HC versus mild PD), but that the PCA model would 
also reflect postural instability progression in PD (mild PD versus moderate PD). We 
hypothesized that some of the resultant principal component scores (eigenvectors) would be able 
to differentiate both early onset and progression of postural instability with increasing PD 
progression.   
 
Methods 
2.1 Participants 
The methods and materials for the biomechanical task of this study have been previously 
published in detail (Stylianou, McVey et al. 2011). A brief description of them follows. All 
participants gave informed written consent as approved by the University’s Institution Review 
Board. Thirteen participants with mild PD (H&Y 2; age 62 ± 8.2 years; height 1.7 ± .10 m; mass 
76 ± 13 kg), ten participants with moderate PD (H&Y 3; age 68 ±3.9 years; height 1.7 ±.10 m; 
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mass 95 ±17 kg) and twenty one age-range matched healthy controls (age 66 ±7.5 years; height 
1.7 ±.10 m; mass 79 ±28 kg). A subset of these participants (n = 12 PD and n = 11 HC) were a 
part of a previous study looking at the effect of Parkinson’s disease on traditional measures of 
postural sway during different visual conditions (Stylianou, McVey et al. 2011). 
PD participants were recruited from the KUMC Parkinson's Disease and Movement 
Disorders Clinic and had their PD diagnosis confirmed by a movement disorder specialist (RP).  
PD participants were able to stand on their own, did not have significant depression (BDI < 
30/63), dementia (MMSE > 24/30), musculoskeletal or neurologic impairments unrelated to PD, 
deep brain stimulators and had an H&Y score of 2 (mild PD) or 3 (moderate PD).  HC 
participants were recruited in the local community and did not have any significant 
musculoskeletal, neurological or cognition deficits. 
2.2 Task 
 Participants self-selected a natural stance and then foot position was marked and 
controlled.  They were instructed to stand still in a natural upright position with their arms at 
their sides for a total of six 30 second postural sway trails with their eyes open or eyes closed in 
random order (Figure 1a). To control the visual field, subjects were instructed to focus on a 
target six feet in front of them during eyes open trials. PD participants were instructed to 
maintain their normal medication schedule and were tested “on” medication (time since last 
antiparkinsonian dosage: 2.1 ± 1.0 hours). 
2.3 Experimental and Clinical Measures 
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 Foot/floor kinetic and video data were collected for all postural sway trials.  Kinetic data 
were collected using two six-channel AMTI force plates (Advanced Mechanical Technology 
Inc., Watertown, MA, USA) and sampled at 1000 Hz using a 16-bit A/D data acquisition system 
(National Instruments, Austin, TX, USA). Video data were used to ensure subject compliance 
with postural sway task instructions.  
Kinetic data were down sampled to 100 Hz and a low pass second-order Butterworth 
filter was applied with a 12.5 Hz cutoff frequency.  Whole body COP path and velocity was then 
calculated for each trial (Figure 1b.). COP path was calculated from the output signals of the 
force plates in the anterior-posterior (AP) and medial-lateral (ML) direction and COP velocity 
was calculated with a fourth order accuracy derivate of the COP path.  COP trajectory, variation, 
and peak parameters were derived to assess postural sway characteristics for the HC and PD 
participants (MATLAB, Natick, MA, USA). The total unified Parkinson’s disease rating scale 
(UPDRS), the pull test (UPDRS item #33), and Schwab and England clinical assessments were 
performed by a movement disorders specialist for all PD participants. Table 1 contains brief 
descriptions of the clinical and biomechanical parameters obtained in this study.  
2.4 Data Processing for PCA Analysis  
Because PCA maximizes the variation within the data, the inputs must have equal 
variance to avoid undue influence of certain parameters caused by different mean values or units. 
Therefore, because the biomechanical and clinical input data had different units, the data were 
first centered along their mean using the z-score standardization: 
𝑧𝑠𝑐𝑜𝑟𝑒  =  (𝑅𝑎𝑤 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 – 𝑀𝑒𝑎𝑛 𝑃𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟)/( 𝑆𝑇𝐷𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟) 
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such that the sample mean equals zero and standard deviation equals one for each input 
parameter.  
2.5 PCA Analysis 
The use of PCA to model the data had two goals. First, feature selection to identify which 
parameters best explained the maximum variation in the overall data set related to the 
biomechanical postural sway and clinical parameters (PCA initial model).  Second, the goal was to 
see if these selected features were able to provide differentiation across the 3 groups of interest in 
a reduced data PCA model based on parameter selection (PCA selection model) in order to track 
both earlier onset and the overall progression of postural instability in PD. 
2.5.1 Parameter Selection  
For both the eyes open and eyes closed task conditions, an input matrix was compiled for 
the PCA initial model used as the basis for parameter selection.  The standardized (z score) 
biomechanical and clinical parameters were compiled into an s x p input matrix where the s rows 
corresponded to an individual subject and the p columns corresponded to the standardized 
parameters. PCA was performed on the input matrix with a correlation structure.  PCA initial 
resulted in a total of p eigenvectors (PCs). Each PC maximized the variability of the initial input 
matrix such that it accounted for the weighted linear combination of the initial input parameters 
in a unique orthogonal dimension. Of the resultant p PCs, a total of m PCs were retained based 
off the PCs corresponding eigenvalues such that a certain percentage of the original variance in 
the input data was explained (Jolliffe 2002). While there are many methods to select the number 
of PCs to retain, we selected a 95% threshold due to the exploratory nature of this study and to 
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ensure that our parameter selection captured a significant portion of the overall variation in the 
input data.  
Because the retained m PCs can be difficult to interpret as each PC is a weighted 
combination of all input parameters, parameter selection was performed to reduce the number of 
variables and to help provide meaningful interpretation of the driving input parameters of the 
PCA initial model.
3
 In order to interpret the meaning of the retained PCs, the parameters that most 
explained the derived PCs were binned.  There are several methods for feature selection of PCs 
that are used in a variety of applications. Because the goal of this study was to explain the 
maximum variation within the initial data matrix, we used a commonly implemented method as 
presented by Jolliffe et al that has been previously used in postural sway studies (Jolliffe 1972, 
Jolliffe 1973, Jolliffe 2002, Rocchi, Chiari et al. 2004)
4
. Briefly, parameter selection involved 
associating one parameter that is most influential (largest coefficient) with each of the m retained 
PCs that has not already been associated with a previous PC.  A total of m parameters were 
retained and the remaining p - m parameters were discarded. The retained m parameters help to 
interpret the primary drivers of variation within the data set and were then used as inputs for new 
reduced parameter PCA selection model to determine if the variation in the data can still be 
preserved with a fewer number of variable inputs.  
2.5.2 PCA Model and Analysis Based on Parameter Selection Data Reduction  
                                                     
3
 An in-depth analysis of the original PCA initial model (based on all input parameters) related to group 
differentiation, the physical meaning of the significant principal components, and varimax rotation is included in 
Appendix B.ii. However because the reduced data set resulted in significant group differentiation as well, only those 
results are presented in this manuscript. 
4
 Multiple methods for parameter selection were used in the data analysis prior to this paper: selection based on the 
largest coefficients from the first PC, selection based on the largest coefficients for the first m PCs (presented here), 
deletion based on the largest coefficients from the last p-m PCs, and sparse PCA. Appendix B.ii provides a brief 
description of these methods and the associated parameter results based on these selection criteria. 
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Towards our second goal, following parameter selection of the PCA initial model, a new 
reduced s x m input matrix based on these selected m (standardized) parameters as columns and 
the s rows corresponding to an individual subject was compiled for the PCA selection model.  PCA 
based on the reduced dimension s x m input matrix with a correlation matrix structure was 
performed to obtain the PCA selection model.  Through considering the reduced parameter PCA 
selection model, we sought to determine if these retained parameters that influence the variation in 
the overall data set are also effective in differentiating the onset and progression of postural 
instability.  Of the resultant m PCs, a total of n PCs were retained based off the PCs 
corresponding eigenvalues such that at least 95% of the original variance in the reduced input 
data was explained. If the resultant PCs (eigenvectors) result in significantly different confidence 
intervals for the HC, mild PD and moderate PD groups, the PC and corresponding parameters 
may be primary indicators of early onset and progression of postural instability in PD.  Group 
differences for PC scores were determined with ANOVA (p<0.05) and Tukey-Kramer post hoc 
tests (SAS). 
 
Results 
3.1 PCA initial Model Parameter Selection  
3.1.1 Eyes Open Postural Sway Model 
For the correlation matrix based PCA initial model with standardized clinical and eyes 
open biomechanical parameter inputs, m = 5 PCs explained 97.3% of the variation in the original 
input data. Three eyes open postural sway biomechanical parameters (AP sway path length, AP 
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sway range, and peak sway speed) and 2 clinical parameters (UPDRS and Pull Test) were the 
parameters with the largest coefficients associated with each subsequent PC.  Table 4.2a 
provides the eigenvectors of the correlation matrix for the first m = 5 PCs for the EO PCA 
model. 
5
 
3.1.2 Eyes Closed Postural Sway Model 
The PCA with a correlation matrix structure for the eyes closed postural sway model also 
resulted in m = 5 PCs that explained 96.9% of the variation in the original input data. For the 
parameter selection based on the largest coefficient per PC, 4 eyes closed biomechanical 
parameters (AP sway path length, ML sway path length, mean sway speed and AP RMS of COP) 
and 1 clinical (UPDRS) were most representative of the first m = 5 PCs. Table 4.2b shows the 
eigenvectors of the correlation matrix for the retained PCs for the EC PCA model. 
6
 
3.2 PCA selection Model Group Differentiation and Physical Meaning 
3.2.1Eyes Open Postural Sway Model 
Group Differentiation 
Based on the results from the eyes open PCA initial model parameter selection, 5 
standardized input parameters (AP sway path length, AP sway range, and peak sway speed, 
UPDRS, Pull Test) made up the columns for the input data matrix for the correlation structure 
PCA selection model.  The first n = 4 PCs explained at least 95% of the overall variation of the 
                                                     
5
 In Appendix B.ii., the exact values of the eigenvectors per PC are listed for the eyes open PCA initial model; 
however for the ease of determining overall trends in the data a plus and minus system is presented here to ease 
interpretation and inferences. 
6
 In Appendix B.ii, the exact values of the eigenvectors per PC are listed for the eyes closed PCA initial model; 
however for the ease of determining overall trends in the data a plus and minus system is presented here to ease 
interpretation and inferences. 
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input data matrix.  To assess the PCA selection model’s differentiation of the three study population 
groups (HC, mild PD, and moderate PD), the resultant scores (the representation of the input data 
in the rotated coordinate system for each PC) per group were tested for significant differences. 
PC 1 scores for all group pairwise comparisons (HC v. mild PD, HC v. moderate PD, mild PD v. 
moderate PD) were significantly different (mean (SD): HC -1.99 (.56), mild PD 0.47 (1.64), 
moderate PD 3.56 (3.58), p < .05)
7
. The 95% confidence intervals for PC1 scores for the HC 
versus Mild PD and Moderate PD groups were unique, with the HC confidence intervals of-2.24 
≤ θ ≤ -1.74, mild PD: -0.52 ≤ θ ≤ 1.46, and moderate PD: 1.00 ≤ θ ≤ 6.02.  No other PCs were 
able to differentiate all group pairwise comparisons for the eyes open PCA selection model.  
Physical Meaning of Retained PCs from the PCA selection Model
8
 
Physical analysis of PC1, the eigenvector that explained 66% of the variance in the data 
and was able to differentiate between the HC, mild PD and moderate PD groups, shows that AP 
sway path length and peak sway speed were the 2 primary parameters influencing the PC based 
on their coefficients. Figure 3a shows representative plots of the 2 primary parameters for this 
PC for the subjects with the smallest and largest score for this PC. As demonstrated by Figure 3a, 
PC 1 is representative of the COP motion in the AP direction and the peak sway speed, while it is 
also affected by the other 3 parameters on similarly high levels, any component could potentially 
characterize this PC. For PC 2, which explained 18% of the variance in the parameter selection 
PCA model, this PC was primarily explained by a clinical (Pull Test score) and biomechanical 
(peak sway speed) measure. PC 3, which explained 9 % of the variation of the model, was 
                                                     
7
 A comprehensive list of the means and SDs for all n = 5 PCs scores by subgroup for the eyes open PCA selection 
model is provided in Appendix B.ii. Because no other PCs provided the same level of differentiation as PC 1, only 
these mean (SD) are mentioned in this paper.  
8
 A varimax rotation to the resultant PCs was also performed in an attempt to increase the interpretability of the PCs, 
but due to the small initial data set the improvement in the interpretation was negligible. The resultant rotated PCs 
and the corresponding parameter coefficients are provided in Appendix B.ii. 
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primarily driven by AP sway path range, thus reflecting differences in peak anterior-posterior 
excursion across subjects during the eyes open postural sway trials.  
3.2.2 Eyes Closed Postural Sway Model 
Group Differentiation 
Based on the results from the eyes closed PCA initial model parameter selection, 5 
standardized input parameters (UPDRS, AP sway path length, ML sway path length, mean sway 
speed, and AP RMS of COP) made up the parameter inputs for the reduced data input matrix for 
the correlation structure PCA selection model.  The first n = 4 PCs explained at least 95% of the 
overall variation of the input data matrix.  In order to assess the ability of the PCA selection model 
to score and differentiate the study population groups (HC, mild PD, and moderate PD), the 
resultant scores per PC were tested for significant differences. PC 1 scores for all group pairwise 
comparisons (HC v. mild PD, HC v. moderate PD, mild PD v. moderate PD) were significantly 
different (mean (SD): HC -1.97 (.54), mild PD 0.47 (2.28), moderate PD 3.61 (3.59), p<.05)
9
. 
The 95% confidence intervals for PC1 scores for the HC group was -2.22 ≤ θ ≤ -1.72, mild PD: -
1.85 ≤ θ ≤ 0.99, and moderate PD: 1.04 ≤ θ ≤ 6.18.  No other PCs were able to differentiate all 
group pairwise comparisons for the eyes closed PCA selection model. 
Physical Meaning of Retained PCs from the PCA selection Model
 
 
Qualitative analysis of PC1 from the eyes closed PCA selection model, which explained 
75% of the variance in the input data and was able to differentiate between the 3 study groups 
had AP sway path length and mean sway speed as the 2 primary parameters (largest coefficients) 
                                                     
9
 A comprehensive list of the means and SDs for all n = 5 PCs scores by subgroup for the eyes open PCA selection 
model is provided in Appendix B.ii. Because no other PCs provided the same level of differentiation as PC 1, only 
these mean (SD) are mentioned in this paper. 
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influencing this PC. Figure 2b shows representative plots of the 2 primary parameters for PC 1 
for the subject with the minimum and maximum score for this PC. As demonstrated by Figure 
2b, PC 1 is representative of the COP motion in the AP direction and the mean sway speed, 
while it is also affected by the other 3 parameters in a similar direction on a lesser level. For PC 
2, which explained 11% of the variance in the parameter selection PCA model, this PC was 
primarily explained by UPDRS Total score, indicating PC2 primarily is a descriptor of clinical 
disease progression. PC 3, which explained 8 % of the variation of the model, was primarily 
driven by ML sway path length, thus reflecting differences in overall medial-lateral movement of 
the COP across subjects during the eyes closed postural sway trials 
 
Discussion 
This work sought to determine if PCA modeling of biomechanical and clinical 
parameters could provide more quantitative scoring of both preclinical onset and progression of 
postural instability in PD.  PCA based on biomechanical parameters has recently been shown to 
help determine identifying features for different ages, pathologies or tasks (Rocchi, Chiari et al. 
2004, Rocchi, Chiari et al. 2006, Labbe, de Guise et al. 2010, Muniz, Liu et al. 2010, Mantovani, 
Lamontagne et al. 2012, Muniz, Nadal et al. 2012, Kobayashi, Hobara et al. 2014). Specifically, 
PCA has been successfully applied to postural sway in PD previously, with this PCA application 
exclusively looking at biomechanical parameters of PD patients and the effect of drug therapy 
(“on” versus “off” medication) (Rocchi, Chiari et al. 2006).   
This present study had the goal of looking for preclinical indicators of postural instability 
in PD compared to HC based on both biomechanical and clinical parameters. This present work 
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takes the next step towards this goal in PCA modeling of postural sway in PD through 
investigating if PC scores based on parameter selection of biomechanical and clinical measures 
could serve as biomarkers of early postural deficits. By modeling postural sway with both eyes 
opened and closed conditions, this provided additional information as to how PD affects postural 
control with (and without) reliance of vision to stabilize postural control across the clinical 
progression of postural instability (Chagdes, Rietdyk et al. 2009). PC scores that both identify 
preclinical postural deficits and differentiate changes in postural instability across PD 
progression would allow clinicians to identify at risk PD patients before they begin to fall and 
develop more timely interventions. Sensitive and specific biomarkers of postural instability 
would also be valuable for properly placing PD participants in therapeutic clinical trials. 
4.1 PCA Feature Selection Analysis 
Variable selection of the PCA initial model for both the eyes open and eyes closed models 
resulted in a combination of biomechanical and clinical parameters as the driving variables of the 
model. This is a promising result as this may suggest that the biomechanical and clinical 
parameters are not redundant, and both are providing unique information about the overall 
variation observed in the HC, mild PD, and moderate PD participants. As the Total UPDRS 
score is a comprehensive measure of overall disease progression, it is not surprising that this 
measure is one of the extracted features for explaining the variation across subjects for both the 
eyes open and eyes closed PCA initial model. More generally, both eyes open and eyes closed 
PCA initial models resulted in measures that described the overall path trace (i.e. AP sway path 
length) and the velocity of the COP during the trial (i.e. peak sway speed for eyes open or mean 
sway speed for eyes closed). 
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Specifically for the eyes open PCA initial model, the biomechanical features extracted 
based on variable selection were a combination of COP trajectory and peak measures.  While for 
the eyes closed PCA initial model, the extracted biomechanical measures were a combination of 
COP trajectory and variation measures. These parameters suggest that during eyes open postural 
sway, the increased variation in the PCA initial model was at least partially due to larger 
excursions of postural control (evidenced by AP sway path range and peak sway speed).   For 
eyes closed postural sway, part of the variation in the PCA initial model can be explained by 
increased variation in the subjects COP movement during the trial (evidenced by AP RMS of 
COP), perhaps reflecting a stiffer postural control strategy.  
4.2 PCA Model Based on Parameter Selection 
4.2.1 Group Differentiation and Physical Meaning of the PCs 
Eyes Open Postural Sway Model 
Although no individual input parameter for the PCA models could provide differentiation 
of both postural instability onset (HC versus mild PD) and also significantly change with clinical 
disease progression (mild PD v. moderate PD and HC v. moderate PD), PC 1 score of the PCA 
selection model was able to do so. PC1 explained 66% of the variance in the model based on the 
weighted cumulative effects of AP Sway path length, AP sway range and peak sway speed, 
UPDRS Total score and Pull Test score. The variance in these input parameters across groups are 
at least partly explained by postural instability progression due to PD as the PC 1 scores resulted 
in significant differences for all comparisons of mean HC versus mild PD versus moderate PD. 
While the other PCs for the eyes open PCA selection model missed significance for all pairwise 
group comparisons, considering the large amount of variation explained by PC 1 it is promising 
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that the input parameters for this model may have the potential to provide additional information 
about postural instability progression in PD.  
Eyes Closed Postural Sway Model 
Similarly to the eyes open PCA models, no individual input parameters could provide 
differentiation of both postural instability onset (HC v. mild PD) and also significantly progress 
with disease clinical progression (mild PD v. moderate PD and HC v. moderate PD). However, 
PC 1 score of the eyes closed model based on the weighted cumulative effects of AP Sway path 
length, ML Sway path length, mean sway speed, AP RMS of the COP and UPDRS Total score 
was able to do so. PC 1 of the eyes closed PCA selection model explained 75% of the variance in 
the model, and considering the significant differences in all group comparisons the variance in 
these parameters across groups are at least partly explained by postural instability progression 
due to PD. Despite no other PCs for the eyes closed PCA selection model exhibiting significance in 
all group pairwise comparisons, considering the very high overall variation explained by PC 1 it 
is promising that the input parameters for this model may have the potential to retain the 
variation within the original data while still providing information about postural instability 
progression in PD.  
Interestingly, despite both the eyes open and eyes closed models having some differing 
input parameters for their respective PCA selection models, in the resultant PC 1 for both eyes open 
and eyes closed, the two parameters with the largest coefficients for this significant PC were very 
similar across tasks. In both visual conditions, AP sway path length and a velocity measure (peak 
sway speed for eyes open and mean sway speed for eyes closed) were the 2 parameters weighted 
most heavily in PC 1 for their respective PCA selection models.  Despite AP sway path length and 
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COP velocity impacting the variation in the PD and HC groups, and thus helping detect postural 
instability earlier in PD, they are unavailable during current clinical assessment of postural 
stability. COP path and velocity parameters cannot be quantified by visual inspection, therefore 
use of biomechanical technology in the clinical setting may allow for additional information 
during balance assessment.  Despite this present study having a differing research question and 
population group to a recent study by Rocchi et al (where they looked at the effect of levodopa 
exclusively in PD participants), our work found similarities to the driving parameters of this 
study.  Mean sway speed and AP sway path range that explained our overall group variation 
(parameter selection) similarly were determined to be driving parameters in the Rocchi study for 
the “on” medication PD model from their study (Rocchi, Chiari et al. 2006). Future work that 
explores these parameters, and all variables selected via parameter selection would provide incite 
as to how sensitive and specific these parameters are to both onset of postural instability and 
clinical PD progression.  
Limitations of this work included the small sample size, that the balance assessment task 
used for the PCA model inputs was quasi-static, and that PD participants were only tested in the 
“on” medication state. These task choices were made due to the clinically driven nature of this 
research. In order for a balance assessment model to be effective in a clinical setting, not 
requiring patients to alter their dosing schedule (“on” medication) could provide easier 
implementation in routine clinic visits. However, future studies with larger sample sizes should 
also include “off” medication assessments to better understand if medication can be masking 
small changes in postural stability that may help facilitate earlier detection of fall risk. With 
larger sample sizes, predicting the scores of subjects based on biomechanical and clinical input 
parameters could help test the robustness of the confidence intervals for the PCs that are able to 
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differentiate the PD groups versus controls. Also, applying such methods to a range of functional 
balance assessments such as gait initiation or balance recovery could provide further information 
based on how postural instability in PD detection changes with quasi static (i.e. postural sway) 
versus dynamic (i.e. balance recovery) tasks. 
 
Conclusions 
This study investigated the use of PCA based on parameters from a quasi-static 
biomechanical task and clinical outcome measures for the detection of preclinical postural 
instability and differentiation of its changes in PD. Parameter selection of the PCA initial model 
found a combination of biomechanical and clinical parameters were the primary drivers of 
variation in the HC and PD participants. The PC 1 scores for both the eyes open and eyes closed 
PCA selection models were able to significantly differentiate early onset and clinical progression of 
postural instability in PD. In both eyes open and eyes closed models, AP sway path length and a 
velocity measure were the primary drivers of the PCA that was able to differentiate the HC and 
PD groups. Future study for a wider range of functional tasks with larger sample sizes as well as 
predicative PCA modeling to test the robustness of PCA to score patients based on postural 
instability severity is needed. 
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Figure 4.1. a. Schematic of the experimental setup for the postural sway task. b. Representative 
center of pressure (COP) changes for HC, mild PD, and moderate PD during eyes open (i) and 
eyes closed (ii) trials. Note the increase in the COP trace with disease progression, and the 
increase in COP trace with task condition (eyes closed > eyes open). 
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Table 4.1. Parameter Name (units, prior to standardization) and Description for the PCA Model Input 
Parameters  
 
Biomechanical Parameters  
Sway Path Length 
(mm):  
Total distance COP travels along its path during postural sway task 
AP Sway Path 
Length (mm):  
Total distance COP travels along its path in anterior-posterior (AP) direction during 
postural sway task 
ML Sway Path 
Length (mm):  
Total distance COP travels along its path in medial-lateral (ML) direction during postural 
sway task 
Sway Area (mm
2
):  Total area the COP path encompasses during postural sway task 
Mean Sway Speed 
(mm/s):  
Average rate of change of the magnitude of COP displacement during postural sway task 
AP RMS of COP 
(mm):  
Square root of the mean squared deviation from average COP in AP direction during 
postural sway task 
ML RMS of COP 
(mm):  
Square root of the mean squared deviation from average COP in ML direction during 
postural sway task 
AP Sway Path Range 
(mm):  
Maximum displacement COP deviates from center point in AP direction during postural 
sway task 
ML Sway Path 
Range (mm):  
Maximum displacement COP deviates from center point in ML direction during postural 
sway task 
Peak Sway Speed 
(mm/s): 
Maximum change in magnitude of COP displacement over time during postural sway 
task 
 
Clinical Parameters:  
Unified Parkinson's 
Disease Rating Scale:  
Assessment of overall PD progression.  Scores can range from 0 – 180, with higher 
scores reflecting greater impairment. 
Motor Exam:  
Third section of UPDRS, assesses motor symptoms related to PD. Scores can range from 
0 – 108, with higher scores reflecting greater impairment. 
Pull Test:   
UPDRS item # 33 assessment of how a patient responds to sudden posterior pull to 
characterize patients' overall postural stability. Scores can range from 0 – 4, with higher 
scores reflecting greater impairment. 
Schwab and 
England:  
Estimation of ability to independently perform activities of daily living. Scores can range 
from 100 – 0%, with 100% being independent (normal) and lower scores reflecting 
greater dependence 
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Table 4.2. Coefficients and Relative Variance Explained for Retained PCs in Eyes 
Open and Eyes Closed PCA initial Models  
Eyes Open PC 1 PC 2 PC 3 PC 4 PC 5 
UPDRS (+)    (-)*  (-) 
Schwab and England (-) (+) (+)   
Motor Exam (+)  (-)  (-) 
Pull Test (+)  (-)    +* 
Sway Path Length (+) (+)    
AP Sway Path Length (+)   (+)*    
ML Sway Path Length (+) (+)  (+)  
Sway Area (+) (-) (+) (+)  
Mean Sway Speed (+) (+)    
AP RMS of COP (+) (-)  - (+) 
ML RMS of COP (+) (-) (+) (+)  
AP Sway Path Range (+) (-)    -*  
ML Sway Path Range  (+)  (+) (+)  
Peak Sway Speed   (+)* (+)   (-) 
      
Variance Explained by PC (%) 61 15.63 14.27 4.08 2.28 
      Eyes Closed PC 1 PC 2 PC 3 PC 4 PC 5 
UPDRS (+)   (-)*    
Schwab and England (-) (+) (-)   
Motor Exam (+) (-) (+)  (+) 
Pull Test (+) (-)  (+)  
Sway Path Length (+)  (-) (+)  
AP Sway Path Length (+)    (-)*   
ML Sway Path Length (+)     +*  
Sway Area (+) (+) (+)   
Mean Sway Speed   (+)*  (-) (+)  
AP RMS of COP (+)      -* 
ML RMS of COP (+) (+) (+)   
AP Sway Path Range (+)  (-)   
ML Sway Path Range  (+) (+) (+)   
Peak Sway Speed (+)  (-)   
      
Variance Explained by PC (%) 66.1 15.4 9.8 3.1 2.5 
Table Key:  + signifies a parameter coefficient of 0.5 or greater (strong positive effect) 
  (+) signifies a parameter coefficient between 0.2 to 0.5 (mild positive effect) 
   - signifies a parameter coefficient of -0.5 or less (strong negative effect) 
  (-) signifies a parameter coefficient between -0.2 to -0.5 (mild negative effect) 
  * indicates the parameter per PC retained (largest coefficient) for the PCA selection model.
108 
 
 
 
 
Figure 4.2. a. Transformed subject scores plotted on the principal component (PC) 1 versus PC 2 
axes (top) and the relative contribution (coefficients) of each input parameter normalized to the 
most influential variable (bottom) for the eyes open PCA selection model. b. Transformed subject 
scores plotted on the principal component (PC) 1 versus PC 2 axes (top) and the relative 
contribution (coefficients) of each input parameter normalized to the most influential variable 
(bottom) for the eyes closed PCA selection model.   
A red star on the coefficient bar graphs indicates being one of the 2 most influential parameters 
for PC 1. Key: red x – HC subject score, green o – mild PD subject score, blue + - moderate PD 
subject score. 
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Table 4.3.Coefficients and Relative Variance Explained for Retained PCs in Parameter 
Selection Based Eyes Open and Eyes Closed PCA Models 
Eyes Open     
 PC1 PC2 PC3 PC4 
UPDRS (+) (+)  + 
Pull Test (+) + (-) - 
AP Sway Path Length (+) (-) (-)  
AP Sway Path Range (+)  + (-) 
Peak Sway Speed (+) -   
     
Variance Explained Per PC (%) 66.20 18.36 9.28 3.58 
     
Eyes Closed     
 PC1  PC2 PC3 PC4 
UPDRS (+) +   
AP Sway Path Length (+) (-) (+) + 
ML Sway Path Length (+) (-) -  
Mean Sway Speed + (-)  (+) 
AP RMS of COP (+)  (+) - 
     
Variance Explained Per PC (%) 75.25 11.37 7.93 5.40 
 
Table Key:  
 + signifies a parameter coefficient of 0.5 or greater (strong positive effect) 
(+) signifies a parameter coefficient between 0.2 to 0.5 (mild positive effect) 
 - signifies a parameter coefficient of -0.5 or less (strong negative effect) 
(-) signifies a parameter coefficient between -0.2 to -0.5 (mild negative effect) 
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Figure 4.3. a. Representative plots of the 2 variables that are primarily responsible for PC 1 (i. 
peak sway speed and ii. AP sway path length) for the subjects with the smallest (left) and largest 
(right) scores in the eyes open PCA selection model. 3b. shows representative plots for the 2 
variables that are primarily responsible for PC 1 (i. mean sway speed and ii. AP sway path 
length) for the subjects with the smallest (left) and largest (right) scores in the eyes closed PCA 
selection mode
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CHAPTER 5: Gait Initiation in Parkinson’s Disease to Assess Preclinical Postural 
Instability and Progression 
112 
 
Abstract  
Background: Postural instability leading to falls is a debilitating Parkinson’s disease (PD) 
symptom due to fall-related consequences on quality of life and life expectancy. Standard 
clinical assessments are unable to predict falls, whereas reducing fall risk through earlier postural 
instability detection could reduce fall-related complications. Biomechanics based assessment of 
gait initiation with the ability to more quantitatively assess preclinical postural instability onset 
and progression in PD could fulfill this unmet need.  
Methods: Light-cued gait initiation was measured in mild PD (n=10), moderate PD (n=11) and 
age-range matched healthy controls (HC, n=19).  Foot/floor reactions, motion, and 
electromyography data were measured and temporal, kinematic, and center of pressure (COP) path 
and velocity parameters were calculated.  
Findings: Peak COP velocity towards the swing foot during locomotion was significantly 
different (p < .05) in mild PD versus HC. Several temporal, kinematic, and COP measures were 
significantly different (p < .05) in HC versus moderate PD, with increasing trends compared to 
HC in mild PD. Total Unified Parkinson’s Disease Rating Scale (UPDRS) and Pull Test clinical 
scores best correlated with the biomechanical measures of gait initiation. 
 Interpretation: Biomechanical assessment of gait initiation in PD may provide preclinical 
recognition of postural instability. To further develop and strengthen postural instability 
detection, the relationship of biomechanical parameters across balance tests of varying motor 
function demands (quasi-static versus dynamic tasks), along with their persistence throughout 
disease progression, is needed to better quantify their efficacy in assessing fall risk.   
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Introduction 
 Postural instability, one of the cardinal motor symptoms of PD, is characterized by flexed 
posture that occurs due to a decrease in postural reflexes. Postural instability is particularly 
disabling due to its link to increased fall risk (Bloem, van Vugt et al. 2001, Michatowska, Fiszer 
et al. 2005, Olanow, Stern et al. 2009). Current clinical assessments in PD are not sufficiently 
sensitive to predict fall risk, making a history of falls to be the best predictor of a future fall.  
Such retrospective diagnostics are clearly undesirable because nursing home placement increases 
and quality of life and life expectancy decrease after just one fall (Morens, Davis et al. 1996, 
Voss, Elm et al. 2012).  Targeted therapies that can reduce fall risk are available, but are not 
implemented without a fall risk diagnosis owing to the associated cost and time for both patient 
and provider.  In a recent survey of individuals with Parkinson’s disease, their caretakers, and 
family members, participants identified improving balance and falls as their number one priority 
for future research (Deane, Flaherty et al. 2014). 
 Biomechanical assessment of postural instability during a range of static and dynamic 
tasks could potentially address this unmet need in fall risk and postural instability diagnostics as 
recent studies have shown that biomechanical analysis can distinguish postural impairments in 
patients with PD for a range of severities (H&Y 1-4) from healthy controls (HC). These studies 
have demonstrated the presence of postural instability in PD compared to HC, however the 
detection of the onset of preclinical balance deficits remains elusive (Rosin, Topka et al. 1997, 
Halliday, Winter et al. 1998, Hass, Waddell et al. 2005, Jiang and Norman 2006, McNeely and 
Earhart 2013).  Identifying biomechanical measures to predict fall risk in PD would provide a 
quantitative justification to implement fall-reducing therapies prior to a first fall and thus help 
prevent the associated debilitating fractures and morbidities. 
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 Biomechanical assessment of the postural control response during gait initiation could 
provide such an indication of postural instability onset due to its demonstrated efficacy to 
distinguish PD and HC groups. Past work by our lab has demonstrated that a quasi-static task 
(postural sway) can provide such differentiation (Barnds Dissertation Chapter 4) and this work 
seeks to expand such analysis to a dynamic task. Gait initiation, in contrast to a quasi-static 
standing task, may provide additional information because it represents a more challenging task 
involving more complex integration of the postural control system. Gait initiation requires an 
individual to transition from a quasi-static standing state, where the COP is contained within a 
fixed base of support, to a dynamic state during gait, with the COP typically located outside of 
the constantly moving base of support.  
 Specifically, previous studies have assessed postural instability in gait initiation through 
using temporal, kinematic, and center of pressure (COP) parameters in PD for a range of 
conditions including: no cue, visual-cued, and auditory-cued (Rosin, Topka et al. 1997, Martin, 
Shinberg et al. 2002, Dibble, Nicholson et al. 2004, Hass, Waddell et al. 2005, McCandless, 
Evans et al. 2010, Hass, Buckley et al. 2012).   For temporal variables, recent studies have shown 
that PD increases the time to respond to a gait initiation stimulus marked by parameters such as 
delayed onset of movement (Rosin, Topka et al. 1997, Dibble, Nicholson et al. 2004).  PD also 
decreases kinematic parameters like step length when compared to age-range matched healthy 
controls (Rosin, Topka et al. 1997, Halliday, Winter et al. 1998, Dibble, Nicholson et al. 2004).  
During step initiation, COP parameters such as COP displacement decrease in PD when 
compared to their healthy counterparts during the preparatory and locomotor phases of the first 
step (Martin, Shinberg et al. 2002, Dibble, Nicholson et al. 2004). Hass et al. looked at the center 
of mass (COM) response in a lesser impaired PD group (HY < 2.0) and a more impaired PD 
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group (HY >2.5) and found that the peak magnitude of the distance between the COP and COM 
to be significantly greater during the end of the single-support phase in the less disabled patients, 
however this study did not compare the findings to age-range matched healthy controls (HC) 
(Hass, Waddell et al. 2005). 
 The results of these previous studies provide evidence that quantifying gait initiation 
using biomechanical parameters has the potential to distinguish differences between PD and HCs 
as well as some of the parameters being sensitive to disease progression.   Parameters that differ 
depending on pathology or disease severity may provide incite as to which parameters are related 
to fall risk.  However, because these studies either do not isolate mild and moderate PD patients 
relative to HC, or only look at these parameters within a group of PD, it is still unclear if such 
deficits can be detected in the early stages of PD progression compared to HC. In order for gait 
initiation parameters to be useful as early indicators of postural instability and then potentially 
used to assess fall risk, these deficits must be demonstrated to be different from HC in the early 
stage of the disease.  This study sought to determine if gait initiation could detect preclinical 
onset and track changes of postural instability with clinical progression in PD during a cued gait 
initiation task. The assessment of gait initiation could be a valuable component within a multi-
faceted approach covering several dimensions of functional balance and clinical measures in the 
effort to detect the onset and then track the progression of postural instability.   
 To address this unmet need in the assessment of postural instability in gait initiation, this 
study had two goals.  First, we investigated if the temporal, kinematic or COP parameters of gait 
initiation were sensitive enough to detect preclinical balance deficits (Mild PD versus HC) and 
assess their efficacy in monitoring the increasing level of postural instability associated with 
clinical disease progression (Moderate versus Mild PD). We hypothesized that a subset of our 
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parameters will be sensitive enough to detect the onset of postural instability prior to clinical 
presentation, and some of parameters will change with clinical PD progression. Second, of the 
parameters that exhibited significant differences between, HC, mild PD or moderate PD, we 
explored how these parameters correlate with existing clinical measures of PD progression. We 
hypothesized that some of the significant gait initiation measures will correlate with current 
clinical measures of postural instability and disease progression in PD.  
 
Methods 
2.1 Participants 
 Ten participants with mild PD, 11 participants with moderate PD and 17 age-range 
matched healthy controls participated in this study (Table 5.1).  All individuals gave informed 
written consent as approved by the University’s Institutional Review Board.  PD participants 
were recruited from the University of Kansas Medical Center (KUMC) Parkinson's Disease and 
Movement Disorder Center. All patients had PD, confirmed by a neurologist specializing in 
movement disorders (RP).  PD participants exclusion criteria were: needing to walk with 
assistance, severe depression (BDI >30/63), dementia (MMSE < 24/30), musculoskeletal or 
neurologic impairments unrelated to PD, having neurosurgery for PD, and a H&Y score other 
than 2 (mild PD) or 3 (moderate PD).  HC participants were recruited from the local community 
and exclusion criteria were significant cognitive, musculoskeletal, or neurologic impairments.  
2.2 Task  
Participants self-selected a natural stance wearing standardized footwear and stood with arms at 
their sides. Participants were instructed to initiate gait followed by several steps when a “cue” 
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light illuminated, which was located at eye level 8 feet in front of them.  A total of 5 “good” 
trials were collected, where a “good” trial was defined as a trial in which the subjects’ first step 
cleanly landed on the force plate directly in front of them. 
2.3 Experimental Measures 
 Kinetic, kinematic, electromyography (EMG) and video data were collected for all gait 
initiation trials. Foot/floor reaction forces and moments were sampled at 1080 Hz using six-
channel AMTI force plates (Advanced Mechanical Technology Inc., Watertown, MA, USA).  
Kinematic data were sampled at 120 Hz where participants wore bilateral markers on the second 
metatarsal, lateral malleolus, heel, calf, and lateral femoral epicondyle (Figure 1a, Vicon 512: 
Vicon Peak, Lake Forest, CA and Optotrak: Northern Digital, Inc., Waterloo, Canada).  EMG 
data were sampled at 1080 Hz where participants had bilateral surface EMG sensors on the 
tibialis anterior and medial gastrocnemius (Figure 1a, 1080 Hz, Noraxon: Noraxon, Scottsdale, 
AZ and Delsys: Delsys, Boston, MA, USA). Video data were used to ensure subject compliance 
with the gait initiation task instructions and ensure a clean strike of the swing foot on the force 
plate. PD participants were instructed to maintain their normal medication schedule and were 
tested “on” medication (mean (SD) time since last antiparkinsonian dosage: 2.1 (1.0) hours). 
2.4 Data Processing 
 Kinetic and kinematic data were filtered using a low pass second-order Butterworth filter 
with a 20 and 30 Hz cutoff frequency, respectively.  EMG data were full wave rectified and 
filtered using a second order low-pass butterworth filter with a 50 Hz cutoff frequency.  
Temporal, kinematic, and kinetic parameters were calculated for each trial.  All data processing 
was done using a custom-written MATLAB code (MATLAB, Natick, MA, USA).  
118 
 
2.5 Gait Initiation Parameters 
 All gait initiation trials were analyzed from the time of the cue onset to the heel strike of 
the first step (of the swing leg).  Temporal, kinematic, and kinetic parameters were analyzed for 
each participant (Table 2). For the kinetic parameters, whole body center of pressure (COP) path 
and velocity was calculated for each trial. Whole body COP path and velocity was then 
calculated for each trial (Figure 1b.). COP path was calculated from the output signals of the 
force plates in the anterior-posterior (AP) and medial-lateral (ML) direction and COP velocity 
was calculated with a fourth order accuracy derivate of the COP path.   Then, 3 stages based on 
the COP trajectory were defined similar to the methodology proposed by Hass et al (Hass, 
Gregor et al. 2004) (Figure 1): 
Stage 1 (S1): The onset of the cue light to the most lateral shift in the COP towards the swing leg 
Stage 2 (S2): End of Stage 1 to the translation of the COP towards the stance leg when the COP 
begins to move anteriorly under the stance foot 
Stage 3 (S3): End of Stage 2 to the heel strike of the swing foot.  
COP step parameters were calculated for events related to the step liftoff and landing, and COP 
stage parameters were calculated for each of the 3 stages above for all participants (Figure1). 
Sample COP traces for HC, mild PD and moderate PD are shown in Figure 2.   
 All parameters that could be affected by subject anthropometry or initial stance 
conditions were normalized to account for these differences. For example, kinematic step 
parameters were normalized to subject height. COP parameters were normalized relative to the 
base of support such that anterior-posterior (AP) parameters were normalized to foot length, 
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medial-lateral (ML) parameters during Stage 1 and Stage 2 were normalized to initial stance 
width, and ML parameters during Stage 3 were normalized to stance foot width (Table 2).  
2.6 Clinical Parameters  
 PD subjects were assessed by a specialist from the KUMC Parkinson's Disease and 
Movement Disorder Center, using the following clinical measures (Table 1): 
Unified Parkinson's Disease Rating Scale (UPDRS):  assessment of the overall 
progression of PD characterized by: Mentation, Behavior and Mood; Activities of Daily Living; 
and a Motor Examination.  Scores can range from 0 – 180, with higher scores reflecting greater 
impairment.  
Motor Exam: the third section of UPDRS completed by the investigator, that assesses 
motor symptoms related to PD. Scores can range from 0 – 108, with higher scores reflecting 
greater impairment. 
Pull Test (Postural Stability, UPDRS item 33): assessment of how a patient responds to a 
sudden posterior pull in order to characterize the patients' overall postural stability. Scores can 
range from 0 – 4, with higher scores reflecting greater impairment (Fahn, Elton et al. 1987, 
Goetz, Poewe et al. 2003).  
Schwab and England: estimation of the overall percentage a PD patient is able to function 
relative to an independent living situation. Scores can range from 100 – 0%, with 100% being 
normal and lower scores reflecting greater impairment (Schwab and England 1969). 
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2.7 Statistical Analysis: 
10
 
 An ANOVA was used to compare baseline demographic and disease severity 
characteristics between groups. All gait initiation parameters were analyzed using repeated 
measures Analysis of Variance (ANOVA) with group (HC, mild PD, moderate PD) as factors for 
all trials. Significant group differences (p < .05) were determined with an ANOVA and Tukey-
Kramer multiple comparison post hoc test when appropriate. A Spearman rank correlation 
analysis was used to characterize the relationship between the biomechanical (gait initiation) and 
clinical parameters for the PD participants (SAS 9.4, SAS Institute Inc., Cary, NC). 
 
Results  
3.1 Temporal Parameters 
 Step duration and time from the light cue to heel strike of the swing foot trended towards 
longer durations with increasing PD progression, with cue to heel strike duration being 
significantly greater in moderate PD compared to HC and mild PD (p< .05).  Step onset time and 
weight shift time trended towards increased time in moderate PD, with step onset time being 
significantly delayed in moderate PD compared to the HC and mild PD groups (p< .05) (Table 
3a). 
3.2 Kinematic Parameters 
                                                     
10
 Principal component analysis was applied to the gait initiation outcome parameters (combined with clinical 
parameters) as was done in Barnds Dissertation Chapter 4 for postural sway. Unfortunately, this analysis did not 
result in any principal components (PCs) that could differentiate both preclinical onset (mild PD v. HC) and 
progression (mild PD v. moderate PD and moderate PD v. HC) of postural instability, so this analysis is not included 
in this present chapter. The relative contributions and exact weights of the coefficients per PC as well as mean PC 
scores by group are in Appendix B.iii.   
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 Moderate PD exhibited significantly decreased (p < .05) total and AP step length 
compared to the HC and mild PD groups. Step speed and step clearance trended towards 
decreased values with PD progression; however only step speed of the swing leg in moderate PD 
was significantly different (p< .05) compared to the HC and mild PD groups. The mild PD group 
tended to step most laterally with the swing foot, but not significant across group comparisons 
occurred (Table 3b). 
3.3 COP Step Parameters 
 AP COP position at step heel off trended towards a more anterior position with disease 
progression, with the moderate PD group being significantly (p< .05) more anterior compared to 
the HC group.  All other COP step parameters were not significantly different across groups 
(Table 3c).  
3.4 COP Stage Parameters 
 Stage 1: AP and ML COP velocity and peak COP velocity towards the swing foot were 
significantly slower in moderate PD compared to HC (p < .05). Peak anterior COP velocity was 
significantly greater in moderate PD compared to HC (p <.05). Stage duration was significantly 
(p<.05) longer in moderate PD compared to both HC and mild PD. (Table 4) 
 Stage 2: Mean COP AP velocity was significantly more anterior in moderate PD 
compared to HC, and mean ML COP velocity was significantly slower in moderate PD 
compared to HC (p<.05). Peak COP velocity towards the stance foot was significantly slower in 
moderate PD compared to the HC group (p< .05). Stage duration was significantly longer in 
moderate PD compared to both the HC and mild PD group (p<.05). (Table 4) 
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 Stage 3: AP COP displacement was significantly less in moderate PD compared to the 
HC group (p<.05) and ML COP velocity was significantly slower in moderate PD compared to 
mild PD (p<.05). Peak COP velocity toward the swing foot was significantly less in mild PD 
compared to the HC and moderate PD groups (p<.05). (Table 4) 
3.5 Clinical Correlation with Gait Initiation Parameters 
 After testing the correlation of the significant gait initiation parameters with the 4 current 
clinical measures, the Motor Exam score had the highest level of correlation with 78% of 
significant parameters being correlated with the measure, closely followed by the pull test (72%), 
and then Motor Exam Score (67%), and Schwab and England (33%). (Table 5)
11
 
 
Discussion 
 This study sought to determine if gait initiation could detect preclinical onset and track 
changes of postural instability with clinical progression in PD during a cued gait initiation task. 
While previous studies have assessed gait initiation in PD for a range of disease severities (H&Y 
1-4), no studies have addressed whether gait initiation can differentiate preclinical postural 
instability (mild PD compared to HC) and quantify the associated progression with disease 
severity (HC v. moderate PD and mild PD v. moderate PD).  The temporal, kinematic, and COP 
parameters from this study are comparable with previous studies that demonstrated that PD 
increased the time to respond to a gait initiation cue and decreased step kinematics and COP 
                                                     
11
 A comprehensive list of the correlation coefficients by PD severity group (mild PD and moderate PD) is included 
in Appendix B.iii. Because this was a pilot study, we did not have enough subjects per group in order to have robust 
enough data sets to make inferences about the relative relationships of mild PD versus moderate PD, so they are 
considered together to increase power and to assess the overall effect of clinical progression for the purpose of this 
paper. 
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displacement (Rosin, Topka et al. 1997, Halliday, Winter et al. 1998, Dibble, Nicholson et al. 
2004, Rocchi, Carlson-Kuhta et al. 2012).  
This work provides the next step in biomechanical assessment of gait initiation in PD 
through investigating if such parameters could serve as biomarkers of early postural deficits 
compared to their healthy counterparts. Finding parameters that identify preclinical postural 
deficits or more quantitatively measure changes in postural instability over the course of PD 
would enable the clinician to identify PD patients at risk of falling and then implement the 
appropriate therapy to reduce that risk before the fall event. This could also be valuable for 
placement of PD participants in clinical trials requiring patient stratification based on the level of 
postural instability.  
4.1 Effect of Mild and Moderate PD Compared to HC: Temporal Parameters 
 All temporal variables trended towards increased time in moderate PD, while HC to mild 
PD parameter values remained similar. The findings that moderate PD significantly delays step 
onset time and the overall duration of the response (from cue to heel strike of the swing foot) is 
consistent with the idea that PD affects motor planning and programming as the moderate PD 
participants were not able to plan and execute as efficient of a response as their healthy 
counterparts(Marsden 1987, Rosin, Topka et al. 1997, Pahapill and Lozano 2000).  The mild PD 
and HC groups were similar in the duration of their response, which may suggest that motor 
planning and programming are not yet deficit, or evidence that if a change has occurred, then the 
selected temporal variables are not sensitive enough to detect the change within mild PD group.  
 4.2 Effect of Mild and Moderate PD Compared to HC: Kinematic Parameters 
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 Step length, speed, and clearance all trended towards decreased values in moderate PD 
compared to HC (p < .05 for step length and speed), with mild PD exhibiting a trend towards 
decrease for step speed and clearance but similar values to HC for weight shift time and step 
onset time. Similar to a recent study by Vitorio et al related to obstacle avoidance in mild and 
moderate PD, our gait initiation task also exhibited decreased step speed and step clearance with 
increased disease progression, but as did Vitorio et al. our study comparisons of mild PD to HC 
for these parameters missed statistical significance (Vitorio, Lirani-Silva et al. 2014). However, 
these findings may also be limited by this being a pilot study, with a power analysis suggesting 
that with n ≈ 50 per group for HC and mild PD, this could potentially differentiate this decrease 
in step clearance. However, the current results from this study suggest that while these kinematic 
parameters of gait initiation decrease with disease severity, the ability to maintain normal 
locomotion to their healthy counterparts in statistically unchanged in mild PD.  
4.3 Effect of Mild and Moderate PD Compared to HC: COP Step Parameters 
 At heel off of the swing foot, the location of the normalized COP trended towards being 
more anterior and towards the stance foot with increasing disease progression (Figure 2), with 
moderate PD vs HC exhibiting a significantly more anterior position of the COP compared to 
HC. There was no distinct trend for the normalized COP location at heel strike in either 
direction. However, the tendency in PD during the preparation phase (S1 and S2) to maintain a 
more anterior location of the COP location may suggest that the PD groups have an aversion to 
allowing their COP to move posteriorly or perhaps they are adopting a more stiff postural control 
response as a compensatory measure to counteract the deficits of PD. Further, the decreased 
movement of the normalized COP in the ML direction during preparation may suggest 
impairment to the functionality of the hip abductors and adductors as these muscles are partly 
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responsible for ML COP movement during gait (Winter 1995).  While this trend missed 
significance statistically, power analysis suggests that n ≈ 30 per group for HC and mild PD 
could differentiate this trend in decreased ML motion of the COP at heel off of the swing foot. 
4.4 Effect of Mild and Moderate PD Compared to HC: COP Stage Parameters 
Stage 1 
 In Stage 1, there was a general trend towards less posterior and lateral movement for both 
COP displacement and mean COP velocity with increasing PD severity, with significantly less 
posterior (AP) and lateral (ML) COP velocity for moderate PD versus HC. This trend towards 
less posterior and more lateral movement is also evidenced by the Peak COP velocity, with peak 
anterior COP and peak COP toward the swing foot (lateral) velocity reaching significant 
differences for HC versus moderate PD. There are several possible reasons that this trend was 
observed, such as PD causes a stooped forward posture (Bloem, Beckley et al. 1999), making the 
COP more anterior in quasi-static stance (Halliday, Winter et al. 1998),  thus evidenced by less 
posterior movement in PD. Or this trend also may reflect evidence of decreased efficiency of this 
preparation phase of the step initiation response due to PD (Marsden and Obeso 1994, Rosin, 
Topka et al. 1997),  evidenced by significant differences (p < 0.05) in mean COP velocity and 
stage 1 duration for moderate PD.   
Stage 2 
 In Stage 2, the PD groups trended towards moving more anteriorly and less quickly 
towards the stance foot, with moderate PD having a significantly more anterior velocity and 
significantly slower ML velocity compared to HC. Similar to the differences in COP location at 
heel off, these differences could be due to an altered postural control strategy, an aversion to 
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posterior movement (for AP measures), an impairment of the hip adductors/adductors (for ML 
measures), or some combination of these deficits related to PD.  However despite many trends 
with PD progression for stage 2 parameters, no significant differences were found between the 
mild PD and HC groups.  
Stage 3 
 In Stage 3, Peak COP Velocity toward the swing foot was significantly less (p < 0.05) in 
mild PD compared to the HC and moderate PD group.  During this stage, mild PD tended to 
move more quickly medially (toward the stance foot), with a trend towards a larger ML 
displacement, effectively decreasing the effective base of support during locomotion. 
Conversely, the moderate PD group exhibited an opposite trend- they stepped slower and more 
laterally, increasing the base of support. Potentially, this can be explained by a bi-phasic effect 
where there is some early rigidity or stiffening of the muscles that cause a less lateral (toward the 
swing foot) step and velocity during locomotion in mild PD, and then as PD progresses, 
compensatory behaviors begin which shortens and decreases the speed of the first step, thus 
reverting this change observed in the mild PD response compared to HC. This relative change in 
ML velocity and narrowing of the base of support during the first step in mild PD compared to 
HC and moderate PD needs further exploration in future studies. 
4.5 Clinical Correlation with Gait Initiation Parameters 
 The total UPDRS and pull test scores had the best level of correlation with the 
biomechanical measures of gait initiation while Schwab and England score had the lowest level 
of overall correlation. Interestingly, this observation is the opposite of a previous study by our 
group on postural sway (quasi-static stance) where Schwab and England had the largest level of 
correlation and pull test score had the lowest level of correlation with postural sway 
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biomechanical parameters (Barnds Dissertation Chapter 3). The differences in the gait initiation 
clinical correlations in relation to the pull test (compared to postural sway) may be explained by 
the fact that both gait initiation and the pull test both involve a step response. While the pull test 
involves backwards compensatory stepping, it nevertheless starts from a quasi-static stance and 
the participant must then initiate gait, which has many similarities to the light cued gait initiation 
task used in this study. The Schwab and England score, which reflects a participants ability to do 
activities of daily living such as getting dressed or showering, may be more closely related to a 
quasi-static standing task opposed to a dynamic task like gait initiation. Because static versus 
dynamic biomechanical tasks exhibit different correlations with clinical scores of disease 
progression, this may provide evidence that different task conditions can provide unique 
information about the effects of PD on postural control.  
 Limitations of this study include the small sample size and the associated potential 
influence of outliers, that PD participants were tested "on" medication, and that initial stance 
conditions were not controlled. When analyzing data from a small sample size, we recognized 
that outliers can greatly impact the overall variability in the data; however the systemic large 
variations within the PD groups that were based on H&Y staging may also demonstrate the need 
for more continuous or quantitative based parameters to score the PD patients in order to limit 
within-group variability.  The decision to test patients “on” medication without restrictions on 
their initial stance conditions was done in an effort to simulate routine clinic conditions where 
cumbersome setup requirements and altering the patient's dosing schedules would be difficult. 
However, future studies should include “off” medication assessments to check how medications 
are altering the PD groups' response, thus potentially decreasing the ability to detect early signs 
of being at risk for postural instability and falling.  Although parameters were normalized to the 
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subject stance conditions, ensuring that stance width and location of the COP at light onset are 
controlled in future studies may further help differentiate differences between HC, mild PD and 
moderate PD groups. Further analysis with increasingly sophisticated mathematical models may 
help establish the threshold where the onset of postural instability can be confirmed from 
multiple biomechanical and clinical measures.   
 
Conclusion 
 This study is a part of an ongoing effort to ascertain biomechanical parameters to identify 
preclinical postural instability in PD patients. Peak COP velocity towards the stance foot during 
the locomotion phase of gait initiation shows promise as a parameter that may detect postural 
instability earlier than current clinical assessment as mild PD patients were significantly slower 
compared to HC. We observed significant differences in temporal, kinematic, and COP 
parameters for moderate PD compared to HC, with many trends with disease progression in mild 
PD. However, due to the pilot nature of this study, many of these observed trends missed 
significance. Once validated with a larger scale study, these biomechanical parameters could 
serve as part of a multi-faceted fall risk assessment that would cover several dimensions of 
functional balance and clinical measures of disease progression. Future work is needed to ensure 
such parameters are correlated to disease progression, sensitive to a decrease in subclinical 
postural stability, specific to fall risk, and simple enough to perform during routine clinical visits.  
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a.        b. Note: AP = anterior-posterior, ML = medial-lateral 
Figure 5.1. a. Schematic of the experimental task setup for the gait initiation trials. The yellow 
markers represent the kinematic markers that were placed bilaterally on the toe, heel, ankle, 
shank, knee, thigh and hip. The green markers represent the EMG electrodes that were placed 
bilaterally on the medial gastrocnemius and tibialis anterior. b. Aerial view of an example COP 
trace during gait initiation (left foot = stance foot, right foot = swing foot) from cue light onset 
(circle) to swing foot heel strike (diamond). S1, S2, and S3 represent the respective stages based 
on the COP trace. The triangle marks the transition from stage 1 to stage 2 and the square marks 
the transition from stage 2 to stage 3. 
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Table 5.1. Mean (SD) Demographic and Clinical Data for Parkinson’s Disease (PD) 
Subjects and Healthy Controls (HC) 
            
I. Subject Demographic Data      
  Gender Age (years) Height (m) Mass (kg)     
HC  M=12, F=5 67.7 (4.8) 1.72 (.08) 74 (13)   
Mild PD M=6 , F=5 62.5 (8.7) 1.67 (.08) 76 (14)     
Moderate PD  M=8, F=2 67.8 (3.9) 1.73 (.10) 85 (19)   
          
II. Parkinson's Disease Specific Participant Data 
  
H&Y Score 
Years Since 
Diagnosis 
UPDRS 
Total 
UPDRS 
Motor 
UPDRS 
item 33 
(Pull Test) 
Schwab & 
England 
(%) 
Mild PD 2 (0) 4.9 (4.3) 24 (10) 18 (7) .2 (.4) 90 (5) 
Moderate PD 3 (0) 7.6 (3.4) 50 (11) 31 (8) 2 (0) 78 (7) 
 
M – male, F – female, H&Y – Hoehn and Yahr, UPDRS – Unified Parkinson’s Disease Rating 
Scale. 
  
134 
 
 
Table 5.2. Names and Descriptions for Gait Initiation Parameters 
Parameter  (units) Description 
Temporal Parameters:  
Weight Shift Time (s) Difference between the reaction time and heel off of the swing 
foot 
Step Onset Time (s) Time from the light cue to heel off of the swing foot 
Step Duration (s) Time from heel off of the swing foot to heel strike of the swing 
foot. 
Cue to Heel Strike 
Duration (s) 
Time from the light cue to heel strike of the swing foot 
Kinematic Parameters:  
Step Length (%) Distance between heel off of the swing foot to heel strike of the 
swing foot normalized to subject height. Also calculated in the 
AP and ML direction. 
Step Speed (%/s) Distance divided by time of heel off of the swing foot to heel 
strike of the swing foot normalized to subject height. 
Step Clearance (mm) Maximum height of the toe from heel off to heel strike of the 
swing foot. 
COP Step Parameters:  
COP Heel Off Location  
(mm) 
Location of the COP at heel off of the swing foot relative to the 
COP at light onset.  Calculated in the AP and ML direction. 
COP Heel Strike Location  
(mm) 
Location of the COP at heel strike of the swing foot relative to 
the COP at light onset.  Calculated in the AP and ML direction. 
COP Stage Parameters:  
COP Displacement (%) Maximum displacement of the COP during the gait initiation 
stage normalized to participant foot length (AP direction) or 
stance width for Stages 1 and 2 and foot width for Stage 3 (ML 
direction.  
COP Velocity (%/s) Average of the normalized COP distance traveled over time 
during the gait initiation stage. Also calculated in the AP and 
ML directions. 
Peak COP Velocity (%/s) Maximum of the normalized velocity in the anterior, posterior, 
toward the swing foot, and toward the stance foot directions 
during each gait initiation stage. 
Stage Duration (s) Total time elapsed during the gait initiation stage. 
  
135 
 
Table 5.3. a. Mean (SEM) for Gait Initiation Temporal Parameters. b. Mean (SEM) for 
Gait Initiation Kinematic Step Parameters. c. Mean (SEM) for Gait Initiation COP Step 
Parameters 
Table 3a. Mean (SEM) for Gait Initiation Temporal Parameters   
  Weight Shift Time 
(s) 
Step Onset Time 
(s) 
Step Duration (s) Cue to Heel Strike 
Duration (s) 
HC   .44 (.03) .68 (.03) .46 (.02) 1.14 (.04) 
Mild PD   .43 (.05) .66 (.03) .48 (.04) 1.16 (.06) 
Moderate PD   .51 (.05) .86 (.04)*
+
 .53 (.03) 1.39 (.06)*+ 
 
Table 3b. Mean (SEM) for Gait Initiation Kinematic Step Parameters 
  Step Length 
(%) 
AP Step 
Length (%) 
ML Step 
Length (%) 
Step Speed 
(mm/s) 
Step Clearance 
(mm) 
HC   27.6 (.7) 27.5 (.7) 1.64 (0.13) 1057.0 (56.1) 113.0 (3.7) 
Mild PD   27.9 (1.7) 27.7 (1.7) 3.18 (0.21) 1005.7 (75.9) 104.4 (6.4) 
Moderate PD   21.9 (1.4)*+ 21.7 (1.4)*+ 1.51 (0.24) 737.2 (64.6)*+ 97.4 (6.8) 
  
Table 3c. Mean (SEM) for Gait Initiation COP Step Parameters 
  AP COP Heel Off 
Location  (%) 
ML COP Heel Off 
Location  (%) 
AP COP Heel 
Strike Location  
(%) 
ML COP Heel 
Strike Location  
(%) 
HC -11.8 (2.6) -26.8 (4.1) 17.0 (2.7) -65.7 (2.8) 
Mild PD  -8.0 (2.4) -15.8 (4.8) 15.8 (3.2) -77.0 (7.6) 
Moderate PD -0.1 (1.5)* -14.7 (4.6) 20.6 (3.5) -61.3 (2.5) 
* indicates the parameter was significantly different (p < .05) than the HC group. 
+
 indicates the parameter was significantly different (p < .05) than the mild PD group (for mild 
PD vs. moderate PD comparisons). 
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Table 5.4. Mean (SEM) for Gait Initiation COP Stage Parameters  
    Stage 1 Stage 2 Stage 3 
AP COP Displacement (%) 
HC 18.3 (1.9) 14.7 (1.0) 38.1 (2.5) 
Mild PD  17.1 (2.0) 15.3 (2.9) 31.9 (3.8)  
Moderate PD 13.0 (2.0) 17.8 (1.7) 26.1 (4.1)* 
ML COP Displacement (%) 
HC 30.8 (1.7) 89.6 (2.6) 16.6 (2.2) 
Mild PD  26.4 (3.0) 85.4 (6.4) 23.7 (4.9) 
Moderate PD 23.2 (2.5) 80.7 (2.0) 11.8 (2.9) 
AP COP Velocity (%/s) 
HC -40.2 (4.9) -10.0 (6.2) 124.6 (11.0) 
Mild PD  -37.8 (5.0) 0.1 (9.7) 99.7 (14.8) 
Moderate PD -21.8 (4.0)* 16.4 (5.6)* 92.1 (12.6) 
Peak A COP Velocity (%/s) 
HC 13.9 (3.1) 127.4 (15.1) 307.1 (31.9) 
Mild PD  18.3 (5.7) 145.4 (37.0) 208.2 (32.6)  
Moderate PD 32.2 (5.4)* 126.1 (12.7) 198.9 (21.5) 
Peak P COP Velocity (%/s) 
HC -131.9 (7.6) -146.5 (14.6) 17.2 (2.7) 
Mild PD  -127.0 (15.0) -132.8 (23.3) 16.6 (5.7) 
Moderate PD -97.5 (15.2) -103.0 (19.7) 25.3 (5.6) 
ML COP Velocity (%/s) 
HC 65.9 (5.4) -281.5 (12.9) -38.3 (7.6) 
Mild PD  58.1 (8.5) -267.7 (27.2) -70.2 (18.1) 
Moderate PD 44.7 (5.3)* -191.0 (16.0)*+ -24.6 (11.7)+ 
Peak COP Velocity toward 
Swing Foot(%/s) 
HC 220.5 (16.9) 5.2 (1.7) 109.4 (21.2) 
Mild PD  199.5 (25.5) 0.3 (0.3) 22.1 (11.8)* 
Moderate PD 142.2 (23.0)* 5.2 (3.2) 121.2 (32.8)+ 
Peak COP Velocity toward 
Stance Foot (%/s) 
HC -8.4 (2.6) -702.2 (60.2) -145.2 (18.6) 
Mild PD  -12.9 (3.1) -588.2 (60.1) -159.3 (23.8) 
Moderate PD -11.6 (3.2) -450.7 (31.8)* -115.8 (14.9) 
Stage Duration (s) 
HC 0.49 (.03) 0.33 (.01) 0.32 (.02) 
Mild PD  0.49 (.03) 0.33 (.02) 0.34 (.03) 
Moderate PD 0.64 (.04)*+ 0.46 (.03)*+ 0.29 (.02) 
* indicates the parameter was significantly different (p < .05) than the HC group. 
+
 indicates the parameter was significantly different (p < .05) than the mild PD group (for mild 
PD vs. moderate PD comparisons). 
1
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CHAPTER 6: Conclusions 
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Summary  
The primary objective of the research in this dissertation was to investigate quasi-static 
and dynamic biomechanical tasks as potential indicators of preclinical postural instability and 
progression in PD.  PD patients without postural deficits (mild PD, H&Y 2), those with postural 
deficits (moderate PD, H&Y 3) and healthy controls (HC) were tested during postural sway and 
gait initiation toward this goal. Force plate, motion, electromyography, and video data were used 
to quantify biomechanical measures in terms of center of pressure, kinematic, and temporal 
parameters. Further, principal component analysis (PCA) models with biomechanical and 
clinical measures as inputs were utilized to better track and score postural instability progression 
by considering the cumulative effect of these parameters.  
Specifically, postural sway was investigated in mild PD, moderate PD, and HC and 
whole body COP measures were extracted to determine if a quasi-static task could show 
evidence of preclinical postural instability (Specific Aim 1, Chapter 3). Then, PCA based on 
postural sway biomechanical parameters and clinical measures was utilized for 2 goals. First, 
PCA identified the parameters driving the variation in the overall data set and then determined if 
the selected variables could differentiate preclinical postural instability and clinical disease 
progression (Specific Aim 2, Chapter 4). Lastly, gait initiation was investigated through 
extracting temporal, kinematic, and COP parameters during the first step of the response to 
determine if a dynamic task could find earlier indication of postural instability in PD (Specific 
Aim 3, Chapter 5).  
Chapter 3 determined if postural sway could differentiate PD patients without clinical 
presentation of postural instability compared to HC, and if such differences persisted once 
clinical presentation of postural instability was present.  Results showed that multiple measures 
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based on the whole body COP path and velocity provided early indication of postural instability 
in PD.  Specifically, trajectory, variation, and peak COP parameters were significantly different 
in mild PD compared to HC, and these differences persisted in moderate PD. However, despite 
some measures providing preclinical indication of postural instability (mild PD compared to 
HC), no individual parameter was also able to differentiate postural instability changes 
associated with clinical disease progression (mild PD compared to moderate PD).  Future work 
with larger sample sizes and additional tasks is needed to ensure such parameters are correlated 
with disease progression, sensitive to a decrease in subclinical postural stability, specific to fall 
risk, and simple enough to perform during routine clinical visits. 
Chapter 4 investigated the use of mathematical modeling for more quantitative scoring of 
postural instability progression in PD. PCA based on a correlation matrix with standardized 
postural sway biomechanical and clinical measures as inputs was used for both parameter 
selection and group differentiation. Parameter selection of the PCA initial model found a 
combination of biomechanical and clinical parameters as the primary drivers of variation in the 
HC and PD participants. And further, the resultant PCA models based on parameter selection 
were able to significantly differentiate early onset (mild PD versus HC) and clinical progression 
(mild PD versus moderate PD and moderate PD versus HC) of postural instability in PD for the 
first principal component scores. Future study for a wider range of functional tasks with larger 
sample sizes as well as predicative PCA modeling to test the robustness of PCA to score patients 
based on postural instability severity is needed. 
Chapter 5 determined if gait initiation could differentiate both preclinical onset of 
postural instability and its associated progression in PD. Peak COP velocity towards the swing 
foot during the locomotion phase of gait initiation showed promise as a parameter that may 
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detect postural instability earlier than current clinical assessment as this measures was 
significantly slower in mild PD group compared to HC. However, this parameter may also be 
representative of a bi-phasic effect, with moderate PD exhibiting compensatory behaviors in 
their initial step that reversed this observed change in mild PC compared to HC. Additionally, 
several significant differences in temporal, kinematic, and COP parameters for moderate PD 
compared to HC were observed, with many trends in early disease progression in mild PD 
compared to HC. Once validated with a larger scale study, these biomechanical parameters could 
serve as part of a multi-factorial fall risk assessment that would cover several dimensions of 
functional balance and clinical measures of disease progression. 
 Due to the pilot nature of the studies involved in this research, several limitations exist. 
The small sample size, the influence of outliers and that PD participants were tested "on" 
medication all affected the outcomes of this study. Because of the clinically driven goals of this 
research, this choice was made in order to reflect potential clinical balance assessments that do 
not require patients to alter their dosing schedule (“on” medication) so that such a task could be 
more easily translated into routine clinical visits. Future studies with larger sample sizes should 
include “off” medication assessments or inclusion of de novo subjects to determine if 
medications are masking subtle changes that may further enhance the detection of those at risk 
for postural instability and falling.  
Overall, postural sway and gait initiation show promise as biomechanical assessment 
tasks that may provide earlier indication of postural instability in PD, Further, using increasingly 
sophisticated mathematical models like PCA could provide a method to more quantitative assess 
the overall progression of postural instability in PD.  Particularly, PCA may be helpful in a 
multi-factorial balance assessment as a means to score a threshold based on multiple measures to 
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detect the onset of postural instability in PD. In both quasi-static (postural sway) and dynamic 
(gait initiation) tasks as well as PCA modeling, COP measures of velocity were found to be 
significantly different in mild PD compared to HC.  Further investigation of all the significant 
parameters and tasks from this research, and particularly COP velocity measures, warrant further 
investigation.  In order for these biomechanical measures to be useful in predicting fall risk, 
future study must confirm that such parameters are correlated to disease progression, sensitive to 
a decrease in subclinical postural stability, and specific to fall risk.   
 
Future Studies 
  Future studies must address several questions. First, do the responses observed in this 
research for mild and moderate PD persist in a larger scale study with additional clinical PD 
stages?  Further, can mathematical modeling through PCA be used across multiple levels of 
functional balance to better assess across and within task correlations? The progression of these 
changes on a larger scale for both quasi-static and dynamic tasks must be further explored. Also, 
how do these biomechanical measures of postural sway and gait initiation correlate to fall risk? 
Future study that longitudinally follows PD patients and relates their biomechanical measures to 
fall incidence could help better establish the specificity of these parameters to fall risk. Lastly, 
once certain biomechanical measures are confirmed as sensitive to preclinical postural instability 
and specific to fall risk, how can these measures be implemented in a clinical setting to better aid 
clinicians in assessing fall risk, and thus implementing earlier compensatory therapies?  The 
ability of these tasks to be easily and reliably implemented in a clinical setting must be further 
investigated.  
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Significance 
Timely prediction of risk of falls in those with PD before recurrent falls begin is a crucial 
need to maintain patient quality of life and increase life expectancy. Because postural instability 
leads to increased risk of falls, a method to diagnose, assess and score postural instability in PD 
is a critical unmet need.  Since no effective screening method exists to measure fall risk, our 
team is developing a multi-factorial method to detect postural instability through clinical balance 
assessment, and in doing so, provide the justification for implementing fall reducing therapies 
before potentially debilitating patient falls begin.  Continued investigation of the significant 
biomechanical tasks and parameters in postural instability assessment through postural control 
modeling could help further understanding of the neurophysiology involved in PD progression. 
Once a set of promising biomechanical markers for a range of balance tasks is identified, these 
can be streamlined and implemented in a clinical setting. Applying the results of this research 
towards a bioinstrumentation device that a clinician can use to assess fall risk quickly and 
accurately would have a direct and tangible positive impact on patient care and the healthcare 
system in general.   
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APPENDIX A.Coordinate Systems and Transformations 
  
2 
 
Landon Center on Aging Experimental Setup 
Postural Sway 
 
Black coordinates represent the initial force plate coordinate system; red (bold) coordinates 
represent the global coordinate system used in the postural sway analysis. Participants stood with 
their left foot on FP 1 on and right foot on FP 2.  
Force Plate Rotations: 
FP 1 Rotation:  𝑛𝑜𝑛𝑒 
FP 2 Rotation: (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) 
Force Plate Transformation to Final Coordinate System Alignment: 
Fx MAIN= Fx FP1 + Fx FP2  
Fy MAIN= Fy FP1 + Fy FP2  
Fz MAIN= Fz FP1 + Fz FP2  
Mx MAIN= Mx FP1 + Mx FP2 – dw (Fz FP1 + Fz FP2) 
My MAIN= My FP1 + My FP2  
Mz MAIN= Mz FP1 + Mz FP2  + dw(Fx FP1 + Fx FP2) 
3 
 
Gait Initiation 
 
Black coordinates represent the initial force plate coordinate system; red (bold) coordinates 
represent the global coordinate system used in the gait initiation analysis. Participants stood on 
FP 1 and then initiated gait onto FP2.   
Force Plate Rotations: 
FP 1 Rotation: (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) 
FP 2 Rotation: (
0 0 1
0 1 0
−1 0 0
) (
0 0 1
0 1 0
−1 0 0
) (
1 0 0
0 0 −1
0 1 0
) 
Force Plate Transformations to Final Coordinate System Alignment: 
Fx MAIN= Fx FP1 + Fx FP2  
Fy MAIN= Fy FP1 + Fy FP2  
Fz MAIN= Fz FP1 + Fz FP2  
Mx MAIN= Mx FP1 + Mx FP2 + dlFz FP1 + dwFz FP2  
My MAIN= My FP1 + My FP2 + (-3dw)Fz FP1 - dwFz FP2  
Mz MAIN= Mz FP1 + Mz FP2  + 3dwFy FP1 - dl Fx FP1 + dwFy FP2 – dlFx FP2 
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Biodynamics Lab Experimental Setup 
Postural Sway 
 
Black coordinates represent the initial force plate coordinate system; red (bold) coordinates 
represent the global coordinate system used in the postural sway analysis. Participants stood with 
their left foot on FP 2 on and right foot on FP 1.  
Force Plate Rotations: 
FP 1 Rotation: (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) 
FP 2 Rotation: (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) 
Force Plate Transformation to Final Coordinate System Alignment: 
Fx MAIN= Fx FP1 + Fx FP2  
Fy MAIN= Fy FP1 + Fy FP2  
Fz MAIN= Fz FP1 + Fz FP2  
Mx MAIN= Mx FP1 + Mx FP2 – dw (Fz FP1 + Fz FP2) 
My MAIN= My FP1 + My FP2  
Mz MAIN= Mz FP1 + Mz FP2  + dw(Fx FP1 + Fx FP2) 
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Gait Initiation 
 
Black coordinates represent the initial force plate coordinate system; red (bold) coordinates 
represent the global coordinate system used in the gait initiation analysis. Participants stood with 
their right foot onon FP 1 and left foot on FP 2 and then initiated gait onto FP3.   
Force Plate Rotations: 
FP 1 Rotation: (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) (
0 −1 0
1 0 0
0 0 1
) 
FP 2 Rotation: (
1 0 0
0 0 −1
0 1 0
) (
1 0 0
0 0 −1
0 1 0
) (
0 −1 0
1 0 0
0 0 1
) 
FP 3 Rotation: (
0 0 1
0 1 0
−1 0 0
) (
0 0 1
0 1 0
−1 0 0
) 
Force Plate Translations Following Rotation: 
Fx MAIN= Fx FP1 + Fx FP2 + Fx FP3 
Fy MAIN= Fy FP1 + Fy FP2 + Fy FP3 
Fz MAIN= Fz FP1 + Fz FP2 + Fz FP3 
Mx MAIN= Mx FP1 + Mx FP2 + Mx FP3  + (dl - dw)Fz FP1 + (dl + dw)Fz FP2 + dlFz FP3 
My MAIN= My FP1 + My FP2 + My FP3  - (2dw + dl)Fz FP1 - (2dw + dl)Fz FP2 – dwFz FP3 
Mz MAIN= Mz FP1 + Mz FP2 + MzFP3  + (2dw + dl)Fy FP1 - (-dw + dl)Fx FP1 + (2dw + dl)Fy FP2 - (dw + dl)Fx 
FP2 +dwFy FP3 - dlFx FP3  
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APPENDIX B. Outcome Parameter Calculations and Additional Results 
7 
 
COP Calculations 
Calculating the Center of Pressure (COP)
12
 
Based on the combined (final) coordinate systems, the force plates measures: 
 three forces (𝐹𝑥, 𝐹𝑦, 𝐹𝑧) 
 three moments (𝑀𝑥, 𝑀𝑦, 𝑀𝑧). 
Each moment component measured by the force plate is the summation of the applied couple and 
the moment-of-force. 
A couple, equivalent to two non-collinear, parallel forces acting in opposite directions, is 
calculated with: 
𝑴 =  𝒓 𝑥 𝑭 
r = any vector connecting the line of action of the first force vector with the second force vector, 
and 
F = the second force vector. 
The moment-of-force is the moment caused by the force acting at a distance, with: 
𝑴𝒐 =  𝒓 𝑥 𝑭 
r = any vector connecting the origin with line of action of the force vector, and 
F = the force vector. 
The total moment about the axis normal to the top surface of the force plate (z for AMTI force 
plates) is equal to: 
𝑴𝒛 =  −𝑭𝒙 ∗  𝒚 +  𝑭𝒚 ∗  𝒙 +  𝑻𝒛 
The horizontal moments about the axes parallel to the top surface of the force plate (x and y for 
AMTI force plates) are equal to: 
                                                     
12
 Adapted from the Luchies ME 751 FORCE PLATES document. 
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𝑴𝒙 =  𝑭𝒛 ∗  𝒚 +  𝑭𝒚 ∗  𝒅𝒛 +  𝑻𝒙 
𝑴𝒚 =  −𝑭𝒛 ∗  𝒙 –  𝑭𝒙 ∗  𝒅𝒛 +  𝑻𝒚 
 
Where dz in the distance below the top surface at which the origin in located (provided with the 
calibration). 
When an individual stands for walks on an AMTI force plate, the only way to induce a couple 
about a horizontal axis is to attach a foot (or shoe) to the platform so that it can twist the top 
surface about the X or Y axis (e.g. similar to the boot on a show board). Otherwise, there are no 
Tx or Ty torques and these equations can be simplified and used to calculate the x and y 
coordinates of the center-of-pressure (COP): 
 
𝑪𝑶𝑷 𝒙 = (−
𝑴𝒚 + 𝑭𝒙 ∗ 𝒅𝒛
𝑭𝒛
) 
𝑪𝑶𝑷 𝒚 =  (
𝑴𝒙 − 𝑭𝒚 ∗ 𝒅𝒛
𝑭𝒛
) 
𝑪𝑶𝑷 = √(−
𝑴𝒚 + 𝑭𝒙 ∗ 𝒅𝒛
𝑭𝒛
)
𝟐
+  (
𝑴𝒙 − 𝑭𝒚 ∗ 𝒅𝒛
𝑭𝒛
)
𝟐
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ii. Specific Aim 2 
PCA initial Model (14 input parameters) in-depth analysis: Eyes Open Postural Sway: 
Group Differentiation 
To assess the PCA model’s differentiation of the three study population groups (HC, mild, and 
moderate), the resultant scores (the representation of the input data in the rotated coordinate 
system for each PC) per group were tested for significant differences. PC 1 scores for all group 
pairwise comparisons (HC v. mild PD, HC v. moderate PD, mild PD v. moderate PD) were 
significantly different (mean (SD): HC -1.99 (.55), mild PD 0.47 (1.58), moderate PD 3.56 
(3.40), p<.05). The 95% confidence intervals for PC1 scores for the HC versus Mild PD group 
and Moderate groups were unique, with the HC confidence intervals of -2.24036 ≤ θ ≤ -1.73964, 
mild PD were -0.48478 ≤ θ ≤ 1.42478, and moderate PD 1.12779 ≤ θ ≤ 5.99221.   
Physical Meaning of PCs 
Qualitative analysis of PC1, the eigenvector that was able to differentiate between the 3 study 
groups, has the mean sway speed and the peak sway speed as the 2 primary parameters 
influencing the PC based on their coefficients. Figure A.ii.2 shows the 2 primary parameters for 
this PC for the subject with the smallest and largest score for this PC. As demonstrated by 
Figures A.ii.1 and A.ii.2, PC 1 is most representative of the overall and peak velocity trajectory; 
however, the path length and range parameters are also highly correlated with the velocity 
measures, suggesting most of these parameters could help to describe the variance in the data set 
across groups. Of the clinical parameters, Schwab and England score has the largest contribution 
to the PC, with an inverse relationship to the biomechanical parameters. This is to be expected as 
Schwab and England score decreases with disease progression, while the COP biomechanical 
parameters are demonstrated to increase with disease progression.   
11 
 
PCA initial Model In-depth analysis: Eyes Closed Postural Sway: 
Group Differentiation 
To assess the PCA model’s differentiation of the three study population groups (HC, mild, and 
moderate), the resultant scores (the representation of the input data in the rotated coordinate 
system for each PC) per group were tested for significant differences. PC 1 scores for all group 
pairwise comparisons (HC v. mild PD, HC v. moderate PD, mild PD v. moderate PD) were 
significantly different (mean (SD): HC -1.96 (.54), mild PD 0.40 (2.19), moderate PD 3.61 
(3.41), p<.05). The 95% confidence intervals for PC1 scores for the HC versus Mild PD group 
and Moderate groups were unique, with the HC confidence intervals of -2.20581 ≤ θ ≤ -1.71419, 
mild PD were --0.92340 ≤ θ ≤ 1.72340, and moderate PD 1.17063 ≤ θ ≤ 6.04937.  
Physical Meaning of PCs 
For the eyes close PCA model, qualitative analysis of PC1, the eigenvector that was able to 
differentiate between the 3 study groups, has mean sway speed and total COP path length as the 
2 primary parameters influencing the PC based on their coefficients. Figure A.ii.3 shows the 2 
primary parameters for this PC for the subject with the smallest and largest score for this PC. As 
demonstrated by Figure A.ii.1 and A.ii.3, PC 1 is most representative of the overall path and 
velocity trajectory; however, the peak velocity and range parameters are also highly correlated 
with the velocity measures, suggesting most of these parameters could help to describe the 
variance in the data set across groups. Similarly to the trend observed in the eyes open PCA 
model, for the clinical parameters in the eyes closed model, Schwab and England score has the 
largest contribution to the PC, with an inverse relationship to the biomechanical parameters. This 
is to be expected as Schwab and England score decreases with disease progression, while the 
COP biomechanical parameters are demonstrated to increase with disease progression.    
12 
 
 
Table A.ii.1. Mean (SD) Scores for PCs by Group Based on PCA initial Model 
EO PCA ANOVA PC1 PC2 PC3 PC4 PC5 
HC -1.99 (0.55) 0.32 (.37) 0.63 (0.32) -0.09 (0.54) 0.19 (0.23) 
Mild PD 0.47 (1.58)* -0.4 (0.64) -0.05 (.79) -0.03 (.71) -0.63 (0.55)* 
Mod PD 3.56 (3.40)*+ -0.15 (2.85) -1.26 (2.27)* 0.22 (1.06) 0.43 (0.31)+ 
  
     
 
     
EC PCA ANOVA PC1 PC2 PC3 PC4 PC5 
HC -1.96 (.54) 0.74 (.23) -0.27 (.43) 0.10 (.26) -0.47 (.43) 
Mild PD 0.4 (2.19)* -0.19 (0.97) 0.15 (.87) -0.47 (.49)* 0.47 (.43)* 
Mod PD 3.61 (3.41)*+ -1.31 (2.24)* 0.37 (2.05) 0.39 (0.96)+ -0.30 (0.54)+ 
* indicates the parameter was significantly different (p < .05) than the HC group. 
+ indicates the parameter was significantly different (p < .05) than the mild PD group (for mild PD vs. moderate PD 
comparisons). 
  
13 
 
Table A.ii.2. Coefficients and Variance for Retained PCs in Eyes Open and Eyes Closed 
PCA initial Models 
a. Eyes Open PC 1 PC 2 PC 3 PC 4 PC 5 
      
Parameter Coefficients per PC 
     
UPDRS 0.262 -0.166 -0.399* 0.082 -0.259 
Schwab and England -0.273 0.207 0.328 -0.158 0.172 
Motor Exam 0.26 -0.185 -0.379 0.145 -0.338* 
Pull Test 0.238 -0.087 -0.378 0.127 0.73 
Sway Path Length 0.282 0.378 0.022 0.038 0.067 
AP Sway Path Length 0.271 0.383* -0.027 -0.193 -0.066 
ML Sway Path Length 0.276 0.348 0.06 0.261 0.177 
Sway Area 0.263 -0.209 0.368 0.209 0.118 
Mean Sway Speed 0.282 0.377 0.028 0.027 0.023 
AP RMS of COP 0.261 -0.287 0.051 -0.517 0.277 
ML RMS of COP 0.234 -0.283 0.388 0.288 -0.066 
AP Sway Path Range 0.28 -0.209 0.102 -0.563* -0.019 
ML Sway Path Range  0.268 -0.195 0.359 0.244 -0.046 
Peak Sway Speed 0.285* 0.22 0.117 -0.232 -0.344 
      
Variance Explained by PC (%) 61.00 15.63 14.27 4.08 2.28 
      
b. Eyes Closed PC 1 PC 2 PC 3 PC 4 PC 5 
      
Parameter Coefficients per PC 
     
UPDRS 0.247 -0.402* 0.198 -0.135 0.177 
Schwab and England -0.261 0.328 -0.263 0.133 -0.13 
Motor Exam 0.244 -0.386 0.237 -0.145 0.264 
Pull Test 0.216 -0.382 0.179 0.395 -0.505 
Sway Path Length 0.309 0.07 -0.213 0.302 0.087 
AP Sway Path Length 0.271 -0.043 -0.457* 0.081 0.12 
ML Sway Path Length 0.287 0.168 0.112 0.533* 0.065 
Sway Area 0.257 0.349 0.277 -0.049 -0.068 
Mean Sway Speed 0.310* 0.076 -0.22 0.262 0.127 
AP RMS of COP 0.274 -0.002 -0.175 -0.267 -0.691* 
ML RMS of COP 0.22 0.385 0.37 -0.157 -0.039 
AP Sway Path Range 0.284 0.025 -0.239 -0.418 -0.13 
ML Sway Path Range  0.255 0.351 0.277 -0.099 0.094 
Peak Sway Speed 0.286 0.033 -0.333 -0.232 0.275 
      
Variance Explained by PC (%) 66.10 15.40 9.80 3.10 2.50 
* indicates the parameter per PC retained (largest coefficient) for the PCA selection model 
PC – Principal Component. 
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Variable Selection 
Four methods of variable selection were used to determine the driving parameters for the PCA 
initial model. First, due to the observation that PC 1 was driving the majority of the variability in 
the model, coupled with the fact that all the parameters were having a mild positive or negative 
effect, the most influential parameters (largest coefficients for PC 1) were selected until 
significant differentiation occurred in the new PCA model based on parameter selection. Then, 
three traditional methods of parameters section were also explored: selection based on the largest 
coefficients for the first m PCs (justification and presentation of this in Barnds Dissertation: 
Chapter 4), deletion based on the largest coefficients from the last p-m PCs, and sparse PCA. 
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Figure A.ii.2. Eyes Open PCA initial model: representative plots for the two most influential parameters (peak sway 
speed and mean sway speed) of PC 1for the PCA initial model for the minimum (left) and maximum (right) PC 1 
subjects scores.  
Key: peak Sway Speed - red *,  Mean Sway Speed -red line.  
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Figure A.ii.3.Eyes Closed PCA initial model: representative plots for the two most influential parameters (mean 
sway speed- upper half, COP path length, lower half) of PC 1for the PCA initial model for the minimum (left) and 
maximum (right) PC 1 subjects scores.  
Key: Mean Sway Speed -red line, upper half; COP trace aerial view -blue line, lower half. 
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Table A.ii.4. Mean (SD) Scores for PCs by Group Based on PCA selection model 
EO PCA ANOVA PC1 PC2 PC3 PC4 
HC -1.99 (.56) 0.32 (.37) 0.63 (.32) -0.09 (.55) 
Mild PD 0.47 (1.64)* -0.4 (1.64) -0.05 (.82) -0.03 (.74) 
Mod PD 3.56 (3.58)*+ -0.15 (3.01) -1.26 (2.39) 0.22 (1.12) 
      
      
EC PCA ANOVA PC1 PC2 PC3 PC4 
HC -1.97 (.54) 0.74 (.23) -0.27 (.44) 0.1 (.27) 
Mild PD 0.4 (2.28)* -0.19 (1.01) 0.15 (.91) -0.47 (.45)* 
Mod PD 3.61 (3.59)*+ -1.31 (2.37)* 0.37 (2.16) 0.39 (1.02)* 
* indicates the parameter was significantly different (p < .05) than the HC group. 
+ indicates the parameter was significantly different (p < .05) than the mild PD group (for mild 
PD vs. moderate PD comparisons). 
  
24 
 
 
Table A.ii.5. Coefficients and Variance Explained for Retained PCs in Eyes Open and 
Eyes Closed PCA selection Models 
Eyes Open 
    
 PC1 PC2 PC3 PC4 
UPDRS 0.453 0.491 -0.009 0.741 
Pull Test 0.425 0.562 -0.293 -0.618 
AP Sway Path Length 0.454 -0.430 -0.456 -0.055 
AP Sway Path Range 0.445 -0.080 0.837 -0.228 
Peak Sway Speed 0.459 -0.502 -0.080 0.115 
     
Variance Explained Per PC (%) 66.20 18.36 9.28 3.58 
     
     
Eyes Closed     
 PC1 PC2 PC3 PC4 
UPDRS 0.371 0.914 -0.078 0.143 
AP Sway Path Length 0.463 -0.225 0.465 0.536 
ML Sway Path Length 0.442 -0.214 -0.763 -0.159 
Mean Sway Speed 0.500 -0.259 -0.088 0.240 
AP RMS of COP 0.450 -0.023 0.434 -0.781 
     
Variance Explained Per PC (%) 75.25 11.37 7.93 5.40 
PC – Principal Component 
Bolded coefficients reflect the two most influential parameters for PC 1 of the PCA selection model 
for eyes open (top) and eyes closed (bottom). 
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iii. Specific Aim 3 
 
Table A.iii.1. a. Mean (SEM) for Gait Initiation Kinematic Parameters. b. Mean (SEM) for 
Gait Initiation Stage COP Parameters 
a. Mean (SEM) for Gait Initiation Kinematic Parameters 
  Ankle Ang at 
Heel Off (deg) 
Ankle Ang at 
Heel Strike 
(deg) 
 
HC   7.6 (1.5) -2.9 (1.9)  
Mild PD   3.0 (2.2) -6.2 (2.8)  
Mod PD   3.4 (0.4) -4.6 (1.2)  
 
b. Mean (SEM) for Gait Initiation Stage COP Parameters 
  Stage 1     
  COP 
Displacement 
(%) 
COP Velocity 
(%/s) 
COP Peak 
Velocity (%/s) 
HC   36.3 (2.3) 78.1 (6.9) 249.0 (20.4) 
Mild PD   32.3 (3.2) 71.2 (8.9) 234.0 (28.1) 
Mod PD   27.2 (2.7) 44.7 (5.4)* 164.2 (24.6)* 
    
  Stage 2     
  COP 
Displacement 
(%) 
COP Velocity 
(%/s) 
COP Peak 
Velocity (%/s) 
HC 91.0 (2.5) 283.5 (12.9) 716.2 (59.8) 
Mild 87.1 (6.6) 269.8 (26.8) 610.1 (63.7) 
Mod 82.94 (1.8) 192.9 (16.4)*+ 466.2 (33.6)* 
    
  Stage 3     
  COP 
Displacement 
(%) 
COP Velocity 
(%/s) 
COP Peak 
Velocity (%/s) 
HC 42.6 (2.6) 135.4 (10.5) 346.6 (33.6) 
Mild 41.5 (5.2) 129.1 (19.2) 253.9 (36.8) 
Mod 29.3 (4.7) 101.8 (13.4) 258.1 (31.6) 
* indicates the parameter was significantly different (p < .05) than the HC group. 
+
 indicates the parameter was significantly different (p < .05) than the mild PD group (for mild 
PD vs. moderate PD comparisons). 
2
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Gait Initiation Correlations by Parameter Type 
Temporal Parameter Correlations 
Step onset time and cue to heel strike duration were significantly correlated (p < 0.05) with total 
UPDRS score (ρ = .53, ρ = .46), Motor Exam score (ρ =.48, ρ = .47), and the Pull Test (ρ =.59, ρ 
=.46), respectively, with increased duration reflecting increased clinical PD progression. (Table 
A.iii.2) 
Kinematic Parameter Correlations 
Step length, AP step length, and step speed were significantly correlated (p < 0.05) with total 
UPDRS score (ρ = -.56, ρ = -.56, ρ =-.51), Motor Exam score (ρ = -.55, ρ = -.55, ρ =-.56), the 
Pull Test (ρ =-.63, ρ =-.63, ρ =-.49), and Schwab and England score,  (ρ = .53, ρ = .53, ρ =.49), 
respectively, with a decreased step length and speed reflecting an increased UPDRS, Motor 
Exam, and Pull Test score and a decreased Schwab and England score (increased clinical PD 
progression). (Table A.iii.2) 
COP Step Parameter Correlations 
COP AP position at step heel off of the swing foot was significantly correlated (p < 0.05) with 
the Pull Test (ρ = .55), with a less posterior COP displacement at step heel off reflecting an 
increased Pull Test score. (Table A.iii.2) 
COP Stage Parameter Correlations 
Stage 1 
30 
 
Average AP COP velocity, ML COP velocity, and peak anterior and toward the swing foot COP 
velocity were significantly correlated (p < 0.05) with total UPDRS score (ρ = .47, ρ =-.55, ρ = 
.62, ρ = -.51, respectively), and the motor exam (ρ = .50, ρ =-.53, ρ = ..51, ρ = -.52, respectively), 
with increased velocity reflecting increased UPDRS and motor exam scores. The Pull test was 
significantly correlated (p < 0.05) with ML COP velocity, stage 1 duration, and peak anterior and 
toward the swing foot COP velocity (ρ = -.48, ρ =-.52, ρ = -.46, ρ = .53, respectively) with 
increased velocity and duration reflecting increased Pull Test scores. Duration of Stage 1 was 
also significantly correlated (p < 0.05) with the total UPDRS score (ρ = .50), with an increased 
stage duration reflecting increased UPDRS score. Only peak anterior COP velocity was 
significantly correlated (p < 0.05) with Schwab and England score (ρ = -.48), with a more 
anterior velocity reflecting a decreased Schwab and England score (increased clinical PD 
progression). (Table A.iii.2) 
Stage 2 
Average ML COP velocity and peak COP velocity toward the stance foot were significantly 
correlated (p < 0.05)  with all clinical parameters (Total UPDRS: ρ = .57, ρ =.57; Motor Exam: ρ 
= .52, ρ -.53; Pull Test: ρ = .51, ρ =.49; Schwab and England: ρ = -.49, ρ =-.50; respectively), 
with increased velocity reflecting increased clinical progression. Duration of Stage 2 was 
significantly correlated (p < 0.05) with Total UPDRS, motor exam and the Pull test (ρ = .44, ρ = 
.46, ρ = .57, respectively), with an increased stage duration reflecting increased clinical 
progression. (Table A.iii.2) 
 
Stage 3 
31 
 
Peak COP velocity towards the swing foot was significantly correlated (p < 0.05) with total 
UPDRS score (ρ = .44) , with an increased velocity correlating with increase in Total UPDRS 
score. (Table A.iii.2) 
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Figure A.iii.1. Transformed subject scores plotted on the principal component(PC) 1 versus PC 2 
axes, PC 3 v. PC 4, PC 5 v. PC 6, PC 7 v. PC 8, and PC 9 v. PC 10 (all significant prinicpal 
components, from top to bottom). 
 Key: red x – HC, green o – mild PD, blue + - moderate PD
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Health Screen: Healthy Controls 
Subject Identification Number: 
 
Date of Screen: 
 
Subject name:   ________________________________________________                                                                                                    
  Last    First   
 
“My name is _____.  I am calling from the Biodynamics Laboratory at the University of Kansas.  
I was given your name as someone who had indicated an interest in participating in a research study.  We 
are now beginning a study looking at how the brain controls our balance and how that might be related to 
risk of falling. If you think you might be interested in participating, and you have a few minutes, I’d like 
to describe the study to you.”   
 
Is subject interested?        YES NO 
 Comments:_____________________________________________________ 
 ______________________________________________________________ 
 
If NO:  “Thank you for your time.  Would you be interested in being contacted for future studies 
or do you prefer that your name is removed from our list?” 
 Comments:________________________________________________________
 _________________________________________________________________ 
 
If YES: “Please feel free to ask questions at any time. This study is a one-time evaluation that 
will look at how Parkinson’s disease affects the ability of the brain to control our balance. We will be 
looking at those with Parkinson’s compared to healthy adults in the same age range.  There are two parts 
to this study. First, there is a medical screening procedure.  The first part is done over the phone and will 
take approximately 20 minutes. This will include questions about current and previous health conditions. 
Once that is completed we will schedule you for a visit to the Biodynamics Laboratory at KU in 
Lawrence where we will do a physical assessment that and then do the balance testing. For the balance 
testing, we will ask you to do four different tests: one that just involves standing still, one that involves 
starting to walk from rest, one that involves walking on a treadmill for about 5 minutes, and a balance 
recovery test.  For the balance recovery test, we will pull you backwards from the waist and you will have 
to regain your balance. During all of the tests, you will be wearing a protective harness to ensure your 
safety. The whole test will take approximately 3 hours. There is no cost for participating in this study, nor 
are there any direct benefits to you.  We will pay you $30 for your participation. If you are still interested, 
I would like to ask you some questions to see if you would be able to participate in this study.” 
 
Notes:_________________________________________________________________________
________________________________________________________________ 
 
**If subject is excluded by any questions, stop the interview and explain to the subject the reason 
for exclusion.  Thank them for their time and willingness to participate. 
 
Name: ___________________________________ Age:___________________ 
Birthdate:_________________________________________________________ 
Gender:  M F   
Address: __________________________________________________________  
Phone #: 
Address: 
42 
 
Phone: ___________________________________________________________ 
Schooling/Occupation: _______________________________________________ 
Height: ________________Weight: ________________________ 
Are you currently participating in any other research studies? 
 
This study will require one trip to the University of Kansas in Lawrence. Would you have 
transportation for this visit? 
 
 
Are you able to get out of bed and also use the bathroom without assistance from anything or 
anyone? 
 
Are you able to stand on your own for 10 minutes without assistance? 
(ex. Can you stand at the bathroom sink to do your morning care without having to hold to 
something?) 
 
 
SUMMARY OF MEDICAL SCREEN: 
 
 
 
  
Pass? If no, why not? 
 
 
 
Height: __________ Weight:__________Age:__________Gender: ____________ 
 
 
 
Comments:  
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Have you been 
diagnosed with: 
Yes No When Details Exclude? 
Ever had major surgery 
or amputation? 
    
Yes if affects legs, 
not recovered 
completely 
Osteoporosis     Yes 
Brittle Bones     Yes 
Fibromyalgia? 
Constant aches and 
fatigue? 
    Yes if constant 
Arthritis     Yes if in legs 
Nerve Damage     Yes if in legs 
Heart Attack     Yes 
Heart Disease or 
problems (surgeries, valve 
replacement, angina, 
pacemaker?) 
    Yes 
Chest Pain from heart 
disease? 
    Yes 
Polio or Post Polio 
Syndrome 
    Yes 
Broken Bones? 
Compression fractures? 
    
Yes if < 2 years ago 
and in leg or spine 
Ever had a hip, knee, or 
ankle replacement or 
surgery? 
    Yes 
Ever had a joint fusion?     Yes 
Diabetes? Thyroid 
conditions? 
    
Yes if not controlled 
or if have neuropathy 
High Blood Pressure     
Yes if not controlled 
on meds 
Neurological Disease 
(MS, ALS, Dementia, 
Seizure disorders, PD) 
    Yes 
Stroke or TIA     Yes 
Cancer, Leukemia, 
Lymphoma? 
    
Yes if currently 
being treated 
Anemia     
Yes if has had blood 
transfusion in last year 
Seizure     Yes 
Meniere’s Disease? 
Inner Ear Damage? 
Vertigo? Ear infection 
now? 
    Yes 
Acoustic Neuroma? 
Tinnitus? (ringing, 
buzzing in ears) Do you 
feel pressure in ears? 
    Yes if constant 
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Do you have any 
problems with: 
Yes No How does it affect ADL? Exclude? 
Pain or stiffness in 
hips? Knee? Ankles? 
Back? Shoulder? 
   
Yes if affects 
walking, standing 
Hip, Knee, or Ankle 
injury? 
   
Yes if affects 
walking, standing 
Back Problems? If yes: 
What motions cause 
pain (bending, twisting, 
lifting, quick movements?) 
How irritable is the 
pain? 
How do you treat the 
pain? 
Have you seen a 
doctor? 
   
Yes if brought on by 
walking, standing, 
quick movements, if 
brought on easily 
Muscle Problems in 
leg? Weakness in legs? 
Does it limit how far you 
can walk or how long you 
can stand? 
   
Yes if affects 
walking, standing 
Poor circulation in legs 
causing them to become 
cold, numb, or causes 
cramping while walking, 
been diagnosed with 
PVD? Claudication? 
   
Only if causes 
problems when 
walking or standing 
Lung disease? 
Emphezema? Chronic 
Bronchitis? SOB? DOE? 
   
Yes if affects 
walking, standing 
Ever had a head or 
neck injury? 
   Not necessarily 
Gout or Psuedogout?    Not necessarily 
Foot problems?    Not necessarily 
Hearing Problems? 
Hearing aid? Last hearing 
exam? 
   Not necessarily 
Have you been 
hospitalized in the past 
year? Major illness in last 
year? 
   Not necessarily 
Headaches    Not necessarily 
Neuropathy    Not necessarily 
Vision    Not necessarily 
Falls    Not necessarily 
Driving    Not necessarily 
Night Driving    Not necessarily 
Shortness of Breath    Not necessarily 
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Edema (swelling of 
legs) 
   Not necessarily 
Fainting or 
lightheadedness? 
   Not necessarily 
Memory    Not necessarily 
Burning pain or 
weakness anywhere 
   Not necessarily 
Depression    Not necessarily 
 
MEDICATIONS: 
What medications are you currently taking? 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
OTC Medications: 
 
 
ACTIVITY: 
Are you able to leave house / apartment on your own? How often? 
___________________________________________________________ 
 
When you walk, do you walk with : Self walker/cane  person assist unable 
How far do you walk on a daily basis? ________ 
How often do you walk? _______ 
How long do you walk (duration) _______ 
 
Do you participate in any exercise/Activities? 
Type ________________________________________________ 
Sessions per week _____________________________________ 
Minutes / hours per session _______________________________ 
 
When you transfer from a sitting to standing position, do you do it:  
Alone With assistive device With person assist Unable 
 
When you transfer from lying down to sitting, do you do it: 
Alone With assistive device With person assist Unable 
 
Hand dominance L R  Leg dominance L R 
(Are you right or left-handed?)  (Which leg would you kick a ball with?) 
 
Recent vision screen? If yes, when? 
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BARTHEL INDEX: SEE FULL VERSION 
       With Help  Independent 
1. Feeding       5   10 
2. Moving from wheelchair to bed and return   5-10   15 
3. Personal toilet (wash face, comb hair, etc.)   0   5 
4. Getting on and off toilet (handling clothes, flush, wipe) 5   10 
5. Bathing self       0   5 
6. Walking on level surface     10   15 
7. Ascend and descend stairs     5   10 
8. Dressing (includes tying shoes, fastening)   5   10 
9. Controlling bowels      5   10 
10. Controlling bladder      5   10 
Is there anything else you can think of about your current or past health state that we might need 
to know?  
 
“With these initial questions it appears that you are eligible for the next step in the study.  The 
next step involves a physical evaluation by a physical therapist and geriatrician here at the Center on 
Aging.  The evaluation will take approximately one hour.  We are now scheduling participants for 
______________.  Would you be able to come to the Center on Aging to participate during this time?” 
 
If NO: “We will be continuing to test more participants in the coming weeks and months.  Can 
we contact you to schedule a time in future?”   
   
“We like to schedule to start in the morning or after lunch around 1:00…..*schedule a time with 
them. 
 
Is participant interested? 
 a. Visit scheduled _________________________________________ 
 b. Visit delayed (specify reason)______________________________ 
 c. Subject requests delay and reinquiry at a later date: _____________ 
 d. Subject and/or family expresses wish for no further contact. 
 
Notes: 
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Health Screen: PD Participants 
Subject Identification Number: 
Date of Screen: 
Subject name:   ________________________________________________                                                                                                    
  Last    First   
 
“My name is _____.  I am calling from the Biodynamics Laboratory at the University of Kansas.  
I was given your name by Dr. Lyons and Dr. Pahwa in the Parkinson’s Disease Center at KUMC as 
someone who had indicated an interest in participating in a research study.  We are now beginning a study 
looking at how Parkinson’s disease affects the ability of the brain to control our balance and how that 
might be related to risk of falling. If you think you might be interested in participating, and you have a 
few minutes, I’d like to describe the study to you.”   
 
Is subject interested?        YES NO 
 Comments:_____________________________________________________ 
 ______________________________________________________________ 
 
If NO:  “Thank you for your time.  Would you be interested in being contacted for future studies 
or do you prefer that your name is removed from our list?” 
 Comments:________________________________________________________
 _________________________________________________________________ 
 
If YES: “Please feel free to ask questions at any time. This study is a one-time evaluation that 
will look at how Parkinson’s disease affects the ability of the brain to control our balance. We will be 
looking at those with Parkinson’s compared to healthy adults in the same age range.  There are two parts 
to this study. First, there is a medical screening procedure.  The first part is done over the phone and will 
take approximately 20 minutes. This will include questions about current and previous health conditions. 
Once that is completed we will schedule you for a visit to the Biodynamics Laboratory at KU in 
Lawrence where we will do a physical assessment that and then do the balance testing. For the balance 
testing, we will ask you to do four different tests: one that just involves standing still, one that involves 
starting to walk from rest, one that involves walking on a treadmill for about 5 minutes, and a balance 
recovery test.  For the balance recovery test, we will pull you backwards from the waist and you will have 
to regain your balance. During all of the tests, you will be wearing a protective harness to ensure your 
safety. The whole test will take approximately 3 hours. There is no cost for participating in this study, nor 
are there any direct benefits to you.  We will pay you $30 for your participation. If you are still interested, 
I would like to ask you some questions to see if you would be able to participate in this study.” 
Notes:_________________________________________________________________________
________________________________________________________________ 
 
**If subject is excluded by any questions, stop the interview and explain to the subject the reason 
for exclusion.  Thank them for their time and willingness to participate. 
Phone #: 
Address: 
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Name: ___________________________________ Age:___________________ 
Birthdate:_________________________________________________________ 
Gender:  M F   
Address: __________________________________________________________  
Phone: ___________________________________________________________ 
Schooling/Occupation: _______________________________________________ 
Height: ________________Weight: ________________________ 
Are you currently participating in any other research studies? 
 
This study will be done at the University of Kansas Lawrence Campus. Would you have 
transportation for this visit?  
 
Are you able to get out of bed and also use the bathroom without assistance from anything or 
anyone? 
 
Are you able to stand on your own for 10 minutes without assistance? 
(ex. Can you stand at the bathroom sink to do your morning care without having to hold to 
something?) 
 
 
SUMMARY OF MEDICAL SCREEN: 
 
 
 
  
Pass? If no, why not? 
 
 
 
Height: __________ Weight:__________Age:__________Gender: ____________ 
 
 
 
Comments:  
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Have you been diagnosed with: Yes No When Details Exclude? 
Ever had major surgery or amputation?     Yes if 
affects legs, 
not recovered 
completely 
Osteoporosis     Yes 
Brittle Bones     Yes 
Fibromyalgia? Constant aches and 
fatigue? 
    Yes if 
constant 
Arthritis     Yes if in 
legs 
Nerve Damage     Yes if in 
legs 
Heart Attack     Yes 
Heart Disease or problems (surgeries, 
valve replacement, angina, pacemaker?) 
    Yes 
Chest Pain from heart disease?     Yes 
Polio or Post Polio Syndrome     Yes 
Broken Bones? Compression fractures?     Yes if < 2 
years ago and 
in leg or spine 
Ever had a hip, knee, or ankle 
replacement or surgery? 
    Yes  
Ever had a joint fusion?     Yes 
Diabetes? Thyroid conditions?     Yes if not 
controlled or 
if have 
neuropathy 
High Blood Pressure     Yes if not 
controlled on 
meds 
Neurological Disease (MS, ALS, 
Dementia, Seizure disorders) 
    Yes 
Stroke or TIA     Yes 
Cancer, Leukemia, Lymphoma?     Yes if 
currently 
being treated 
Anemia     Yes if has 
had blood 
transfusion in 
last year 
Seizure     Yes 
Meniere’s Disease? Inner Ear 
Damage? Vertigo? Ear infection right 
now? 
    Yes 
Acoustic Neuroma? Tinnitus? (ringing, 
buzzing in ears) Do you feel pressure in 
ears? 
 
    Yes if 
constant 
Do you have any problems with: Yes No How does it affect ADL? Exclude? 
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Pain or stiffness in hips? Knee? 
Ankles? Back? Shoulder? 
   Yes if 
affects 
walking, 
standing 
Hip, Knee, or Ankle injury?    Yes if 
affects 
walking, 
standing 
Back Problems? If yes: 
What motions cause pain (bending, 
twisting, lifting, quick movements?) 
How irritable is the pain? 
How do you treat the pain? 
Have you seen a doctor? 
   Yes if 
brought on by 
walking, 
standing, 
quick 
movements, if 
brought on 
quickly 
Muscle Problems in leg? Weakness in 
legs? Does it limit how far you can walk 
or how long you can stand? 
   Yes if 
affects 
walking, 
standing 
Poor circulation in legs causing them 
to become cold, numb, or causes 
cramping while walking, been diagnosed 
with PVD? Claudication? 
   Only if 
causes 
problems 
when walking 
or standing 
Lung disease? Emphezema? Chronic 
Bronchitis? SOB? DOE? 
   Yes if 
affects 
walking, 
standing 
Ever had a head or neck injury?    Not 
necessarily 
Gout or Psuedogout?    Not 
necessarily 
Foot problems?    Not 
necessarily 
Hearing Problems? Hearing aid? Last 
hearing exam? 
   Not 
necessarily 
Have you been hospitalized in the past 
year? Major illness in last year? 
   Not 
necessarily 
Headaches    Not 
necessarily 
Neuropathy    Not 
necessarily 
Vision    Not 
necessarily 
Falls    Not 
necessarily 
Driving    Not 
necessarily 
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Night Driving    Not 
necessarily 
Shortness of Breath    Not 
necessarily 
Edema (swelling of legs)    Not 
necessarily 
Fainting or lightheadedness?    Not 
necessarily 
Memory    Not 
necessarily 
Burning pain or weakness anywhere in 
body? 
   Not 
necessarily 
Depression    Not 
necessarily 
 
MEDICATIONS: 
What medications are you currently taking? 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
Name: _________________________ Amt _______________Time________________ 
**Testing should occur 1-2 hours after last dose of medication.  
 
OTC Medications: 
 
 
ACTIVITY: 
Are you able to leave house / apartment on your own? How often? 
___________________________________________________________ 
 
When you walk, do you walk with : Self walker/cane  person assist unable 
How far do you walk on a daily basis? ________ 
How often do you walk? _______ 
How long do you walk (duration) _______ 
 
Do you participate in any exercise/Activities? 
Type ________________________________________________ 
Sessions per week _____________________________________ 
Minutes / hours per session _______________________________ 
 
When you transfer from a sitting to standing position, do you do it:  
Alone With assistive device With person assist Unable 
 
When you transfer from lying down to sitting, do you do it: 
Alone With assistive device With person assist Unable 
 
Hand dominance L R  Leg dominance L R 
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(Right or left-handed?)   (Which leg would you kick a ball with?) 
 
Recent vision screen? If yes, when? 
 
Is there anything else you can think of about your current or past health state that we might need 
to know?  
 
 
 
When were you first diagnosed with Parkinson’s disease?  
 
What was the first symptom you experienced?  When did you experience the first symptom? 
  
 
Are you affected on one or both sides of your body? Which side is more affected? 
 
 
Do you feel like you have bad balance? Do you have difficulty maintaining your balance while: 
standing still, walking, changing positions?   
 
 
Have you fallen in the past year?  
Event: _______________________Date:________________Injury:_________________ 
Circumstances: ___________________________________________________________ 
Event: _______________________Date:________________Injury:_________________ 
Circumstances: ___________________________________________________________ 
Event: _______________________Date:________________Injury:_________________ 
Circumstances: ___________________________________________________________ 
 
How often do you fall? 
 
Do you currently use any devices to assist you (canes, walker, etc?) 
 
“With these initial questions it appears that you are eligible for this study.  We are now 
scheduling participants for ______________.  Would you be able to come to the Center on Aging to 
participant during this time?” 
 
If NO: “We will be continuing to test more participants in the coming weeks and months.  Can 
we contact you to schedule a time in future?”   
“We like to schedule to start in the morning or after lunch around 1:00…..*schedule a time with 
them. 
Is participant interested? 
 a. Visit scheduled _________________________________________ 
 b. Visit delayed (specify reason)______________________________ 
 c. Subject requests delay and reinquiry at a later date: _____________ 
 d. Subject and/or family expresses wish for no further contact. 
Notes: 
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Appointment Letter 
 
 
Notes: 
 
 
Dear _____________, 
Thank you for agreeing to participate in our research study!  This study looking at how 
Parkinson’s disease affects balance will be conducted in the Biodynamics Lab, which is located on the 
second floor of Learned Hall on the University of Kansas Lawrence Campus. 
Your appointment is scheduled for Wed, Oct. 20
th
 at 3pm and will be about 3
 
hours long. 
Directions and a campus map are included with this letter. Parking is located on the east side of Eaton 
Hall (Learned is adjacent to Eaton Hall), and one of four meters will be hooded and marked “Reserved”- 
this is for you. A research associate will be there to meet you and take you up to the research lab. If you 
have any problems finding anything please give me a call at the number below.  
If you have any questions or need to reschedule your appointment, please contact Molly McVey 
at 785-218-2714.  
Thanks again for participating. 
Sincerely, 
 
Molly McVey 
Graduate Research Assistant  
Biodynamics Laboratory- Mechanical Engineering Department 
The University of Kansas 
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Barthel Index 
INSTRUCTIONS: The Barthel Index is a record of what a patient does not a record of what a 
patient could do.  Full credit is not given for an activity if the patient needs even minimal 
help/supervision.  A score of (0) is given when a patient cannot meet the criteria as defined. Circle the 
appropriate answer to each question. 
 
1.  Today, are you able to feed yourself? 
10:  Independent; feeds self from tray or table; can put on assistive device if 
needed; accomplishes feeding in reasonable time. 
5:  Assistance necessary with cutting food, etc. 
0:  Cannot meet criteria 
88:  Contraindicated due to 
_________________________________________ 
2.  Today, are you able to get out of bed or into a chair? 
 15:  Independent in all phases of this activity 
10:  Minimal help needed or patient needs to be reminded or supervised for 
safety of one or more parts of this activity. 
5: Patient can come to sitting position without help of second person, but 
needs to be lifted out of bed and assisted with transfers 
0:  Cannot meet criteria 
88:  Contraindicated due to _______________________________________ 
3.  Today, are you able to wash your face, brush your teeth, brush your hair, etc.? 
5: Can wash hands, face; combs hair, cleans teeth. Can shave (males) or 
apply makeup (females) without assistance; females need not braid or style hair. 
0:  Cannot meet criteria 
 88:  Contraindicated due to________________________________________ 
4.  Today are you able to get on and off the toilet? 
10:  Able to get on and off the toilet, fastens/unfastens clothes; can use toilet paper 
without assistance.  May use wall bar or other support if needed; if bedpan is necessary, patient 
can place it on chair, empty, and clean it. 
5: Needs help because of imbalance or other problems with clothes or toilet 
paper 
0:  Cannot meet criteria 
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88:  Contraindicated due to 
_________________________________________ 
 
5.  Today, are you able to bathe yourself? 
5: May use tub, shower, or sponge bath.  Patient must be able to perform all 
functions without another person being present. 
0:  Cannot meet criteria 
88:  Contraindicated due to 
_________________________________________ 
6.  Today, are you able to walk without help? 
15:  Patient can walk at least 50 yards without assistance or supervision; may 
use braces, prostheses, crutches, canes, or walker, but not a rolling walker. Must be able 
to lock/unlock braces, assume standing or seated position, get mechanical aids into 
position for use and dispose of the mechanical aids when seated (putting on and off 
braces should be scored under dressing). 
10:  Assistance needed to perform above activities, but can walk 50 yards 
with little help. 
0:  Cannot meet criteria 
88:  Contraindicated due to ________________________________________ 
7.  Today, are you able to use a wheelchair? (Do not score if patient competes score for 
walking- item #6). 
5:  Patient cannot ambulate, but can propel wheelchair independently; can 
go around corners, turn around and maneuver chair to table, bed, toilet, etc; must be able 
to push chair 50 yards. 
0:  Cannot meet criteria 
88:  Contraindicated due to________________________________________ 
8.  Today, are you able to walk up and down stairs? 
10: Able to go up and down flights of stairs safely without supervision; using 
canes, handrails, or crutches when needed and can carry these items as 
ascending/descending. 
5: Needs help or supervision of any of the above items. 
0:  Cannot meet criteria 
88:  Contraindicated due to ________________________________________ 
9.  Today, are you able to dress and undress yourself? 
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10:  Able to put on, fasten, and remove all clothing; ties shoelaces unless 
necessary adaptations used.  Activity includes fastening braces and corsets when 
prescribed; suspenders, loafer shoes, and dresses opening in the front may be used when 
necessary.   
5: Needs help putting on, fastening, or removing clothing; must accomplish 
at least half of task alone within reasonable time; women need not be scored on use of 
brassiere or girdle undless prescribed. 
0:  Cannot meet criteria 
88:  Contraindicated due to ________________________________________ 
10.  Today, are you able to control your bowels? 
10:  Able to control bowels and have no accidents.  Can use a suppository or 
take an enema when necessary (as for spinal cord injury patients who have had bowel 
training). 
5: Needs help in using a suppository or taking an enema or has occasional 
accidents. 
0:  Cannot meet criteria 
88:  Contraindicated due to _______________________________________ 
11.  Today, are you able to control your bladder? 
10:  Able to control bladder day and night. Spinal injury patients must be able 
to put on external devices and leg bags independently, clean and empty bag, and must 
stay dry day and night. 
5:  Occasional accidents occur, cannot wait for bedpan, does not get to toilet 
in time or needs help with external device. 
0:  Cannot meet criteria 
88:  Contraindicated due to ________________________________________ 
12. Information for today’s Barthel data gathered from: 
 01: Patient 
 02: Proxy- Caregiver 
 03: Proxy- Other 
 04: Chart 
 05: Both patient and proxy 
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Beck Depression Inventory 
1.  Sadness 
0   I do not feel sad. 
1   I feel sad much of the time. 
2   I am sad all of the time. 
3   I am so sad or unhappy that I can’t stand it. 
 
2.   Pessimism 
0   I am not discouraged about my future. 
1   I feel more discouraged about my future than I used to be. 
2   I do not expect things to work out for me. 
3   I feel my fortune is hopeless and will get only worse. 
 
3.   Past Failure 
0   I do not feel like a failure. 
1   I have failed more than I should have. 
2   As I look back I see a lot of failures. 
3   I feel I am a total failure as a person. 
 
4.   Loss of Pleasure 
0   I get as much pleasure as I ever did from the things I enjoy. 
1   I don’t enjoy things as much as I used to. 
2   I get very little pleasure from the things I used to enjoy. 
3   I can’t get any pleasure from the things I used to enjoy. 
 
5.   Guilty Feelings 
0   I don’t feel particularly guilty. 
1   I feel guilty over many things I have done or should have done. 
2   I feel quite guilty most of the time. 
3   I feel guilty most of the time. 
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6.   Punishment Feelings 
0   I don’t feel I am being punished. 
1   I feel I may be punished. 
2   I expect to be punished. 
3   I feel I am being punished. 
 
7.   Self-Dislike 
0   I feel the same about myself as ever. 
1   I have lost confidence in myself. 
2   I am disappointed in myself. 
3   I dislike myself. 
 
8.   Self-Criticisms 
0   I don’t criticize or blame myself more than usual. 
1   I am more critical of myself than I used to be. 
2   I criticize myself for all of my faults. 
3   I blame myself for everything bad that happens. 
 
9.   Suicidal Thoughts or Wishes 
0   I don’t have any thoughts of killing myself. 
1   I have thoughts of killing myself, but I would not carry them out. 
2   I would like to kill myself. 
3   I would kill myself if I had the chance. 
 
10.  Crying 
0   I don’t cry anymore than I used to. 
1   I cry more than I used to. 
2   I cry over every little thing. 
3   I feel like crying, but I can’t. 
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11.  Agitation  
0   I am no more restless or would up than usual. 
1   I feel more restless or would up than usual. 
2   I am so restless or agitated that it’s hard to stay still. 
3   I am so restless that I have to keep moving or doing something. 
 
12.  Loss of Interest 
0   I have not lost interest in other people or activities. 
1   I am less interested in other people or things than before. 
2   I have lost most of my interest in other people or things. 
3   It’s hard to get interested in anything. 
 
13.  Indecisiveness 
0   I make decisions about as well as ever. 
1   I find it more difficult to make decisions than usual. 
2   I have much greater difficulty in making decisions than usual. 
3   I have trouble making any decision. 
 
14.  Worthlessness 
0   I do not feel I am worthless. 
1   I don’t consider myself as worthwhile and useful as I used to. 
2   I feel more worthless as compared to other people. 
3   I feel utterly worthless. 
 
15.  Loss of Energy 
0   I have as much energy as ever. 
1   I have less energy than I used to have. 
2   I don’t have enough energy to do very much. 
3   I don’t have enough energy to do anything. 
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16.  Changes in Sleeping Patterns 
0   I have not experienced any change in my sleeping pattern. 
1   I sleep somewhat more/less than usual. 
2   I sleep a lot more/less than usual. 
3   I sleep most of the day. 
     I wake up 1-2 hours early and can’t get back to sleep. 
 
17.  Irritability 
0   I am no more irritable than usual. 
1   I am more irritable than usual. 
2   I am much more irritable than usual. 
3   I am irritable all the time. 
 
18.  Changes in Appetite 
0   I have not experienced any change in my appetite. 
1   My appetite is somewhat greater/lesser than usual. 
2   My appetite is much greater/lesser than usual. 
3   I crave food all the time or I have no appetite at all. 
 
19.  Concentration Difficulty 
0   I can concentrate as well as ever. 
1   I can’t concentrate as well as usual. 
2   It’s hard to keep my mind on anything for very long. 
3   I find I can’t concentrate on anything. 
 
20.  Tiredness or Fatigue 
0   I am no more tired or fatigued than usual. 
1   I get more tired or fatigued more easily than usual. 
2   I am too tired or fatigued to do a lot of the things I used to do. 
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3   I am too tired or fatigued to do most of the things I used to do. 
 
21.  Loss of Interest in Sex 
0   I have not noticed any recent change in my interest in sex. 
1   I am less interested in sex than I used to be. 
2   I am much less interested in sex now. 
3   I have lost interest in sex completely. 
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Environmental Assessment  
1. Do you live in a home, apartment, or assisted living facility? 
 
2. Do you have stairs in your home? How often do you use them? 
 
Staircase #1: _______________________ Frequency: _______________________ 
Staircase #2: _______________________ Frequency: _______________________ 
Staircase #3: _______________________ Frequency: _______________________ 
Staircase #4: _______________________ Frequency: _______________________ 
 
3. Do you live alone? With a spouse or partner? Do you have a caretaker (live-in or 
otherwise)? 
 
4. Do you use any type of assistive devices at any time during a normal day? 
(Walkers, canes, etc?) 
 
5. Do you ever use assistance from someone else during a normal day? (Taking a 
hand to go down steps, get out of a car, etc.)? 
 
6. Have you ever modified anything in your home to reduce the risk of falling? 
When? 
 
Modification: __________________________ Date: ________________________ 
Modification: __________________________ Date: ________________________ 
Modification: __________________________ Date: ________________________ 
Modification: __________________________ Date: ________________________ 
Modification: __________________________ Date: ________________________ 
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Mini-Mental State Examination  
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Physical Examination  
Height  Weight  
Sitting BP-P   
Supine BP-P Standing BP-P 
Strength Left Right  Left Right 
Shld Abd   Hip Ext   
Biceps   Hip Abd   
Triceps   Hip Add   
Wst Flex   Knee Ext   
Wst Ext   Knee Flex   
Grip   Ankle Df   
Hip Flex   Ankle Pf   
Reflexes   Patellar   
Biceps   Achilles   
Triceps   Babinski   
Sensory Position Vibration Pin Prick 
 Left Right Left Right Left Right 
Upp Ext       
Low Ext       
Cerebellar Left Right 
Fing-Nose   
Heel-Shin   
Other/comments 
 
Examiner Name: 
________________________________________________________________________ 
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UPDRS Assessment  
The Unified Parkinson Disease Rating Scale (UPDRS) 
 
I. Mentation, Behavior and Mood 
1. Intellectual Impairment 
0 = None 
1 = Mild. Consistent forgetfulness with partial recollection of events and no other difficulties 
2 = Moderate memory loss, with disorientation and moderate difficulty handling complex problems. 
Mild but definite impairment of function at home with need of occasional prompting. 
3 = Severe memory loss with disorientation for time and often to place. Severe impairment in handling 
problems. 
4 = Severe memory loss with orientation preserved to person only. Unable to make judgments or solve 
problems. Requires much help with personal care. Cannot be left alone at all. 
2. Thought Disorder 
0 = None 
1 = Vivid dreaming. 
2 = "Benign" hallucinations with insight retained. 
3 = Occasional to frequent hallucinations or delusions; without insight; could interfere with daily 
activities. 
4 = Persistent hallucinations, delusions, or florid psychosis. Not able to care for self. 
3. Depression 
0 = Not present 
1 = Periods of sadness or guilt greater than normal, never sustained for days or weeks. 
2 = Sustained depression (1 week or more). 
3 = Sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss of interest). 
4 = Sustained depression with vegetative symptoms and suicidal thoughts or intent. 
4. Motivation / Initiative 
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0 = Normal 
1 = Less assertive than usual; more passive. 
2 = Loss of initiative or disinterest in elective (non-routine) activities. 
3 = Loss of initiative or disinterest in day-to-day (routine) activities. 
4 = Withdrawn, complete loss of motivation. 
II. Activities of daily living (Determine for ON and OFF medications) 
5. Speech 
0 = Normal 
1 = Mildly affected. No difficulty being understood. 
2 = Moderately affected. Sometimes asked to repeat statements. 
3 = Severely affected. Frequently asked to repeat statements. 
4 = Unintelligible most of the time. 
6. Salivation 
0 = Normal 
1 = Slight but definite excess of saliva in mouth; may have nighttime drooling. 
2 = Moderately excessive saliva; may have minimal drooling. 
3 = Marked excess of saliva with some drooling. 
4 = Marked drooling, requires constant tissue or handkerchief. 
7. Swallowing 
0 = Normal 
1 = Rare choking. 
2 = Occasional choking. 
3 = Requires soft food. 
4 = Requires NG tube or gastrostomy feeding. 
8. Handwriting 
0 = Normal 
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1 = Slightly slow or small. 
2 = Moderately slow or small; all words are legible. 
3 = Severely affected; not all words are legible. 
4 = The majority of words are not legible. 
9. Cutting food and handling utensils. 
0 = Normal 
1 = Somewhat slow and clumsy, but no help needed. 
2 = Can cut most foods, although clumsy and slow; some help needed. 
3 = Food must be cut by someone, but can still feed slowly. 
4 = Needs to be fed. 
10. Dressing 
0 = Normal 
1 = Somewhat slow, but no help needed. 
2 = Occasional assistance with buttoning, getting arms in sleeves. 
3 = Considerable help required, but can do some things alone. 
4 = Helpless. 
11. Hygiene 
0 = Normal 
1 = Somewhat slow, but no help needed. 
2 = Needs help to shower or bathe; or very slow in hygienic care. 
3 = Requires assistance for washing, brushing teeth, combing hair, going to bathroom. 
4 = Foley catheter or other mechanical aids. 
12. Turning in bed and adjusting bed clothes 
0 = Normal 
1 = Somewhat slow and clumsy, but no help needed. 
2 = Can turn alone or adjust sheets, but with great difficulty. 
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3 = Can initiate, but not turn or adjust sheets alone. 
4 = Helpless. 
13. Falling (unrelated to freezing) 
0 = None 
1 = Rare falling. 
2 = Occasionally falls, less than once per day. 
3 = Falls an average of once daily. 
4 = Falls more than once daily. 
14. Freezing when walking 
0 = None 
1 = Rare freezing when walking; may have start-hesitation. 
2 = Occasional freezing when walking. 
3 = Frequent freezing. Occasionally falls from freezing. 
4 = Frequent falls from freezing. 
15. Walking 
0 = Normal 
1 = Mild difficulty. May not swing arms or may tend to drag leg. 
2 = Moderate difficulty, but requires little or no assistance. 
3 = Severe disturbance of walking, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
16. Tremor (score right and left side separately) 
0 = Absent 
1 = Slight and infrequently present 
2 = Moderate; bothersome to patient. 
3 = Severe; interferes with many activities. 
4 = Marked, interferes with most activities. 
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17. Sensory complaints related to parkinsonism 
0 = None 
1 = Occasionally has numbness, tingling, or mild aching. 
2 = Frequently has numbness, tingling, or aching; not distressing. 
3 = Frequent painful sensations. 
4 = Excruciating pain. 
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Motor Exam 
III. Motor Examination 
18. Speech 
0 = Normal 
1 = Slight loss of expression, diction and/or volume. 
2 = Monotone, slurred but understandable; moderately impaired. 
3 = Marked impairment, difficult to understand. 
4 = Unintelligible. 
19. Facial expression 
0 = Normal 
1 = Minimal hypomimia, could be normal "poker face". 
2 = Slight but definitely abnormal diminution of facial expression. 
3 = Moderate hypomimia; lips parted some of the time. 
4 = Masked or fixed facies with severe or complete loss of facial expression; lips parted ¼ inch or more. 
20. Tremor at rest (score face, lip and chin; right upper; left upper; right lower; left lower) 
0 = Absent 
1 = Slight and infrequently present. 
2 = Mild in amplitude and persistent or moderate in amplitude, but only intermittently present. 
3 = Moderate in amplitude and present most of the time. 
4 = Marked in amplitude and present most of the time. 
21. Action or postural tremor of hands (score right and left separately) 
0 = Absent 
1 = Slight; present with action 
2 = Moderate in amplitude, present with action. 
3 = Moderate in amplitude with posture holding as well as action. 
4 = Marked in amplitude; interferes with feeding. 
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22. Rigidity (Judged on passive movement of major joints relaxed in sitting position. Cogwheeling to be 
ignored. 
Score neck; right upper, left upper; right lower; left lower) 
0 = Absent 
1 = Slight or detectable only when activated by mirror or other movements. 
2 = Mild to moderate. 
3 = Marked, but full range of motion easily achieved. 
4 = Severe, range of motion achieved with difficulty. 
23. Finger taps (tap thumb with index finger in rapid succession, with widest amplitude possible, score 
each hand 
separately) 
0 = Normal 
1 = Mild slowing and/or reduction in amplitude 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movement or arrests in ongoing movement. 
4 = Can barely perform the task. 
24. Hand movements (Patient opens and closes hands in rapid succession with widest amplitude possible, 
score 
each hand separately). 
0 = Normal 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movement or arrests in ongoing movement. 
4 = Can barely perform the task. 
25. Rapid alternating movements of hands (Pronation/supination movements of hands, vertically of 
horizontally, 
with as large an amplitude as possible, both hands simultaneously but score each hand separately.) 
0 = Normal 
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1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movement or arrests in ongoing movement. 
4 = Can barely perform the task. 
26. Leg agility with knee bent (Patient taps heel on ground in rapid succession, picking up entire foot. 
Amplitude 
should be about 3 inches, score each leg separately). 
0 = Normal 
1 = Mild slowing and/or reduction in amplitude. 
2 = Moderately impaired. Definite and early fatiguing. May have occasional arrests in movement. 
3 = Severely impaired. Frequent hesitation in initiating movement or arrests in ongoing movement. 
4 = Can barely perform the task. 
27. Arising from chair (Patient attempts to arise from straight backed chair with arms folded across chest) 
0= Normal 
1= Slow; or may need more than one attempt. 
2 = Pushes self up from arms of seat. 
3 = Tends to fall back and may have to try more than one time, but can get up without help. 
4 = Unable to rise without help. 
28. Posture 
0 = Normal erect 
1 = Not quite erect, slightly stooped posture; could be normal for older person. 
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning to one side. 
3 = Severely stooped posture with kyphosis; can be moderately leaning to one side. 
4 = Marked flexion with extreme abnormality of posture. 
29. Gait 
0 = Normal 
1 = Walks slowly, may shuffle with short steps but no festination or propulsion. 
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2 = Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or 
propulsion. 
3 = Severe disturbance of gait, requiring assistance. 
4 = Cannot walk at all, even with assistance. 
30. Postural stability (Response to sudden posterior displacement produced by pull on shoulders while 
patient erect 
with eyes open and feet slightly apart. Patient is prepared). 
0 = Normal 
1 = Retropulsion, but recovers unaided. 
2 = Absence of postural response; would fall if not caught by examiner. 
3 = Very unstable, tends to lose balance spontaneously. 
4 = Unable to stand without assistance. 
31. Body bradykinesia and hypokinesia (Combining slowness, hesitancy, decreased arm swing, small 
amplitude, 
and poverty of movement in general). 
0 = None 
1 = Minimal slowness, giving movement a deliberate character; could be normal for some persons. 
Possibly reduced amplitude. 
2 = Mild degree of slowness and poverty of movement which is definitely abnormal. Alternatively, some 
reduced amplitude. 
3 = Moderate slowness, poverty or small amplitude of movement. 
4 = Marked slowness, poverty or small amplitude of movement. 
IV. Complications of Therapy 
A. Dyskinesia 
32. Duration What proportion of the waking day are dyskinesia present? Historical information. 
0 = None 
1 = 1%-25% of day. 
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2 = 26%-50% of day. 
3 = 51%-75% of day. 
4 = 76%-100% of day. 
33. Disability How disabling are the dyskinesia? Historical information; may be modified by office 
examination 
0 = Not disabling. 
1 = Mildly disabling. 
2 = Moderately disabling. 
3 = Severely disabling. 
4 = Completely disabling. 
34. Painful dyskinesia How painful are the dyskinesia? 
0 = No painful dyskinesia 
1 = Slight 
2 = Moderate 
3 = Severe 
4 = Marked 
35. Presence of early morning dystonia Historical information 
0 = No 
1 = Yes 
B. Clinical fluctuations 
36. Are any “off ” periods predictable as to timing after a dose of medications? 
0 = No 
1 = Yes 
37. Are any “off ” periods unpredictable as to timing after a dose of medication? 
0 = No 
1 = Yes 
38. Do any of the ‘off ” periods come on suddenly, e.g. over a few seconds? 
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0 = No 
1 = Yes 
39. What proportion of the waking day is the patient “off ” on average? 
0 = None 
1 = 1%-25% of day. 
2 = 26%-50% of day. 
3 = 51%-75% of day. 
4 = 76%-100% of day. 
C. Other complications 
40. Does the patient have anorexia, nausea, or vomiting? 
0 = No 
1 = Yes 
41. Does the patient have any sleep disturbances, e.g. insomnia or hypersomnolence? 
0 = No 
1 = Yes 
42. Does the patient have symptomatic orthostasis? 
0 = No 
1 = Yes 
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Hoehn and Yahr  
V. Modified Hoehn and Yahr Staging 
Stage 0 = No signs of disease 
Stage 1 = Unilateral disease 
Stage 1.5 = Unilateral plus axial involvement 
Stage 2 = Bilateral disease, without impairment of balance 
Stage 2.5 = Mild bilateral disease, with recovery on pull test 
Stage 3 = Mild to moderate bilateral disease; some postural instability; physically independent 
Stage 4 = Severe disability; still able to walk or stand unassisted 
Stage 5 = Wheelchair bound or bedridden unless aided 
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Schwab and England 
VI. Schwab and England Activities of Daily Living Scale 
100% - Completely independent. Able to do all chores without slowness, difficulty or impairment. 
Essentially 
normal. Unaware of any difficulty. 
90% - Completely independent. Abe to do all chores with some degree of slowness, difficulty and 
impairment. 
Might take twice as long. Beginning to be aware of difficulty. 
80% - Completely independent in most chores. Takes twice as long. Conscious of difficulty and slowness. 
70% - Not completely independent. More difficulty with some chores. Three to four times as long in 
some. 
Must spend a large part of the day with chores. 
60% - Some dependency. Can do most chores, but exceedingly slowly and with much effort. Errors; some 
impossible. 
50% - More dependent. Help with half, slower, etc. Difficulty with everything. 
40% - Very dependent. Can assist with all chores, but few alone. 
30% - With effort, now and then does a few chores alone or begins alone. Much help needed. 
20% - Nothing alone. Can be a slight help with some chores. Severe invalid. 
10% - Totally dependent, helpless. Complete invalid. 
0% - Vegetative functions such as swallowing, bladder and bowel functions are not functioning. 
Bedridden. 
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APPENDIX D. Experimental Protocol Documentation 
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Landon Center on Aging 
 Protocol 
 
Subject Setup 
Participants will be set up at the start of the session.  This setup will remain the same for all protocols. 
 
Consent  
Clarify history (falls in previous 3 months, severity and duration, medication status) 
Mini-mental exam 
Change into standard shorts, shoes, and socks. 
 
Measurements and EMG Placement 
Have subject lie down in setup room; take the following measurements while subject is lying down: 
Leg Length (distance from ASIS to medial ankle via knee) 
Inter-ASIS Distance  
Place EMGs: bilateral TA, solius, hamstring, quad 
 Tips for placement: 
 Solius: 
Hamstring: have subject lay on side, then hold their lower leg and ask them to try to bend their leg while 
you resist.  
Have subject stand for the following measurements: 
Knee Width (between femoral condyles) 
Ankle Width (align measuring device with axis of ankle) 
Ankle Height 
Foot Width 
Foot Length 
Calf Circumference 
Thigh Circumference 
Height 
Weight 
 
EMG:  
Bilateral application of electrodes to the following muscles: 
Gastroc, solius, quadriceps, anterior tib, hamstring.  
 
Connect EMG as follows: 
EMG lead Muscle  EMG out-> Vicon BNC in 
#1   R TA     9 – 1 
#2   R gatroc  10 – 2  
#3   R solius/ham  11 – 3  
#4  R quad   12 – 4    
#5  L TA   13 – 5  
#6   L gatroc  14 – 6  
#7   L solius/ham  15 – 7  
#8  L quad    16 – 8 
Black   ground   17 – 9 
 
Vicon markers 
80 
 
15 14 mm markers will be placed on the lower body as follows (see Vicon PlugIn Gait marker placement 
guide for more information about specific placement methods): 
Complete Setup: Bilateral – ASIS, sacrum, thigh, knee, shin, ankle, heel, toe 
Knee alignment devices (KADS) will be used during the patient setup to establish the knee joint 
coordinate system. 
Modified Setup: Bilateral- greater trochanter, thigh, knee, shin, ankle, heel, toe 
 
Marker Placement Tips: 
 ASIS/Sacrum: tape around the waist, and then attach markers to the tape 
Thigh: Find greater trochanter, have subject rotate their foot to make sure you have it, then place marker 
on the line between the greater troch and knee. Place the marker on the right side higher than the left side. 
Knee: Identify tibial plateau, then move back and up to find the femoral condyle- Place KADS first, then 
replace with individual markers. 
Shin: Place on line between axis of knee and axis of ankle, marker on the right side higher than left 
 Heel: Place on shoe, at same height of toe marker 
 Ankle: Place marker in line of joint 
 Toe: 2nd metatarsal head  
 
• Put harness on 
• Put EMG belt on 
 
Data Collection 
Walk the subject over to the forceplates for the EMG check and subject calibration trials. 
 
• Subject Calibration Trial 
• Remove KADs and replace with knee markers 
• EMG check trial 
 
Sway (trial type: PD_sway/ trial name: sway1) 
Sway testing consists of three trials in each of two different conditions, eyes open (EO) and eyes closed 
(EC). Force plate, EMG, and motion data will be collected. Each test will last 30 seconds with 30 seconds 
of rest in between trials. 
Should have complete marker setup, EMG on gastroc, SOLEUS, TA, quads 
 
• Have participant stand comfortably with one foot on each force plate. Feet should be shoulder 
wide and at a self-selected angle.  Arms rest to the side and the subject is looking at a marker 
placed 5 feet in front of the at approximately eye height.  
• Attach safety harness 
• Check EMG and visibility of markers  
• Read script to the participant 
• Before each test, remind the participant of the condition being tested (EO or EC). 
• Disconnect Solius EMG channel and connect to hamstring electrode 
 
Balance Recovery (trial type: general w/analog/ trial name: pull1) 
The balance recovery testing consists of 3 backwards pull trials.  Force plate, EMG, and motion data will 
be collected during all trials.  The weight-drop device will be used to pull the participant. 
Should have modified marker setup (no sacrum or ASIS, but including great troch markers), EMG on 
gastroc, hamstring, TA, quad 
 
• Attach safety harness 
• TAKE STATIC TRIAL IN MODIFIED MARKER SETUP 
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• Put on the rigid belt  
• Measure waist height, adjust pull device to 8.7% of waist height 
• Attach pull device cable 
• Read script, explaining task (no practice trials) 
• Research assistant should spot the participant throughout all trials 
• Once subject is ready, release the weight-dropping mechanism 
• Tell the subject to relax after they have regained their balance for three seconds 
• Check trial in Vicon for marker visibility  
• Perform a total of 3 trials with 30 seconds rest in between trials 
• Disconnect safety harness, cable to pull device, and remove belt 
 
Gait Initiation (trial type: general w/analog/ trial name: gait_ini1) 
Participants will perform 5 gait initiation trials, all starting from standing on a forceplate. EMG, force and 
movement data will be collected. 
Should have complete marker setup, foot switches, EMG on gastroc, hamstring, TA, quad 
 
• Attach foot switches and foot switch belt 
• Attach foot switches to scope to check and monitor foot switch signal 
• Have participant stand in collection area. 
• Attach safety harness 
• Read the script to the participant. 
• Do a few practice trials to get a good starting location ensuring clean FP strikes. 
• Participant should start each trial with their feet in a comfortable stance and their arms relaxed at 
their sides. 
• At the end of the trial, remove the light switch cable and replace with a grounding resistor to 
AUX 4. 
• A research assistant should be spotting the participant throughout. 
 
Gait (trial type: PD_gait/ trial name: gait) 
Participant will walk on the treadmill for 3 minutes at a self-selected speed.  EMG and movement data 
will be collected. 
Should have complete marker setup, foot switches, EMG on gastroc, hamstring, TA, quad 
 
• Move treadmill into the Vicon collection volume under the safety support. 
• Have participant put on safety harness. 
• Attach foot switches and foot switch belt 
• Attach foot switches to scope to check and monitor foot switch signal 
• Instruct participant to step onto the treadmill. 
• Attach the cable to the safety harness. 
• Attach kill switch to subject’s clothing. 
• Power up the treadmill. 
• Read the script to the participant, explaining the tasks. 
• Slowly increase the speed of the treadmill until the desired speed is reached. Record the final 
speed on the data collection sheet. 
• Once the participant has reached a comfortable gait begin data collection. 
• At the end of data collection, inform participant they are finished and then stop the treadmill 
(manually decrease the speed to zero). 
• Remove safety cable and assist the participant in stepping off the treadmill. 
 
Take another subject calibration trial (should have two subject calibration trials- one for use with br, one 
for all others) 
82 
 
 
Take another force plate zero trial 
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Technical Setup 
 
Camera and Volume setup  
 Set camera locations based on Vicon Camera Setup Sheet for study. 
 Check that the volume and surrounding area is free of reflective objects. 
 
Check connections with peripheral equipment 
 Force plates: Attach the cables labeled “Vicon Raw” to the force plate amplifiers.  These 
terminate at the Vicon BOB.  Make sure the cable from the Vicon BOB is connected to the data 
station.  Power on force plates at least 15 minutes before collection. 
 EMG:  Attach BNC to the Vicon BOB using channels 1-8. 
 Pull device input: Connect to the Vicon BOB - normal to AUX1, shear  to AUX2.   
 Video (If using): Attach fire wire from camera to the fire wire port of PC.   If the camera cord 
length is too short, you may use the Dazzle, connecting the fire wire from the camera to Dazzle 
and fire wire from Dazzle to the PC.  Make sure the Dazzle and camera are powered on. The 
Dazzle should be set at “Pass through”. 
 
Power up 
 Power up and log into computer 1st, then power up Vicon Datastation.  If you do not do this in the 
correct order, the computer will not be able to find the network. 
   
Turn on all equipment, including cameras and strobes at least 15 minutes before start of a 
session. 
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Session setup: 
 Start Workstation  
 Open Eclipse. In the correct database (Browse D: Capture\Data\ Antonis.enf), double click on 
the project level (green icon) to activate it. With this level highlighted, select System| System 
Configuration 
o Select “MJF_pilot” system configuration (not a bad idea to check analog setup to 
confirm the change in the system settings).  The session settings are taken from the active 
config, so if you build the session before making this change, your settings will be 
incorrect and you will need to start over. 
 Click System | Control Setup and ensure that no remote triggers are enabled (no checks). 
 Click System | Start Link to establish a connection to the datastation.  This should illuminate the 
camera strobes. Allow the cameras to be on for 10 minutes before calibrating.  
 Click System | Live Monitors to look at the capture volume. Check and adjust camera placement 
to ensure your capture space is covered and viewed by cameras (a quick check of the volume by 
walking through it with the wand). 
o If you are not receiving data from a camera, unplug the line to the datastation for that 
camera (1-3 or 4-6) and replug it in.  This will reinitialize that group of cameras.  
 Check camera angles and camera sensitivity in Workstation 
 Go to System | Calibrate cameras. Make sure all cameras are selected and that the proper 
calibration props are selected (clinical L-frame and 500mm wand). 
 Set the calibration L-frame in place to create the desired coordinate system. 
 Perform a static calibration followed by dynamic calibration* and check for acceptable 
calibration values.  
o Make sure the wand stays in the calibration volume during the capture.   
 Enter the calibration information in the log. 
Wand visibility – measure of whether both markers are visible to each 
camera.  Higher is better (<50% = failed). 
Static reproducibility – how well the L frame measured matches expected 
measurements.  Lower is better. 
Residuals - < 0.1% of the distance from the cameras to the center of the 
capture volume.  Check the log for acceptable values, typically 1-1.6 for 
larger volumes. 
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 Build the session (add a new patient, and a new session). 
 With the session highlighted, go to System | Calibrate Analog Zero Levels and select the force 
plate channels.  Make sure that the force plates are completely setup before this step (powered on, 
balanced, etc.) and that there is no load on them. 
 Go to System | Live Movie to check the view of the video camera if using it.   
Begin Capture with Subject  
 Once subject is set up with markers, have them stand in the capture volume. Make sure there is 
nothing besides markers which appear on the subject (reflective jewelry etc). 
 To capture a trial: 
o Select the appropriate trial type  
o Check that the appropriate data will be collected by clicking Types. 
o Give the trial a name and any description desired.  
*Note 1: make sure that the person performing the calibration is not wearing anything reflective.  This can 
be checked in live monitor by having the person walk around the capture volume.   Also, ensure 
that your subject is not in view of the cameras if he/she has markers on. 
 Note 2: if a camera is moved at all during testing you must recalibrate! 
 
**Checking and preliminary processing 
 You may want to use diagnostic mode to check video quality.  
 Analog data can be checked using Graph | Analog.  This data will be the analog data as acted on 
by the scale factors specified for each channel in the analog setup.  The raw data can be 
visualized by Window | New Analog Data or by double clicking the ‘A’. 
Control the data presentation by the following keys with or without shift key: 
L - # of traces 
T – timeline 
G – gain  
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Protocol Checklist 
 
Start Equipment Setup: 
_____Check Vicon camera positions 
_____Cables from force plate amplifiers are labeled “Vicon BOB” 
_____BNC connectors from EMG are connected to Vicon BOB. 
_____Connect video camera 
_____Connect pull device – normal (AUX1), shear (AUX2) 
_____Balance force plates 
 
Start Subject Setup: 
_____Consent  
_____Clarify history (falls in previous 3 months, severity and duration, medication status) 
_____Mini-mental exam 
_____5 Self-Report Tests  
 
Complete Equipment Setup: 
_____Complete Vicon session start-up as in Vicon Collection Procedures (do not calibrate more than 30 
minutes prior to testing) 
_____Check system configuration (MJF Pilot), analog setup and control setup 
_____Zero analog channels for the force plates while in correct session 
_____Collect a FP zero trial for tracking drift (trial name: FPzero)  
_____Calculate appropriate weight for pull and load pull device (see paper) 
_____Test Pull Device 
_____Place “GO” switch box and target  
 
Complete Subject Setup: 
_____Measurements and EMG Placement 
_____Vicon markers 
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_____Put harness on 
_____Put EMG belt on 
_____Place KADs for subject calibration trial 
 
Data Collection: 
_____Check to make sure Vicon is setup for this experiment 
_____Collect a subject calibration trial (trial type: subject calibration/ trial name: static) 
_____Check that movie camera is working  
_____Check to make sure all markers are visible  
_____Remove KADs and replace with knee markers 
_____Collect EMG trial (trial type: analog only/ trial name: EMGcheck) 
_____Check EMG signal (viewnew analog data) (shift-t to zoom) 
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Sway (trial type: PD_sway/ trial name: sway1) *Comment EO/EC in Vicon* 
3 EO/3 EC Each test will last 30 seconds with 30 seconds of rest in between trials. 
Should have complete marker setup, EMG on gastroc, SOLEUS, TA, quads 
 
_____Disconnect Solius EMG channel and connect to hamstring electrode 
 
Balance Recovery (trial type: general w/analog/ trial name: pull1) 
3 Backward Pull Trials 
Should have modified marker setup (no sacrum or ASIS, but including great troch markers), EMG on 
gastroc, hamstring, TA, quad 
 
_____Change markers: move calf and thigh markers out of alignment with knee, ankle, and hip markers. 
Add a great troch marker if not already in place. Remove ASIS markers. 
_____Take a static trial for use with BR (w/troch markers) 
_____ Put on the rigid belt 
_____Calculate weight drop height (8.7% of waist height) and adjust- measured from brushes 
_____Perform a total of 3 trials with 30 seconds rest in between trials 
_____Check each trial in Vicon 
_____Remove belt 
 
Gait Initiation (trial type: general w/analog/ trial name: gait_ini1) 
5 trials, all starting from standing on a force plate.  
Should have complete marker setup, foot switches, EMG on gastroc, hamstring, TA, quad 
 
_____Connect foot switch to Vicon BOB- AUX3 
_____Connect light switch to Vicon BOB- AUX4 
_____Adjust safety harness so that it is moveable 
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_____Attach foot switches and foot switch belt 
_____Attach foot switches to scope to check and monitor foot switch signal 
_____Check each trial in Vicon 
_____At the end of all trials, remove the light switch cable and replace with a grounding resistor to AUX 
4. 
 
Gait (trial type: PD_gait/ trial name: gait) 
Participant will walk on the treadmill for 3 minutes at a self-selected speed.   
Should have complete marker setup, foot switches, EMG on gastroc, hamstring, TA, quad 
 
_____Attach foot switches and foot switch box, check signal on scope. 
_____Take another force plate zero trial 
_____Make sure that you have two static trials 
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Study Scripts 
Postural Sway 
 
“For this set of tests you will stand here with your hands to your sides and have either your eyes 
focused on the target in front of you or have them closed.  We will do several trials with rest in 
between. I will tell you when to begin each trial and I will tell you when to relax.” 
 
EO: 
Instructions to subject:   
“For this test, you will stand as still as possible.  Focus your gaze at the target in front of you”   
 
EC: 
Instructions to subject:   
“For this test, you will stand as still as possible with your eyes closed.  Keep your eyes closed until the 
end of the trial.” 
 
Gait Initiation 
 
5 trials start with feet on forceplates (capture push off and first step. 
 
Instructions to subject:  
“For this set of tests you will start standing still and then begin walking when you see the green light. 
Keep walking until I tell you to stop. You will take approximately 3-4 steps. We will do several trials 
with rest in between and there will be two different starting positions.”  
 
Repeat for each trial: 
“For this test, you will stand here as still as possible and when you see the green light you will start 
walking forward, looking ahead while you walk.” 
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Balance Recovery 
 
Instructions to subject: 
“This study will let us look at your response to a balance disturbance.  You will be asked to stand 
here on these force plates and a cable will be attached to your waist. The cable will pull you 
backwards and you need to regain your balance. We will have you repeat this several times.  We 
will explain each step and give you a rest between trials.” 
“First we will have you put on this waist belt, which will be attached to the cable that will pull you 
for each trial.  For your safety, you will wear a safety harness.  The harness will catch you if you are 
unable to regain your balance.” 
“Now, we will have you place your right foot on this plate and your left one on this plate.  Stand 
comfortably with your feet approximately shoulder-width apart. Please stand quietly with your hands at 
your sides. Please remain as still as possible before and after you regain your balance, until I tell you 
to relax. Do you have any questions? 
“Okay, now we will start the test.  Please remember to stand up straight and remain still before the pull 
and after you step.” 
 
Gait 
 
Instructions to subject: 
“For this test you will walk on this treadmill for approximately 3 minutes at a pace that is comfortable 
for you. First we will determine a pace and then the test will begin. Again, you will wear a safety 
harness that will catch you in the event that you lose your balance.  Also, if at any time you feel 
uncomfortable, you can push this button and the treadmill will stop abruptly.” 
“First, we will start the treadmill slowly and choose a speed that feels like a comfortable, normal 
walking pace to you.  Do you have any questions?” 
(Choose pace) 
“Now, we will start the test. Just continue to walk normally. The test will last approximately 3 
minutes.” 
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Data Collection Sheet 
 
Parkinson’s Test 
Date: ____________  Time: ____________  Subject #: ___________ 
Engineer: ______________  
Engineer: ______________ 
PT: ___________________ 
 
PD Duration: ____________ 
 
Medications: 
Name: ____________ Frequency: ___________  Last Dose: ___________ 
Name: ____________ Frequency: ___________  Last Dose: ___________ 
Name: ____________ Frequency: ___________  Last Dose: ___________ 
 
Fall History: 
Falls in previous 3 months: 
Date: _____________ Description: __________________________________ 
Date: _____________ Description: __________________________________ 
Date: _____________ Description: __________________________________ 
Date: _____________ Description: __________________________________ 
 
Mini-Mental Score: ___________ 
 
Measurements: 
Leg Length (ASIS to medial ankle via knee):    L: ________  R: _________ 
Inter ASIS distance:     ________________________ 
Knee Width (between femoral condyles):   L: ________  R: _________ 
Ankle Width:      L: ________  R: _________ 
Ankle Height:      L: ________ R: _________ 
Foot Width:      L: ________ R: _________ 
Foot Length:      L: ________ R: _________ 
Calf Circumference:     L: ________ R: _________ 
Calf Length:      L: ________ R: _________ 
Thigh Circumference:     L: ________ R: _________ 
Thigh Length:       L: ________ R: _________ 
Height:       ________________________ 
Weight:       ________________________ 
Waist Height:       ________________________ 
    
Testing Notes: 
 
 
Subject Calibration Trial 
Static 1: ________________________________________________________________ 
Static 2: ________________________________________________________________ 
EMG Check: ____________________________________________________________ 
 
 
93 
 
 
Sway(PD_sway) 
Sway1: _________________________________________________________________ 
Sway2: _________________________________________________________________ 
Sway3: _________________________________________________________________ 
Sway4: _________________________________________________________________ 
Sway5: _________________________________________________________________ 
Sway6: _________________________________________________________________ 
 
Balance Recovery (general w/analog capture) 
Pull1: __________________________________________________________________ 
Pull2: __________________________________________________________________ 
Pull3: __________________________________________________________________ 
 
 
Gait Initiation (general w/analog capture) 
Gait_ini1: ______________________________________________________________ 
Gait_ini2: ______________________________________________________________ 
Gait_ini3: ______________________________________________________________ 
Gait_ini4: ______________________________________________________________ 
Gait_ini5: ______________________________________________________________ 
 
 
Gait (PD_gait) 
Gait: ___________________________________________________________________ 
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Biodynamics Labratory 
Protocol 
0-45 minutes: Subject Paperwork, Health Assessments, Measurements 
Location: subject setup area 
 
-Consent Form 
-Take weight on force plates 
-Questionnaires 
-Offer a bathroom break! 
-Change into shorts, socks, shoes, T-shirt 
-Health Assessment, take weight and height 
-Measurements 
Laying down: Leg Length, ASIS distance, ankle width 
Sitting up: calf circumference 
Standing: knee width, ankle height, food width, foot length, thigh circumference 
*While taking measurements, mark placement for Knee Marker, ASIS, great troch, and hamstring EMG. 
 
Measurement Descriptions: 
Weight: When the subject first arrives, weigh with shoes and clothes on on force plates.  Then, after the 
subject has changed into testing clothing, weight without shoes on on force plates again.  
ASIS Breadth: Measure the horizontal distance between the two ASIS 
Thigh length: Measure the vertical distance between the top of the great troch and the top of the lateral 
tibia (can use tibial plateau). 
Thigh Circumference: Measure mid-thigh 
Calf Length: Measure the vertical distance between the top of the lateral tibia and the lateral malleolus 
(ankle).  
Calf Circumference: Measure the circumference of the calf at the largest spot. 
Knee Diameter: Measure the maximum breadth of the knee across the femoral epicondyles. 
Foot Length: Measure the distance from the back of the heel to the tip of the longest toe. 
Ankle height: Measure the vertical distance from the floor to the lateral malleolus. 
Ankle width: Measure the maximum distance between the medial and lateral malleoli. 
Foot width: Measure the width across the distal ends of metatarsals 1 and 5.  
 
45-90 minutes: Sensor placement and Equipment Setup 
Location: Platform Area 
 
Put safety harness on. 
 
Place EMGs: bilateral TA, gastroc, hamstring, quad 
Connect EMG as follows: 
EMG lead Muscle  EMG out-> DAQ Board Channel in 
#1   R TA   1 – 22 
#2   R gastroc  2 – 23  
#3   R solius/ham  3 – 24  
#4  R quad   4 – 25  
#5  L TA   5 – 26  
#6   L gastroc  6 – 27  
#7   L solius/ham  7 – 28  
#8  L quad    8 – 29 
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Test EMGs, take sitting break 
 
Optotrak Markers 
15 markers will be placed on the lower body as follows (see Vaughan’s Gait Model and Helen Hayes 
Marker Set for more information about specific placement methods): 
Complete Setup: Bilateral – ASIS, sacrum, thigh, knee, shin wand, ankle, heel, toe 
Modified Setup(for balance recovery only): Bilateral- greater trochanter, thigh, knee, shin wand, ankle, 
heel, toe 
 
Marker Placement Tips: 
ASIS/Sacrum: tape around the waist, and then attach markers to the tape. Use a foam piece to orient the 
sacrum towards one of the cameras. 
Thigh: Find greater trochanter, have subject rotate their foot to make sure you have it, then place marker 
on the line between the greater troch and knee (along the long axis of the thigh). Marker should be on 
lower thigh and in line with the flexion/extension axis of the knee.  
Knee: Identify tibial plateau, then move back and up to find the femoral epicondyle- along the 
flexion/extension axis of the knee.  
Shin Wand : Place on lower shank, on long axis, and in line with flexion/extension axis of the ankle. 
Heel: Place on shoe, at same height of toe marker, use a foam piece to orient the marker towards the 
cameras.  
Ankle: Place marker in line of flexion/extension axis of ankle. 
Toe: 2
nd
 metatarsal head on joint closest to body  (2
nd
 biggest) Use a foam  piece to orient the marker 
towards the cameras. 
 
Walk subject into data collection area and test to make sure all markers are visible. 
Subject calibration trial (stand still)  
Take a sitting break 
 
90-180 minutes: Experimental Testing/Data Collection 
Location: Platform Area 
Balance Recovery (trial type: general w/analog/ trial name: pull1) 
The balance recovery testing consists of 3 backwards pull trials.  Force plate, EMG, and motion data will 
be collected during all trials.  The weight-drop device will be used to pull the participant. 
Should have modified marker setup (no sacrum or ASIS, but including great troch markers) 
 
Attach safety harness 
TAKE STATIC TRIAL IN MODIFIED MARKER SETUP 
Mark foot position with tape 
Put on the rigid harness 
Measure waist height, adjust pull device to 8.7% of waist height 
Take a still trial 
Mark the feet so they stay in the same position as for the “still trial.” 
Attach pull device cable 
Read script, explaining task (no practice trials) 
Start the video camera 
Research assistant should spot the participant throughout all trials 
Once subject is ready, release the weight-dropping mechanism 
Replace weights and  tell the subject to relax after they have regained their balance for three seconds 
Check trial for marker visibility  
Perform a total of 3 trials with 30 seconds rest in between trials 
Disconnect safety harness, cable to pull device, and remove rigid harness 
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Take a sitting break 
 
 
Sway (trial type: PD_sway/ trial name: sway1) 
Sway testing consists of three trials in each of two different conditions, eyes open (EO) and eyes closed 
(EC). Force plate, EMG, and motion data will be collected. Each test will last 30 seconds with 30 seconds 
of rest in between trials. 
Should have complete marker setup 
 
Have participant stand comfortably with one foot on each force plate. Feet should be shoulder wide and at 
a self-selected angle.  Arms rest to the side and the subject is looking at a marker placed 5 feet in front of 
the at approximately eye height.  
Attach safety harness 
Check EMG and visibility of markers  
Read script to the participant 
Before each test, remind the participant of the condition being tested (EO or EC). 
Take a sitting break 
 
Gait Initiation (trial type: general w/analog/ trial name: gait_ini1) 
Participants will perform 5 gait initiation trials, all starting from standing on a forceplate. EMG, force and 
movement data will be collected. 
Should have complete marker setup 
 
Have participant stand in collection area with one foot on each force plate. They will be oriented so that 
they are looking at the South wall. 
Take a static trial 
Mark foot position 
Attach safety harness 
Read the script to the participant. 
Subject will start with one foot on each force plate, then step forward when the light comes on. 
Participant should start each trial with their feet in a comfortable stance and their arms relaxed at their 
sides. 
A research assistant should be spotting the participant throughout. 
Take a sitting break 
 
Gait (trial type: PD_gait/ trial name: gait) 
Participant will walk on the treadmill for 3 minutes at a self-selected speed.  EMG and movement data 
will be collected. 
Should have complete marker setup, foot switches, EMG on gastroc, hamstring, TA, quad 
 
Move treadmill into the collection volume under the safety support. 
Instruct participant to step onto the treadmill. 
Attach the cable to the safety harness. 
Attach kill switch to subject’s clothing. 
Power up the treadmill. 
Read the script to the participant, explaining the tasks. 
Slowly increase the speed of the treadmill until the desired speed is reached. Record the final speed on the 
data collection sheet. 
Once the participant has reached a comfortable gait begin data collection. 
At the end of data collection, inform participant they are finished and then stop the treadmill (manually 
decrease the speed to zero). 
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Remove safety cable and assist the participant in stepping off the treadmill. 
 
Take another subject calibration trial (should have two subject calibration trials- one for use with br, one 
for all others)  
 
Take another force plate zero trial 
 
 
Optotrak Data Key 
Marker Location Columns 
1 Right Thigh 2:4 
2 Right Knee 5:7 
3 Right Shank 8:10 
4 Right Ankle 11:13 
5 Right Heel 14:16 
6 Right Toe 17:19 
7 Left Thigh 20:22 
8 Left Knee 23:25 
9 Left Shank 26:28 
10 Left Ankle 29:31 
11 Left Heel 32:34 
12 Left Toe 35:37 
13 Right ASIS/Great Troch 38:40 
14 Sacrum 41:43 
15 Left ASIS/Great Troch 44:46 
 
Pre Data Collection Tasks 
Recruitment: 
Once a participant has passed the health screen and is scheduled, send them a confirmation letter and 
directions to the lab.   
If it is a PD participant, also email them to ask them to see Dr. Lyons within 3 months of the testing date.  
Attach the letter called “UPDRS Appt.”  
Email David to confirm testing dates/times.  
Misc: 
Email David Moore, parking guy, about reserving a parking meter. His email is moore-ku@ku.edu and 
phone number is 785-864-7293 (office) or 785-840-5693 (cell).  
Make sure David Thomas has a parking pass for the week of testing. If there are 3 or more tests in a week 
it makes sense to get him a weekly parking permit.  A red weekly visitor permit is $8.00/week.  Contact 
Mary Olson at KU Parking. I just sent an email to kupark@ku.edu and that is who responded to me.  You 
can either pay for the permit and get reimbursed or ask them to invoice the ME department (specify that 
this is for Luchies’s PD Pilot project so the office knows what it is).  If there are 2 or fewer tests in a 
week, it makes sense for him to just park in the parking garage and pay $1/hour.  In this case, we add the 
parking fee to his timesheet (there is a column for parking).  Just note the number of hours he parked for.  
Email Kelly Lyons (klyons@kumc.edu) to let her know if we are testing a PD patient so she can make 
sure and see them in clinic in case they happen to have an appointment before they come in for testing.  
Make sure the laundry is all clean (sheets, shorts, socks, etc).   
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Post Data Collection Tasks 
File Backup: 
Take “PD Project Data Transfer” external hard drive from out of Molly’s desk and transfer the optotrak 
files to the hard drive.  
Connect the video camera to the Labview computer and turn it on.   
Connect the external hard drive to the Labview computer. 
Copy the video and optotrak data to the appropriate folder in the Labview computer. 
Copy all files from the labview computer folder to the “Master Backup Hard Drive” (the 1 TB one that 
sits on the desk by the labview computer) as well as on the PD Project Data Transfer hard drive. 
Double check that you have complete sets of data on both the labview computer, the master backup hard 
drive, and the transfer drive.  
Take the transfer drive home with you.  
DT Timesheet 
Update the spreadsheet “DT Timesheet” with the date and hours that he worked and any parking that we 
owe him for.  
Payment and Thank You’s: 
At the end of a testing week, collect all of the payment forms out of the folders of each participant.  
Complete the back side of the forms, and take to Carl to sign.   
Make copies of the signed forms for our records and turn in the originals to Leslie in the ME office. 
Write and send a thank-you card from our lab to the participant.  
PD Patient Appt. with Dr. Lyons Record 
Dr. Lyons needs to know about each patient that we test and when we test them.  Update the spreadsheet 
called “Testing Dates” to include each PD participant.  Really this should be updated as soon as the 
patient is scheduled in case they go in to see Dr. Pahwa between scheduling and testing.  
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Technical Setup 
Data Acquisition Setup 
Setup data files on both the labview and optotrak computers.  For the labview computer, setup a 
folder for each subject in each task folder. My documentsResearchMollyPD Project 
2010DataBR, GI, Sway, Gait, etc. For the optotrak computer, just setup a subject folder in the PD 
ProjectData folder. It is imperative to keep track of which optotrak file goes with which data file from 
the other computer. I usually do this on the data collection sheet.  
Decide the order of tasks for the experiment and order of EO/EC trials for sway.  Balance 
Recovery will always go first.  Use “randperm(3)” to determine the order of the other tasks.  1= gait 
initiation, 2= sway, 3= gait. For sway, use “randperm(6)” and each even number it gives= eyes open trial, 
and each odd number= eyes closed trial.  Write the orders on the data collection sheet and on the the 
whiteboard.  
 
Loading the Pull Device 
Take the subject’s weight on the force plate. Add 10 lbs to account for the weight of all of the 
sensors and rigid harness.  
Go to the “Pull Weight Combinations” sheet and look up the weight to add amount. Remember 
that the actual amount of weight you will add is 7 lbs less than what it says in the “weight to add” column. 
If you add the weight together from the weight combinations that it gives, that is the right amount to add. 
Or, you can just subtract 7 lbs from the amount it tells you to add. 
To determine the drop distance, measure the distance from the middle of the waist harness loop 
that the rope connects in to the floor. Take 8.7% of this number and then add 0.5cm.  So the calculation is 
waist height*.087 + 0.5 cm.   
To set the drop distance, note that a “zero” distance is 11cm on the meter stick that is in the 
device.  So you will want to move the brushes to whatever drop distance you calculated + 11cm.   
Optotrak Setup 
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Place Optotrak sensors in location- 12 feet from midline of force plates on East and West sides 
Connect 3020 and Certus sensors to the SCU using the correct cables (they are labeled). Ensure 
that the cable from the SCU to the computer is connected, and that the power is connected. 
Turn on both sensors and the SCU unit. 
Start up the optotrak computer, logon, and open First Principles 
Choose FileNew Experiment 
Perform a new registration and alignment with coordinate system origin at the SE corner of force 
plate #3.  
*Note- if the software does not detect both sensors it will not ask you to perform a registration- 
make sure that it finds both sensors. If it doesn’t, try “Query System,” and then start the setup over again. 
Note that sensor 3-03-63 is the 3020 system. 
Connect all markers and strobers and make sure the software recognizes the correct number of 
markers.  You can go through and name them here as well if you want to.  
Choose to enable the trigger 
Setup your data collection parameters 
Make sure that all markers are visible. 
 
Force Plate Setup 
Turn on and leave alone for 10-15 minutes 
Balance amplifiers 
Take zero trial prior to data collection 
 
EMG Setup 
Scrub area with pumice stone and rub with alcohol wipe 
Place sensors and arrange wires 
Connect output cables 
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Ensure that the gain is turned to 1k on all 8 channels 
Check signal using labview 
 
Labview Startup 
Open My DocumentsResearchMollyPD Project 2010Labview Vis and open the 
“PD_data_collection_allinone.” 
After balancing force plates, take a force plate zero trial. 
-Set collection time to 1 sec 
-Select “no” for “Use Trigger?” 
-Select “no” for “Do you want to track the COP before data collection?” 
-Save the zero trial as My DocumentsResearchMollyPD Project 2010Data 
Then choose the appropriate experiment folder and label file as “fp_zero” 
 
For the balance recovery experiment,  
Have the subject stand on force plates one and two in the same position as they will stand for the 
balance recovery task.  Mark the feet with tape. Take a trial and label it “still” This will serve as the static 
trial, too- so make sure that all markers are visible and use the trigger to collect optotrak data.  
Run “zero trial calculation simplify” VI to calculate the still position COP. Save the file as 
“still_cop.” 
Now open PD_data_collection_allinone and select “yes” to monitor the COP and “yes” to use the 
trigger.  Set the collection time to 5 seconds. 
Make sure that the drop mechanism is ready to go (hit “open cleats” and front “drop” and front 
“cleat” to arm it.   
Begin the VI by pushing the start arrow on the upper left hand side of the window. 
When the green light comes on (indicating they have met the COP requirements), click on the 
“GO” button. Now the program is waiting for your trigger. 
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Press the red trigger button to trigger optotrak, labview, and to drop the weights. Weights are 
dropped 500ms after data collection begins. 
Save the trial as br1.  Note on the data collection sheet which optotrak file goes with which data 
file. 
Check that all of the data looks good 
 
For all other tasks, 
-Select “no” for “Do you want to track the COP before data collection?” 
Take another fp_zero trial (1 sec), and save it in the correct task folder.  
Gait Initiation trials are 5 seconds (unless they need to be adjusted for a very slow subject), Sway 
trials are 30 seconds, and we don’t need to collect data through labview for gait trials. 
Gait initiation also needs a static trial- only marker data is needed, but all markers must be in 
view. Static trials are 5 seconds long.  
 
Post Data Collection Tasks 
File Backup: 
Take “PD Project Data Transfer” external hard drive from out of Molly’s desk and transfer the 
optotrak files to the hard drive.  
Connect the video camera to the Labview computer and turn it on.   
Connect the external hard drive to the Labview computer. 
Copy the video and optotrak data to the appropriate folder in the Labview computer. 
Copy all files from the labview computer folder to the “Master Backup Hard Drive” (the 1 TB 
one that sits on the desk by the labview computer) and also to the transfer hard drive. 
Double check that you have complete sets of data on both the labview computer, the transfer hard 
drive, and the master backup hard drive.  
Someone should take the transfer hard drive home with them each night.  
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DT Timesheet 
Update the spreadsheet “DT Timesheet” with the date and hours that he worked.  
 
Payment and Thank You’s: 
At the end of a testing week, collect all of the payment forms out of the folders of each 
participant.  Complete the back side of the forms, and take to Carl to sign.   
Make copies of the signed forms for our records and turn in the originals to Leslie in the ME 
office. 
Write and send a thank-you card from our lab to the participant.  
 
PD Patient Appt. with Dr. Lyons Record 
Dr. Lyons needs to know about each patient that we test and when we test them.  Update the 
spreadsheet called “Testing Dates” to include each PD participant.  Really this should be updated as soon 
as the patient is scheduled in case they go in to see Dr. Pahwa between scheduling and testing.  
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Protocol Checklist 
 
Start Equipment Setup: 
_____Check camera positions 
_____Turn on force plates, cameras, SCU 
_____Verify force plates (channels 0-11,16-21), EMG (channels 22-29), pull device load cell 
(channels 12-13), gait initiation light (channel 14), and trigger (PFIO) are connected to DAQ 
board 
_____Connect video camera 
_____Connect pull device – normal (channel 12), shear (channel 13) 
_____Balance force plates 
 
Start Subject Setup: 
_____Consent  
_____Physical Screening 
_____Clarify history (falls in previous 3 months, severity and duration, medication  
status) 
_____Mini-mental exam 
_____5 Self-Report Tests  
 
Complete Equipment Setup: 
_____Complete Optotrak startup (registration, calibration) 
_____Collect a FP zero trial for tracking drift (trial name: FPzero1)  
_____Calculate appropriate weight for pull and load pull device (see paper) 
_____Test Pull Device 
_____Place “GO” switch box and target  
 
Complete Subject Setup: 
_____Measurements and EMG Placement 
_____Optotrak markers 
_____Put harness on 
_____Put EMG belt on 
 
Data Collection: 
_____Connect markers and make sure they are all seen in Optotrak 
_____Collect a subject calibration trial (static trial) 
_____Check that movie camera is working  
_____Check to make sure all markers are visible  
_____Check EMG signal 
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Sway (trial name: sway1EO) 
3 EO/3 EC Each test will last 30 seconds with 30 seconds of rest in between trials. 
Should have complete marker setup, EMG on gastroc, SOLEUS, TA, quads 
 
_____Disconnect Solius EMG channel and connect to hamstring electrode 
 
Balance Recovery (trial name: pull1) 
3 Backward Pull Trials 
Should have modified marker setup (no sacrum or ASIS, but including great troch markers), 
EMG on gastroc, hamstring, TA, quad 
 
_____Change markers: move calf and thigh markers out of alignment with knee, ankle, and hip 
markers. Add a great troch marker if not already in place. Remove ASIS markers. 
_____Take a static trial for use with BR (w/troch markers) 
_____ Put on the rigid belt 
_____Calculate weight drop height (8.7% of waist height) and adjust- measured from brushes 
_____Perform a total of 3 trials with 30 seconds rest in between trials 
_____Check each trial in Optotrak 
_____Remove belt 
 
Gait Initiation (trial name: gait_ini1) 
5 trials, all starting from standing with one foot on each force plate 
Should have complete marker setup, EMG on gastroc, hamstring, TA, quad 
 
_____Check each trial in Optotrak 
 
Gait (trial name: gait) 
Participant will walk on the treadmill for 3 minutes at a self-selected speed.   
Should have complete marker setup, foot switches, EMG on gastroc, hamstring, TA, quad 
 
_____Take another force plate zero trial 
_____Make sure that you have two static trials 
 
 
 
  
106 
 
Study Scripts 
 
Postural Sway 
“For this set of tests you will stand here with your hands to your sides and have either your eyes 
focused on the picture in front of you or have them closed.  We will do several trials with rest in 
between. I will tell you when to begin each trial and I will tell you when to relax.” 
 
EO: 
Instructions to subject:   
“For this test, you will stand as still as possible.  Focus your gaze at the target in front of you”   
 
EC: 
Instructions to subject:   
“For this test, you will stand as still as possible with your eyes closed.  Keep your eyes closed until the 
end of the trial.” 
 
Gait Initiation :6 trials start with feet on force plates and check for clean strike on back force plate 
(capture push off and first step) 
 
Instructions to subject:  
“For this set of tests you will start standing still and then begin walking when you see the green light. 
Keep walking until I tell you to stop. You will take approximately 3-4 steps. We will do several trials 
with rest in between. 
 
Repeat for each trial: 
“For this test, you will stand here as still as possible and when you see the green light you will start 
walking forward, looking ahead while you walk.” 
 
Balance Recovery: 3-5 trials 
Instructions to subject: 
“This study will let us look at your response to a balance disturbance.  You will be asked to stand 
here on these force plates and a cable will be attached to your waist. The cable will pull you 
backwards and you need to regain your balance. We will have you repeat this several times.  We 
will explain each step and give you a rest between trials.” 
“First we will have you put on this waist belt, which will be attached to the cable that will pull you 
for each trial.  For your safety, you will wear a safety harness.  The harness will catch you if you are 
unable to regain your balance.” 
“Now, we will have you place your right foot on this plate and your left one on this plate.  Stand 
comfortably with your feet approximately shoulder-width apart. Please stand quietly with your hands at 
your sides. Please remain as still as possible before and after you regain your balance, until I tell you 
to relax. Do you have any questions? 
“Okay, now we will start the test.  Please remember to stand up straight and remain still before the pull 
and after you step.” 
 
Gait: 1 trial 
Instructions to subject: 
“For this test you will walk on this treadmill for approximately 3 minutes at a pace that is comfortable 
for you. First we will determine a pace and then the test will begin. Again, you will wear a safety 
harness that will catch you in the event that you lose your balance.  Also, if at any time you feel 
uncomfortable, you can push this button and the treadmill will stop abruptly.” 
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“First, we will start the treadmill slowly and choose a speed that feels like a comfortable, normal 
walking pace to you.  Do you have any questions?” 
(Choose pace) 
“Now, we will start the test. Just continue to walk normally. The test will last approximately 3 
minutes.” 
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Data Collection Sheet 
 
Date: __________________  Time: ____________  Subject #: ___________ 
Engineer: ______________  Testing Order: _______________________________ 
Engineer: ______________ 
PA: ___________________ 
 
PD Duration: ____________ 
 
PD Medications (list other medications on health screen): 
Name: _____________________Dosage: __________  Frequency: __________ Last Dose: __________ 
Name: _____________________Dosage: __________  Frequency: __________ Last Dose: __________ 
Name: _____________________Dosage: __________  Frequency: __________ Last Dose: __________ 
Name: _____________________Dosage: __________  Frequency: __________ Last Dose: __________ 
Name: _____________________Dosage: __________  Frequency: __________ Last Dose: __________ 
Name: _____________________Dosage: __________  Frequency: __________ Last Dose: __________ 
 
Fall History: 
Falls in previous 3 months: 
Date: _____________ Description: __________________________________ 
 
Date: _____________ Description: __________________________________ 
 
Date: _____________ Description: __________________________________ 
 
Date: _____________ Description: __________________________________ 
 
Mini-Mental Score: ___________ 
 
Measurements: 
Height:       ________________________ 
Weight:       ________________________ 
Leg Length (ASIS to medial ankle via knee):     L: ________  R: _________ 
Inter ASIS distance:     ________________________ 
Knee Width (between femoral condyles):   L: ________  R: _________ 
Ankle Width:      L: ________  R: _________ 
Foot Width:      L: ________ R: _________ 
Foot Length:      L: ________ R: _________ 
Thigh Length (troch. to lat’l tibial plateau):  L: ________ R: _________ 
Calf Length (lat’l tibial plateau to lat’l mall.):  L: ________ R: _________ 
Ankle Height:      L: ________ R: _________ 
Calf Circumference (largest pt.):   L: ________ R: _________ 
Thigh Circumference (mid-thigh):    L: ________ R: _________ 
Waist Height:       ________________________ 
Weight loaded for pull device: 
 
Drop distance for pull device:    
Testing Notes: 
 
EMG Check: ____________________________________________________________ 
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Sway (30 seconds @ 1000Hz EMG/FP, 100Hz Opto) 
Need 3 EO and 3EC perfect trials 
*Most important data- force plates and EMG 
 
Trial 
Video 
File Name 
Labview 
File Name 
Optotrak 
File Name 
Trial 
Notes 
FPzero     
Sway1     
Sway2     
Sway3     
Sway4     
Sway5     
Sway6     
     
     
 
 
Balance Recovery (5 seconds @1000 Hz EMG/FP, 100Hz Opto) 
Need 3 perfect trials 
*Most important data- force plates, EMG (TA), markers (up to knee, both sides), load cell 
channels, video 
Trial 
Video 
File Name 
Labview 
File Name 
Optotrak 
File Name 
Trial 
Notes 
FPzero     
Static 
Trial 
    
Pull1     
Pull2     
Pull3     
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Gait Initiation (5 seconds @1000 Hz EMG/FP, 100Hz Opto) 
Most important data: force plates, gait initiation light, EMG (all), markers (all). Watch for a clean 
force plate strike on fp3 for the first step.  If it is not a clean strike, the trial is not good.  
Need 5 perfect trials 
Trial 
Video 
File Name 
Labview 
File Name 
Optotrak 
File Name 
Trial 
Notes 
FPzero     
Static 
Trial 
    
Gait_ini1     
Gait_ini2     
Gait_ini3     
Gait_ini4     
Gait_ini5     
     
     
     
 
 
 
Gait (100 Hz Opto only) 
Most important data: Markers (all)- this is all we have for gait. 
Trial 
Video 
File Name 
Labview 
File Name 
Optotrak 
File Name 
Trial 
Notes 
Static 
Trial 
 n/a   
Gait  n/a   
 
 
 
 
 
